ALTERATION	EVIDENCE_LEVEL	EVIDENCE_RATING	EVIDENCE_TYPE	EFFECT	DRUG	TUMOR_NAME	TUMOR_DOID	TUMOR_CODE	TOPNODE_NAME	TOPNODE_DOID	MOLECULAR_ID	VARIANT_ID	VARIANT_TYPE	VARIANT_GROUP	EVIDENCE_SCORE	ORIGIN
BRAF_V600E	A	5	Predictive	Sensitivity/Response	Vemurafenib	skin melanoma	8923	MEL	skin cancer	4159	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	A	5	Predictive	Sensitivity/Response	Cetuximab, Encorafenib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	12	12	missense_variant		1378.5	Somatic
ERBB2_AMP	A	5	Predictive	Sensitivity/Response	Margetuximab	breast cancer	1612	BREAST	breast cancer	1612	302	306	transcript_amplification		891	Somatic
.::ALK	A	5	Predictive	Sensitivity/Response	Crizotinib, Alectinib, Ceritinib, Brigatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	495	499	transcript_fusion	ALK Fusion	798	Somatic
KRAS_Mutation	A	5	Predictive	Resistance	Selumetinib, Docetaxel	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	332	336	protein_altering_variant		545.5	Somatic
KRAS_Mutation	A	5	Predictive	Resistance	Panitumumab, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	332	336	protein_altering_variant		545.5	Somatic
BRCA2_Mutation	A	5	Predictive	Sensitivity/Response	Olaparib	castration-resistant prostate carcinoma	80909	PROSTATE	prostate cancer	10283	186	186	gene_variant,loss_of_function_variant		462.5	Unknown
BRCA2_Mutation	A	5	Predictive	Sensitivity/Response	Rucaparib	ovarian cancer	2394	OVARY	ovarian cancer	2394	186	186	gene_variant,loss_of_function_variant		462.5	Somatic
BRAF_V600	A	5	Predictive	Sensitivity/Response	Dabrafenib, Trametinib	skin melanoma	8923	MEL	skin cancer	4159	17	17	protein_altering_variant	Other BRAF V600's	460	Somatic
BRAF_V600	A	5	Predictive	Sensitivity/Response	Cobimetinib, Vemurafenib, Binimetinib, Encorafenib, Atezolizumab	melanoma	1909	MEL	cancer	162	17	17	protein_altering_variant	Other BRAF V600's	460	Somatic
BRCA1_Mutation	A	5	Predictive	Sensitivity/Response	Rucaparib	ovarian cancer	2394	OVARY	ovarian cancer	2394	185	185	gene_variant,loss_of_function_variant		455	Somatic
NPM1_EXON_12_MUTATION	A	5	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
PIK3CA_Mutation	A	5	Predictive	Sensitivity/Response	Alpelisib, Fulvestrant	breast cancer	1612	BREAST	breast cancer	1612	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
TP53_Mutation	A	5	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	222	222	protein_altering_variant		437	Somatic
EGFR_Exon_19_Deletion	A	5	Predictive	Sensitivity/Response	Osimertinib, Dacomitinib, Ramucirumab, Erlotinib, Chemotherapy, Gefitinib, Lazertinib, Amivantamab, Pemetrexed, Carboplatin	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4432	133	inframe_deletion		410	Somatic
EGFR_T790M	A	5	Predictive	Resistance	Erlotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	34	34	missense_variant	EGFR TKI Resistance	406.25	Somatic
EGFR_T790M	A	5	Predictive	Sensitivity/Response	Osimertinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	34	34	missense_variant	EGFR TKI Resistance	406.25	Somatic
EGFR_L858R	A	5	Predictive	Sensitivity/Response	Erlotinib, Afatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	33	33	missense_variant		379	Somatic
BCR::ABL1	A	5	Predictive	Sensitivity/Response	Imatinib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	1	1	transcript_fusion	ABL1 fusions in B-ALL	353.5	Somatic
BCR::ABL1	A	5	Predictive	Sensitivity/Response	Imatinib, Nilotinib, Dasatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	1	1	transcript_fusion	ABL1 fusions in B-ALL	353.5	Somatic
EGFR_Exon_19_Deletion	A	5	Predictive	Sensitivity/Response	Erlotinib, Afatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	133	133	inframe_deletion		318	Somatic
IKZF1_DEL	A	5	Prognostic	Poor Outcome		b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	200	200	transcript_ablation		240	Somatic
IKZF1_DEL	A	5	Prognostic	Poor Outcome		b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	200	200	transcript_ablation		240	Somatic
IDH1_R132	A	5	Predictive	Sensitivity/Response	Ivosidenib	cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	58	58	protein_altering_variant		199	Somatic
KRAS_G12C	A	5	Predictive	Sensitivity/Response	Sotorasib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	78	78	missense_variant	EGFR TKI Resistance	176.5	Somatic
KRAS_Exon_2_Mutation	A	5	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	75	75	missense_variant		168	Somatic
.::PDGFRB	A	5	Diagnostic	Positive		hematologic cancer	2531	HEMATO	hematologic cancer	2531	564	568	transcript_fusion		140	Somatic
MGMT_Promoter_Methylation	A	5	Predictive	Sensitivity/Response	Temozolomide	glioblastoma	3068	GB	central nervous system cancer	3620	85	85	N/A		136	Somatic
.::NTRK1	A	5	Predictive	Sensitivity/Response	Entrectinib, Larotrectinib	solid tumor	NA	SOLID	cancer	162	415	419	transcript_fusion	NTRK1 Fusions	135	Somatic
PML::RARA	A	5	Predictive	Sensitivity/Response	Tretinoin, Arsenic Trioxide	acute promyelocytic leukemia	60318	APL	hematologic cancer	2531	108	108	transcript_fusion		132.5	Somatic
PML::RARA	A	5	Diagnostic	Positive		acute promyelocytic leukemia	60318	APL	hematologic cancer	2531	108	108	transcript_fusion		132.5	Somatic
ATM_Mutation	A	5	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	178	178	transcription_variant,loss_of_function_variant		130.5	N/A
SF3B1_Mutation	A	5	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	215	215	protein_altering_variant		130	Somatic
RUNX1::RUNX1T1	A	5	Prognostic	Better Outcome		acute myeloid leukemia with t(8;21); (q22; q22.1)	81093	AMLRUNX1RUNX1T1	hematologic cancer	2531	2995	3126	transcript_fusion		120	Somatic
.::NTRK3	A	5	Predictive	Sensitivity/Response	Entrectinib, Larotrectinib	solid tumor	NA	SOLID	cancer	162	1251	1277	transcript_fusion		105	Somatic
.::FGFR1	A	5	Diagnostic	Positive		hematologic cancer	2531	HEMATO	hematologic cancer	2531	565	569	transcript_fusion		103	Somatic
NOTCH1_Mutation	A	5	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	206	206	protein_altering_variant		100	Somatic
.::PDGFRA	A	5	Diagnostic	Positive		myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1	80164	MLNER	hematologic cancer	2531	563	567	transcript_fusion		100	Somatic
TCF3::PBX1	A	5	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma with tcf3-pbx1	80649	BLLTCF3PBX1	hematologic cancer	2531	4800	4690	transcript_fusion		90	Somatic
FLT3_Mutation	A	5	Predictive	Sensitivity/Response	Gilteritinib, Midostaurin	acute myeloid leukemia	9119	AML	hematologic cancer	2531	515	519	transcript_variant,gain_of_function_variant		85	Somatic
ERBB2_Overexpression	A	5	Predictive	Sensitivity/Response	Trastuzumab Deruxtecan	solid tumor	NA	SOLID	cancer	162	849	875	N/A		77.5	Somatic
TPM3::NTRK1	A	5	Predictive	Sensitivity/Response	Larotrectinib Regimen	solid tumor	NA	SOLID	cancer	162	2861	2992	transcript_fusion		77	Somatic
FOXL2_C134W	A	5	Diagnostic	Positive		ovarian sex-cord stromal tumor	80369	SCST	sex cord-gonadal stromal tumor	192	198	198	missense_variant		70	Somatic
PCM1::JAK2	A	5	Diagnostic	Positive		hematologic cancer	2531	HEMATO	hematologic cancer	2531	567	571	transcript_fusion	JAK2 fusions in B-ALL	57.5	Somatic
.::ROS1	A	5	Predictive	Sensitivity/Response	Crizotinib, Entrectinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	2562	2693	transcript_fusion		50	Somatic
CALR_Mutation	A	5	Diagnostic	Positive		essential thrombocythemia	2224	ET	hematologic cancer	2531	2261	2388			50	Somatic
ETV6::RUNX1	A	5	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma with etv6-runx1	80645	BLLETV6RUNX1	hematologic cancer	2531	3009	3140	transcript_fusion		50	Somatic
.::BRAF	A	5	Predictive	Sensitivity/Response	Tovorafenib	childhood low-grade glioma	80830	LGG	central nervous system cancer	3620	5077	2639	transcript_fusion		0	Somatic
BRAF_V600E	A	5	Predictive	Sensitivity/Response	Tovorafenib	childhood low-grade glioma	80830	LGG	central nervous system cancer	3620	4453	12	missense_variant		0	Somatic
IDH1_R132C	A	5	Predictive	Sensitivity/Response	Vorasidenib	low grade glioma	80829	LGG	central nervous system cancer	3620	5298	59	missense_variant		0	Somatic
IDH2_R172G	A	5	Predictive	Sensitivity/Response	Vorasidenib	low grade glioma	80829	LGG	central nervous system cancer	3620	5297	4459			0	Somatic
PIK3CA_H1047L	A	5	Predictive	Sensitivity/Response	Alpelisib, Fulvestrant	breast cancer	1612	BREAST	breast cancer	1612	5288	1151	missense_variant		0	Somatic
BRAF_V600E	A	4	Predictive	Sensitivity/Response	Trametinib, Dabrafenib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	12	12	missense_variant		1378.5	Somatic
ERBB2_AMP	A	4	Predictive	Sensitivity/Response	Trastuzumab, Neratinib	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	302	306	transcript_amplification		891	Somatic
ERBB2_AMP	A	4	Predictive	Sensitivity/Response	Trastuzumab	gastric adenocarcinoma	3717	STAD	stomach cancer	10534	302	306	transcript_amplification		891	N/A
.::ALK	A	4	Predictive	Sensitivity/Response	Crizotinib	anaplastic large cell lymphoma	50744	ALCL	hematologic cancer	2531	495	499	transcript_fusion	ALK Fusion	798	Somatic
BRCA1_Mutation	A	4	Predictive	Sensitivity/Response	Olaparib	castration-resistant prostate carcinoma	80909	PROSTATE	prostate cancer	10283	185	185	gene_variant,loss_of_function_variant		455	Unknown
BCR::ABL1	A	4	Diagnostic	Positive		chronic myeloid leukemia	8552	CML	hematologic cancer	2531	1	1	transcript_fusion	ABL1 fusions in B-ALL	353.5	Somatic
ETV6::NTRK3	A	4	Predictive	Sensitivity/Response	Larotrectinib	congenital fibrosarcoma	8418	FIBS	connective tissue cancer	201	779	801	transcript_fusion		314	Somatic
ETV6::NTRK3	A	4	Diagnostic	Positive		congenital fibrosarcoma	8418	FIBS	connective tissue cancer	201	779	801	transcript_fusion		314	Somatic
NRAS_Mutation	A	4	Predictive	Resistance	Cetuximab, Panitumumab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	208	208	transcript_variant,gain_of_function_variant		213	Somatic
KIT_Exon_11_Mutation	A	4	Predictive	Sensitivity/Response	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	66	66	coding_sequence_variant	KIT Exon 11	197.5	Somatic
.::RET	A	4	Predictive	Sensitivity/Response	Selpercatinib, Pralsetinib	thyroid cancer	1781	THYROID	thyroid cancer	1781	1595	1687	transcript_fusion		192.5	Somatic
.::RET	A	4	Predictive	Sensitivity/Response	Pralsetinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1595	1687	transcript_fusion		192.5	Somatic
CDKN2A_p16_Expression	A	4	Prognostic	Better Outcome		oropharynx cancer	8557	OPHC	head and neck cancer	11934	268	272	N/A		180	N/A
KRAS_G12C	A	4	Predictive	Sensitivity/Response	Adagrasib, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	78	78	missense_variant	EGFR TKI Resistance	176.5	Somatic
SS18::SSX1	A	4	Diagnostic	Positive		synovial sarcoma	5485	SYNS	connective tissue cancer	201	444	448	transcript_fusion	SYT-SSX fusions	145	Somatic
.::PDGFRB	A	4	Predictive	Sensitivity/Response	Imatinib	myeloproliferative neoplasm	2226	MPN	hematologic cancer	2531	564	568	transcript_fusion		140	Somatic
ATM_Mutation	A	4	Predictive	Sensitivity/Response	Olaparib	castration-resistant prostate carcinoma	80909	PROSTATE	prostate cancer	10283	178	178	transcription_variant,loss_of_function_variant		130.5	Unknown
KIT_Exon_9_Mutation	A	4	Predictive	Sensitivity/Response	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	505	509	exon_variant		122.5	Somatic
RUNX1::RUNX1T1	A	4	Diagnostic	Positive		acute myeloid leukemia with t(8;21); (q22; q22.1)	81093	AMLRUNX1RUNX1T1	hematologic cancer	2531	2995	3126	transcript_fusion		120	Somatic
METx14del	A	4	Predictive	Sensitivity/Response	Capmatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	320	324	exon_loss_variant		108.5	Somatic
EGFR_Exon_20_Insertion	A	4	Predictive	Sensitivity/Response	Amivantamab, Mobocertinib, Chemotherapy	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	707	726	inframe_insertion		105	Somatic
IDH2_Mutation	A	4	Predictive	Sensitivity/Response	Enasidenib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	566	570	protein_altering_variant		101.5	Somatic
RET_Mutation	A	4	Predictive	Sensitivity/Response	Selpercatinib	thyroid gland medullary carcinoma	3973	THME	thyroid cancer	1781	1598	1690			95	Unknown
SS18::SSX2	A	4	Diagnostic	Positive		synovial sarcoma	5485	SYNS	connective tissue cancer	201	445	449	transcript_fusion	SYT-SSX fusions	85	Somatic
CALR_EXON_9_FRAMESHIFT	A	4	Prognostic	Better Outcome		myelofibrosis	4971	PMF	hematologic cancer	2531	555	559	exon_variant		80	Somatic
FGFR2::.	A	4	Predictive	Sensitivity/Response	Pemigatinib	cholangiolocellular carcinoma	7642	CHOL	biliary tract cancer	4607	4685	4612	transcript_fusion		75	Somatic
FGFR2::.	A	4	Predictive	Sensitivity/Response	Infigratinib	cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	4685	4612	transcript_fusion		75	Somatic
FGFR3_Mutation	A	4	Predictive	Sensitivity/Response	Erdafitinib	transitional cell carcinoma	2671	TCC	cancer	162	805	827			70	Somatic
MYCN_AMP	A	4	Prognostic	Poor Outcome		neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	294	298	transcript_amplification		46	Somatic
BRCA1_Mutation	A	4	Predictive	Sensitivity/Response	Niraparib	epithelial ovarian cancer	2152	OVT	ovarian cancer	2394	4409	185	gene_variant,loss_of_function_variant		40	Combined
CDK12_Mutation	A	4	Predictive	Sensitivity/Response	Olaparib	castration-resistant prostate carcinoma	80909	PROSTATE	prostate cancer	10283	2633	2764			40	Unknown
PALB2_Mutation	A	4	Predictive	Sensitivity/Response	Olaparib	castration-resistant prostate carcinoma	80909	PROSTATE	prostate cancer	10283	2628	2759			40	Unknown
KMT2A::MLLT3	A	4	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	428	432	transcript_fusion		40	Somatic
PAX8_Expression	A	4	Diagnostic	Positive		female reproductive organ cancer	120	GYN	female reproductive organ cancer	120	671	683	N/A		40	N/A
ESR1_Mutation	A	4	Predictive	Sensitivity/Response	Elacestrant	breast cancer	1612	BREAST	breast cancer	1612	3778	3910			30	Somatic
.::RET	A	4	Predictive	Sensitivity/Response	Selpercatinib	solid tumor	NA	SOLID	cancer	162	4424	1687	transcript_fusion		0	Somatic
FGFR2::.	A	4	Predictive	Sensitivity/Response	Erdafitinib	transitional cell carcinoma	2671	TCC	cancer	162	5201	4612	transcript_fusion		0	Somatic
IDH1_Mutation	A	4	Predictive	Sensitivity/Response	Vorasidenib	glioma	60108	GLIOMA	central nervous system cancer	3620	4756	645	transcript_variant		0	Somatic
PIK3CA_E545A	A	4	Predictive	Sensitivity/Response	Fulvestrant, Alpelisib	breast cancer	1612	BREAST	breast cancer	1612	5296	882	missense_variant		0	Somatic
.::ALK	A	3	Predictive	Sensitivity/Response	Crizotinib	inflammatory myofibroblastic tumor	50905	IMT	cancer	162	495	499	transcript_fusion	ALK Fusion	798	Somatic
FLT3_ITD	A	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
ETV6::NTRK3	A	3	Predictive	Sensitivity/Response	Larotrectinib	solid tumor	NA	SOLID	cancer	162	779	801	transcript_fusion		314	Somatic
ZFTA::RELA	A	3	Diagnostic	Positive		supratentorial ependymoma, zfta fusion-positive	81252	EPM	central nervous system cancer	3620	4548	4528	transcript_fusion		103	Somatic
IDH1_Mutation	A	3	Predictive	Sensitivity/Response	Ivosidenib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	641	645	transcript_variant		90.5	Somatic
PIK3CA_E542K	A	3	Predictive	Sensitivity/Response	Alpelisib, Fulvestrant	breast cancer	1612	BREAST	breast cancer	1612	103	103	missense_variant		75.5	Somatic
FIP1L1::PDGFRA	A	3	Predictive	Sensitivity/Response	Imatinib	myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1	80164	MLNER	hematologic cancer	2531	570	574	transcript_fusion		63.5	Somatic
EGFR_G719A	A	3	Predictive	Sensitivity/Response	Afatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4499	999	missense_variant		50	Somatic
EZH2_Activating_Mutation	A	3	Predictive	Sensitivity/Response	Tazemetostat	follicular lymphoma	50873	FLC	hematologic cancer	2531	3605	3737			35	Somatic
CHEK2_mutation	A	3	Predictive	Sensitivity/Response	Olaparib	castration-resistant prostate carcinoma	80909	PROSTATE	prostate cancer	10283	4386	4436			30	Unknown
RAD54L_Mutation	A	3	Predictive	Sensitivity/Response	Olaparib	castration-resistant prostate carcinoma	80909	PROSTATE	prostate cancer	10283	4388	4438			30	Unknown
AKT1_Mutation	A	3	Predictive	Sensitivity/Response	Fulvestrant, Capivasertib	breast cancer	1612	BREAST	breast cancer	1612	5065	4906			0	Somatic
BRAF_V600E	B	5	Predictive	Sensitivity/Response	Trametinib, Dabrafenib, Vemurafenib, Cobimetinib	melanoma	1909	MEL	cancer	162	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	5	Predictive	Sensitivity/Response	Binimetinib, Vemurafenib, Irinotecan, Dabrafenib, Panitumumab, Trametinib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	5	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	5	Prognostic	Poor Outcome		thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	5	Diagnostic	Positive		thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	12	12	missense_variant		1378.5	Somatic
ERBB2_AMP	B	5	Predictive	Sensitivity/Response	Docetaxel, Pertuzumab, Lapatinib, Capecitabine, Trastuzumab Emtansine, Afatinib	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	302	306	transcript_amplification		891	Somatic
DNMT3A_R882	B	5	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	5	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	5	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	5	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
BRAF_V600	B	5	Predictive	Sensitivity/Response	Trametinib, Dabrafenib	melanoma	1909	MEL	cancer	162	17	17	protein_altering_variant	Other BRAF V600's	460	Somatic
NPM1_EXON_12_MUTATION	B	5	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
FLT3_ITD	B	5	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	5	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
TP53_Mutation	B	5	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	5	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	5	Prognostic	Poor Outcome		medulloblastoma shh activated	80703	MBL	central nervous system cancer	3620	222	222	protein_altering_variant		437	N/A
EGFR_L858R	B	5	Predictive	Sensitivity/Response	Dacomitinib, Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	33	33	missense_variant		379	Somatic
EGFR_Mutation	B	5	Predictive	Sensitivity/Response	Gefitinib, Afatinib, Erlotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	438	442	inframe_variant		260	Somatic
NRAS_Mutation	B	5	Predictive	Sensitivity/Response	Binimetinib, Ribociclib	skin melanoma	8923	MEL	skin cancer	4159	208	208	transcript_variant,gain_of_function_variant		213	Somatic
IDH1_R132	B	5	Prognostic	Better Outcome		glioblastoma	3068	GB	central nervous system cancer	3620	58	58	protein_altering_variant		199	Somatic
IDH1_R132	B	5	Prognostic	Better Outcome		astrocytoma	3069	ASTR	central nervous system cancer	3620	58	58	protein_altering_variant		199	Somatic
BCOR_ITD_	B	5	Diagnostic	Positive		kidney clear cell sarcoma	4880	CCSK	kidney cancer	263	4547	4527	tandem_duplication		165	Somatic
ABL1_T315I	B	5	Predictive	Sensitivity/Response	Ponatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4373	2	missense_variant	Imatinib Resistance	149	Somatic
MGMT_Promoter_Methylation	B	5	Prognostic	Better Outcome		glioblastoma	3068	GB	central nervous system cancer	3620	85	85	N/A		136	Somatic
SF3B1_Mutation	B	5	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	215	215	protein_altering_variant		130	Somatic
ABL1_F317L	B	5	Predictive	Resistance	Dasatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4376	1028	missense_variant		121.5	Somatic
KIAA1549::BRAF	B	5	Diagnostic	Positive		pilocytic astrocytoma	4851	PAST	central nervous system cancer	3620	614	618	transcript_fusion	BRAF Fusions	109.5	Somatic
IDH2_R172	B	5	Prognostic	Better Outcome		glioblastoma	3068	GB	central nervous system cancer	3620	199	199	protein_altering_variant		105	Somatic
IDH2_R172	B	5	Prognostic	Better Outcome		astrocytoma	3069	ASTR	central nervous system cancer	3620	199	199	protein_altering_variant		105	Somatic
ASXL1_Mutation	B	5	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	177	177	protein_altering_variant		100	Somatic
BAP1_Mutation	B	5	Prognostic	Poor Outcome		clear cell renal cell carcinoma	4467	CCRCC	kidney cancer	263	183	183	protein_altering_variant,loss_of_function_variant		98.5	Somatic
BAP1_Mutation	B	5	Prognostic	Poor Outcome		renal cell carcinoma	4450	RCC	kidney cancer	263	183	183	protein_altering_variant,loss_of_function_variant		98.5	Somatic
BAP1_Mutation	B	5	Prognostic	Poor Outcome		clear cell renal cell carcinoma	4467	CCRCC	kidney cancer	263	183	183	protein_altering_variant,loss_of_function_variant		98.5	Somatic
EWSR1::FLI1	B	5	Diagnostic	Positive		ewing sarcoma	3369	ES	bone cancer	184	687	706	transcript_fusion		90	Somatic
RET_M918T	B	5	Diagnostic	Positive		thyroid gland medullary carcinoma	3973	THME	thyroid cancer	1781	113	113	missense_variant	RET Motesanib Resistance	86	Somatic
DNAJB1::PRKACA	B	5	Diagnostic	Positive		fibrolamellar carcinoma	5015	FLC	liver cancer	3571	31	31	transcript_fusion		75	Somatic
BRAF_V600D	B	5	Predictive	Sensitivity/Response	Dabrafenib	melanoma	1909	MEL	cancer	162	11	11	missense_variant	Other BRAF V600's	47	Somatic
BRAF_Non-V600	B	5	Prognostic	Better Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	2281	2408	protein_altering_variant		45	Somatic
TERT_C228T	B	5	Prognostic	Poor Outcome		thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	244	248	regulatory_region_variant		40	Somatic
EWSR1::ERG	B	5	Diagnostic	Positive		ewing sarcoma	3369	ES	bone cancer	184	4668	4602	transcript_fusion		32.5	Somatic
ERBB2_Exon_20_Insertion	B	5	Predictive	Sensitivity/Response	Trastuzumab Deruxtecan	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	2723	2854			25	Somatic
CEBPA_BIALLELIC_INACTIVATION	B	5	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	590	594	loss_of_function_variant		25	Somatic
PLCG2_MUTATION	B	5	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	2046	2170			25	Somatic
SRSF2_MUTATION	B	5	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	591	595	gene_variant		25	Somatic
SMARCA4_MUTATION	B	5	Diagnostic	Positive		small-cell carcinoma of the ovary of hypercalcemic type	7651	SCCO	ovarian cancer	2394	217	217	gene_variant,loss_of_function_variant		25	Somatic
IGH::CRLF2	B	5	Prognostic	Poor Outcome		childhood b-cell acute lymphoblastic leukemia	80146	BLL	hematologic cancer	2533	2532	2663	transcript_fusion		20	Somatic
BRAF_V600E	B	4	Predictive	Resistance	FOLFOX-4 Regimen, Cetuximab, Panitumumab, Oxaliplatin, Irinotecan, Bevacizumab, Capecitabine	colorectal cancer	9256	COADREAD	large intestine cancer	5672	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	4	Predictive	Sensitivity/Response	Trametinib, Dabrafenib	skin melanoma	8923	MEL	skin cancer	4159	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	4	Predictive	Sensitivity/Response	Vemurafenib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	4	Predictive	Sensitivity/Response	Trametinib, Dabrafenib, Vemurafenib	thyroid gland anaplastic carcinoma	80522	THAP	thyroid cancer	1781	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	4	Predictive	Sensitivity/Response	Vemurafenib	langerhans cell sarcoma	7146	LCS	hematologic cancer	2531	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	4	Predictive	Sensitivity/Response	Vemurafenib	thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	4	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	4	Prognostic	Poor Outcome		thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	4	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	4	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	4	Prognostic	Poor Outcome		childhood low-grade glioma	80830	LGG	central nervous system cancer	3620	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	4	Prognostic	Poor Outcome		thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	4	Diagnostic	Positive		hairy cell leukemia	285	CLL	hematologic cancer	2531	12	12	missense_variant		1378.5	Somatic
ERBB2_AMP	B	4	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	302	306	transcript_amplification		891	N/A
ERBB2_AMP	B	4	Predictive	Sensitivity/Response	Trastuzumab, Lapatinib, Pertuzumab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	302	306	transcript_amplification		891	N/A
ERBB2_AMP	B	4	Prognostic	Poor Outcome		endometrial serous adenocarcinoma	5750	USC	uterine cancer	363	302	306	transcript_amplification		891	Somatic
.::ALK	B	4	Predictive	Sensitivity/Response	Lorlatinib, Pemetrexed	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	495	499	transcript_fusion	ALK Fusion	798	Somatic
KRAS_Mutation	B	4	Predictive	Sensitivity/Response	Docetaxel, Selumetinib, Abemaciclib, Pemetrexed, Trametinib, Atezolizumab, Nivolumab	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	332	336	protein_altering_variant		545.5	Somatic
KRAS_Mutation	B	4	Predictive	Resistance	Bevacizumab, Chemotherapy	colorectal cancer	9256	COADREAD	large intestine cancer	5672	332	336	protein_altering_variant		545.5	Somatic
KRAS_Mutation	B	4	Prognostic	Poor Outcome		lung adenocarcinoma	3910	LUAD	lung cancer	1324	332	336	protein_altering_variant		545.5	Somatic
DNMT3A_R882	B	4	Predictive	Sensitivity/Response	Idarubicin	acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
BRAF_V600	B	4	Predictive	Sensitivity/Response	Vemurafenib	cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	17	17	protein_altering_variant	Other BRAF V600's	460	Somatic
BRAF_V600	B	4	Predictive	Sensitivity/Response	Cetuximab, Encorafenib, Alpelisib, Vemurafenib, Irinotecan	colorectal cancer	9256	COADREAD	large intestine cancer	5672	17	17	protein_altering_variant	Other BRAF V600's	460	Somatic
BRAF_V600	B	4	Diagnostic	Positive		melanoma	1909	MEL	cancer	162	17	17	protein_altering_variant	Other BRAF V600's	460	Somatic
NPM1_EXON_12_MUTATION	B	4	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	4	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	4	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	4	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
FLT3_ITD	B	4	Predictive	Sensitivity/Response	Lestaurtinib, Sorafenib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	4	Predictive	Resistance	Anthracycline Antineoplastic Antibiotic, Tretinoin	acute promyelocytic leukemia	60318	APL	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
PIK3CA_Mutation	B	4	Predictive	Resistance	Anti-EGFR Monoclonal Antibody, Cetuximab, Panitumumab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	B	4	Predictive	Sensitivity/Response	Everolimus	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	B	4	Predictive	Sensitivity/Response	Capivasertib, Copanlisib	cancer	162	CANCER	cancer	162	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
TP53_Mutation	B	4	Predictive	Sensitivity/Response	Eprenetapopt, Azacitidine	myelodysplastic syndrome	50908	MDS	hematologic cancer	2531	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	4	Prognostic	Poor Outcome		esophagus squamous cell carcinoma	3748	ESCC	esophageal cancer	5041	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	4	Prognostic	Poor Outcome		b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	4	Prognostic	Poor Outcome		myelodysplastic syndrome	50908	MDS	hematologic cancer	2531	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	4	Prognostic	Poor Outcome		myeloid neoplasm	70004	MYELOID	hematologic cancer	2531	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	4	Prognostic	Poor Outcome		head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	4	Prognostic	Poor Outcome		b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	4	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	222	222	protein_altering_variant		437	Somatic
EGFR_Exon_19_Deletion	B	4	Predictive	Sensitivity/Response	Erlotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	4432	133	inframe_deletion		410	Somatic
EGFR_T790M	B	4	Predictive	Resistance	Dacomitinib, Afatinib, Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	34	34	missense_variant	EGFR TKI Resistance	406.25	Somatic
EGFR_T790M	B	4	Predictive	Sensitivity/Response	Rociletinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	34	34	missense_variant	EGFR TKI Resistance	406.25	Somatic
EGFR_T790M	B	4	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	34	34	missense_variant	EGFR TKI Resistance	406.25	Somatic
EGFR_T790M	B	4	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	34	34	missense_variant	EGFR TKI Resistance	406.25	Somatic
EGFR_L858R	B	4	Predictive	Sensitivity/Response	Afatinib, Gefitinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	33	33	missense_variant		379	Somatic
BCR::ABL1	B	4	Diagnostic	Positive		acute myeloid leukemia with bcr::abl1 fusion	80976	AMLBCRABL1	hematologic cancer	2531	1	1	transcript_fusion	ABL1 fusions in B-ALL	353.5	Somatic
BCR::ABL1	B	4	Diagnostic	Positive		acute myeloid leukemia with bcr::abl1 fusion	80976	AMLBCRABL1	hematologic cancer	2531	1	1	transcript_fusion	ABL1 fusions in B-ALL	353.5	Somatic
BCR::ABL1	B	4	Diagnostic	Positive		acute myeloid leukemia with bcr::abl1 fusion	80976	AMLBCRABL1	hematologic cancer	2531	1	1	transcript_fusion	ABL1 fusions in B-ALL	353.5	Somatic
BCR::ABL1	B	4	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma with bcr-abl1	80643	BLLBCRABL1	hematologic cancer	2531	1	1	transcript_fusion	ABL1 fusions in B-ALL	353.5	Somatic
BCR::ABL1	B	4	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma with bcr-abl1	80643	BLLBCRABL1	hematologic cancer	2531	1	1	transcript_fusion	ABL1 fusions in B-ALL	353.5	Somatic
CD274_Expression	B	4	Predictive	Sensitivity/Response	Nivolumab, Pembrolizumab	melanoma	1909	MEL	cancer	162	272	276	N/A		330	N/A
CD274_Expression	B	4	Predictive	Sensitivity/Response	Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	272	276	N/A		330	N/A
CD274_Expression	B	4	Predictive	Resistance	Radiation Therapy	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	272	276	N/A		330	N/A
CD274_Expression	B	4	Prognostic	Poor Outcome		cancer	162	CANCER	cancer	162	272	276	N/A		330	N/A
EGFR_Exon_19_Deletion	B	4	Predictive	Sensitivity/Response	Gefitinib, Dacomitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	133	133	inframe_deletion		318	Somatic
EGFR_Exon_19_Deletion	B	4	Predictive	Sensitivity/Response	Afatinib, Gefitinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	133	133	inframe_deletion		318	Somatic
EGFR_Exon_19_Deletion	B	4	Predictive	Resistance	Anti-PD1 Monoclonal Antibody, Anti-PD-L1 Monoclonal Antibody	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	133	133	inframe_deletion		318	Somatic
PTEN_DEL	B	4	Predictive	Resistance	Everolimus	bladder carcinoma	4007	BLADDER	urinary bladder cancer	11054	214	214	loss_of_function_variant		272	Somatic
PTEN_DEL	B	4	Predictive	Sensitivity/Response	Everolimus	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	214	214	loss_of_function_variant		272	Somatic
BRCA2_Loss-of-function	B	4	Predictive	Sensitivity/Response	Olaparib	prostate cancer	10283	PROSTATE	prostate cancer	10283	132	132	loss_of_function_variant	BRCA Germline Variants	261	Somatic
EGFR_Mutation	B	4	Predictive	Sensitivity/Response	Hyperthermic Intraperitoneal Chemotherapy, Cytoreductive Surgery	peritoneal mesothelioma	1788	PEMESO	peritoneum cancer	1725	438	442	inframe_variant		260	Somatic
EGFR_Mutation	B	4	Prognostic	Better Outcome		lung adenocarcinoma	3910	LUAD	lung cancer	1324	438	442	inframe_variant		260	Somatic
IKZF1_DEL	B	4	Predictive	Sensitivity/Response	Fludarabine, Daunorubicin, Imatinib, Cytarabine, Methotrexate	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	200	200	transcript_ablation		240	Somatic
IKZF1_DEL	B	4	Prognostic	Poor Outcome		b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	200	200	transcript_ablation		240	Somatic
IKZF1_DEL	B	4	Prognostic	Poor Outcome		b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	200	200	transcript_ablation		240	Somatic
IKZF1_DEL	B	4	Prognostic	Poor Outcome		b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	200	200	transcript_ablation		240	Somatic
IDH1_R132	B	4	Prognostic	Poor Outcome		myelodysplastic syndrome	50908	MDS	hematologic cancer	2531	58	58	protein_altering_variant		199	Somatic
.::RET	B	4	Predictive	Sensitivity/Response	Selpercatinib, Vandetanib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1595	1687	transcript_fusion		192.5	Somatic
.::RET	B	4	Predictive	Sensitivity/Response	Selpercatinib	thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	1595	1687	transcript_fusion		192.5	Somatic
KRAS_G12/G13	B	4	Predictive	Resistance	Trametinib, Gemcitabine	pancreatic adenocarcinoma	4074	PAAD	pancreatic cancer	1793	77	77	protein_altering_variant		191	Somatic
FGFR1_AMP	B	4	Prognostic	Poor Outcome		lung squamous cell carcinoma	3907	LUSC	lung cancer	1324	263	267	transcript_amplification		185.5	Somatic
FGFR1_AMP	B	4	Prognostic	Poor Outcome		cancer	162	CANCER	cancer	162	263	267	transcript_amplification		185.5	Somatic
CDKN2A_p16_Expression	B	4	Prognostic	Better Outcome		head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	268	272	N/A		180	N/A
KRAS_G12C	B	4	Predictive	Sensitivity/Response	Divarasib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	78	78	missense_variant	EGFR TKI Resistance	176.5	Somatic
EGFR_AMP	B	4	Predictive	Sensitivity/Response	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Gefitinib, Erlotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	190	190	transcript_amplification		173	Somatic
EGFR_AMP	B	4	Prognostic	Poor Outcome		head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	190	190	transcript_amplification		173	Somatic
KRAS_Exon_2_Mutation	B	4	Predictive	Resistance	Erlotinib, Gemcitabine	pancreatic cancer	1793	PANCREAS	pancreatic cancer	1793	75	75	missense_variant		168	Somatic
BRAF_Mutation	B	4	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	395	399	gene_variant,gain_of_function_variant		166	Somatic
BRAF_Mutation	B	4	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	395	399	gene_variant,gain_of_function_variant		166	Somatic
MYOD1_L122R	B	4	Prognostic	Poor Outcome		rhabdomyosarcoma	3247	RMS	muscle cancer	4045	2901	3032	missense_variant		165	Somatic
MYOD1_L122R	B	4	Prognostic	Poor Outcome		spindle cell rhabdomyosarcoma	3260	SCRMS	muscle cancer	4045	2901	3032	missense_variant		165	Somatic
MYOD1_L122R	B	4	Prognostic	Poor Outcome		spindle cell rhabdomyosarcoma	3260	SCRMS	muscle cancer	4045	2901	3032	missense_variant		165	Somatic
BCOR_ITD_	B	4	Diagnostic	Positive		central nervous system tumor with bcor internal tandem duplication	81315	CNS	central nervous system cancer	3620	4547	4527	tandem_duplication		165	Somatic
BCOR_ITD_	B	4	Diagnostic	Positive		kidney clear cell sarcoma	4880	CCSK	kidney cancer	263	4547	4527	tandem_duplication		165	Somatic
MYOD1_L122R	B	4	Diagnostic	Positive		spindle cell rhabdomyosarcoma	3260	SCRMS	muscle cancer	4045	2901	3032	missense_variant		165	Somatic
MYOD1_L122R	B	4	Diagnostic	Positive		spindle cell rhabdomyosarcoma	3260	SCRMS	muscle cancer	4045	2901	3032	missense_variant		165	Somatic
MYOD1_L122R	B	4	Diagnostic	Positive		spindle cell rhabdomyosarcoma	3260	SCRMS	muscle cancer	4045	2901	3032	missense_variant		165	Somatic
MYOD1_L122R	B	4	Diagnostic	Positive		spindle cell rhabdomyosarcoma	3260	SCRMS	muscle cancer	4045	2901	3032	missense_variant		165	Somatic
KRAS_G12D	B	4	Prognostic	Poor Outcome		pancreatic cancer	1793	PANCREAS	pancreatic cancer	1793	79	79	missense_variant	EGFR TKI Resistance	162	Somatic
ABL1_T315I	B	4	Predictive	Resistance	Imatinib, Dasatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4373	2	missense_variant	Imatinib Resistance	149	Somatic
EGFR_Overexpression	B	4	Predictive	Sensitivity/Response	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	193	193	N/A		145	N/A
SS18::SSX1	B	4	Prognostic	Poor Outcome		synovial sarcoma	5485	SYNS	connective tissue cancer	201	444	448	transcript_fusion	SYT-SSX fusions	145	Somatic
SS18::SSX1	B	4	Diagnostic	Positive		synovial sarcoma	5485	SYNS	connective tissue cancer	201	444	448	transcript_fusion	SYT-SSX fusions	145	Somatic
SS18::SSX1	B	4	Diagnostic	Positive		synovial sarcoma	5485	SYNS	connective tissue cancer	201	444	448	transcript_fusion	SYT-SSX fusions	145	Somatic
MGMT_Promoter_Methylation	B	4	Predictive	Sensitivity/Response	Carmustine	glioblastoma	3068	GB	central nervous system cancer	3620	85	85	N/A		136	Somatic
MGMT_Promoter_Methylation	B	4	Prognostic	Better Outcome		glioblastoma	3068	GB	central nervous system cancer	3620	85	85	N/A		136	Somatic
MGMT_Promoter_Methylation	B	4	Prognostic	Better Outcome		oligodendroglioma	3181	ODG	central nervous system cancer	3620	85	85	N/A		136	Somatic
.::NTRK1	B	4	Predictive	Sensitivity/Response	Larotrectinib	sarcoma	1115	SARCOMA	sarcoma	1115	415	419	transcript_fusion	NTRK1 Fusions	135	Somatic
SF3B1_Mutation	B	4	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	215	215	protein_altering_variant		130	Somatic
SF3B1_Mutation	B	4	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	215	215	protein_altering_variant		130	Somatic
FLT3_TKD_MUTATION	B	4	Predictive	Resistance	Sorafenib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	56	56			120	Somatic
FLT3_TKD_MUTATION	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	56	56			120	Somatic
TET2_Mutation	B	4	Prognostic	Better Outcome		myelodysplastic syndrome	50908	MDS	hematologic cancer	2531	157	157	gene_variant,loss_of_function_variant		120	Somatic
TET2_Mutation	B	4	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	157	157	gene_variant,loss_of_function_variant		120	Somatic
TET2_Mutation	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	157	157	gene_variant,loss_of_function_variant		120	Somatic
TET2_Mutation	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	157	157	gene_variant,loss_of_function_variant		120	Somatic
CCND1_Overexpression	B	4	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	20	20	N/A		116	N/A
CCND1_Overexpression	B	4	Prognostic	Poor Outcome		head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	20	20	N/A		116	N/A
CCND1_Overexpression	B	4	Prognostic	Poor Outcome		mantle cell lymphoma	50746	MCL	hematologic cancer	2531	20	20	N/A		116	N/A
CCND1_Overexpression	B	4	Diagnostic	Positive		breast cancer	1612	BREAST	breast cancer	1612	20	20	N/A		116	N/A
DNMT3A_Mutation	B	4	Prognostic	Poor Outcome		acute t cell leukemia	5603	ATL	hematologic cancer	2531	189	189	transcript_variant		115	Somatic
DNMT3A_Mutation	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	189	189	transcript_variant		115	Somatic
DNMT3A_Mutation	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	189	189	transcript_variant		115	Somatic
KRAS_G12	B	4	Prognostic	Poor Outcome		multiple myeloma	9538	MM	hematologic cancer	2531	76	76	protein_altering_variant		115	Somatic
RUNX1_Mutation	B	4	Predictive	Resistance	Cytarabine	acute myeloid leukemia	9119	AML	hematologic cancer	2531	155	155	transcript_variant,loss_of_function_variant		110	Somatic
RUNX1_Mutation	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	155	155	transcript_variant,loss_of_function_variant		110	Somatic
RUNX1_Mutation	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	155	155	transcript_variant,loss_of_function_variant		110	Somatic
RUNX1_Mutation	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	155	155	transcript_variant,loss_of_function_variant		110	Somatic
KIAA1549::BRAF	B	4	Prognostic	Better Outcome		childhood low-grade glioma	80830	LGG	central nervous system cancer	3620	614	618	transcript_fusion	BRAF Fusions	109.5	Somatic
KIAA1549::BRAF	B	4	Prognostic	Better Outcome		childhood low-grade glioma	80830	LGG	central nervous system cancer	3620	614	618	transcript_fusion	BRAF Fusions	109.5	Somatic
KIAA1549::BRAF	B	4	Diagnostic	Positive		pilocytic astrocytoma	4851	PAST	central nervous system cancer	3620	614	618	transcript_fusion	BRAF Fusions	109.5	Somatic
KRAS_G13D	B	4	Predictive	Sensitivity/Response	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	81	81	missense_variant		108.5	Somatic
KRAS_G13D	B	4	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	81	81	missense_variant		108.5	Somatic
BRAF_V600K	B	4	Predictive	Sensitivity/Response	Vemurafenib, Trametinib, Dabrafenib	melanoma	1909	MEL	cancer	162	559	563	missense_variant	Other BRAF V600's	107.5	Somatic
CEBPA_Mutation	B	4	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	29	29	transcript_variant,loss_of_function_variant		105	Somatic
CEBPA_Mutation	B	4	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	29	29	transcript_variant,loss_of_function_variant		105	Somatic
CEBPA_Mutation	B	4	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	29	29	transcript_variant,loss_of_function_variant		105	Somatic
IDH2_R172	B	4	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	199	199	protein_altering_variant		105	Somatic
TERT_Promoter_Mutation	B	4	Prognostic	Poor Outcome		glioblastoma	3068	GB	central nervous system cancer	3620	220	220	regulatory_region_variant		105	Somatic
IDH2_R172	B	4	Diagnostic	Positive		peripheral t-cell lymphoma	50749	PTCL	hematologic cancer	2531	199	199	protein_altering_variant		105	Somatic
JAK2_V617F	B	4	Predictive	Sensitivity/Response	Peginterferon Alfa-2b	polycythemia vera	8997	PV	hematologic cancer	2531	64	64	missense_variant,gain_of_function_variant		103	Somatic
ZFTA::RELA	B	4	Prognostic	Poor Outcome		supratentorial ependymoma, zfta fusion-positive	81252	EPM	central nervous system cancer	3620	4548	4528	transcript_fusion		103	Somatic
JAK2_V617F	B	4	Diagnostic	Positive		chronic myeloid leukemia	8552	CML	hematologic cancer	2531	64	64	missense_variant,gain_of_function_variant		103	Somatic
JAK2_V617F	B	4	Diagnostic	Positive		chronic myeloid leukemia	8552	CML	hematologic cancer	2531	64	64	missense_variant,gain_of_function_variant		103	Somatic
JAK2_V617F	B	4	Diagnostic	Positive		bone marrow cancer	4960	MYELOID	hematologic cancer	2531	64	64	missense_variant,gain_of_function_variant		103	Somatic
IDH2_Mutation	B	4	Prognostic	Better Outcome		chondrosarcoma	3371	CHS	connective tissue cancer	201	566	570	protein_altering_variant		101.5	Somatic
PDGFRA_D842V	B	4	Predictive	Resistance	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	99	99	missense_variant	Imatinib Resistance	100.5	Somatic
NRAS_Q61	B	4	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	94	94	missense_variant		100	Somatic
RRM1_Underexpression	B	4	Predictive	Sensitivity/Response	Gemcitabine, Cisplatin, Paclitaxel, Vinorelbine, Carboplatin	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1231	1257	N/A		100	N/A
ASXL1_Mutation	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	177	177	protein_altering_variant		100	Somatic
BAP1_Mutation	B	4	Predictive	Resistance	Everolimus, Sunitinib	renal cell carcinoma	4450	RCC	kidney cancer	263	183	183	protein_altering_variant,loss_of_function_variant		98.5	Somatic
IDH1_Mutation	B	4	Prognostic	Better Outcome		chondrosarcoma	3371	CHS	connective tissue cancer	201	641	645	transcript_variant		90.5	Somatic
EWSR1::FLI1	B	4	Diagnostic	Positive		ewing sarcoma of bone	3368	ES	bone cancer	184	687	706	transcript_fusion		90	Somatic
TCF3::PBX1	B	4	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma with tcf3-pbx1	80649	BLLTCF3PBX1	hematologic cancer	2531	4800	4690	transcript_fusion		90	Somatic
TCF3::PBX1	B	4	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma with tcf3-pbx1	80649	BLLTCF3PBX1	hematologic cancer	2531	4800	4690	transcript_fusion		90	Somatic
RET_M918T	B	4	Predictive	Sensitivity/Response	Cabozantinib, Sorafenib	thyroid gland medullary carcinoma	3973	THME	thyroid cancer	1781	113	113	missense_variant	RET Motesanib Resistance	86	Somatic
RET_M918T	B	4	Prognostic	Poor Outcome		thyroid gland medullary carcinoma	3973	THME	thyroid cancer	1781	113	113	missense_variant	RET Motesanib Resistance	86	Somatic
VHL_Mutation	B	4	Predictive	Sensitivity/Response	Everolimus	renal cell carcinoma	4450	RCC	kidney cancer	263	160	160	gene_variant,loss_of_function_variant		85	Somatic
VHL_Mutation	B	4	Prognostic	Better Outcome		clear cell renal cell carcinoma	4467	CCRCC	kidney cancer	263	160	160	gene_variant,loss_of_function_variant		85	Somatic
CALR_EXON_9_FRAMESHIFT	B	4	Predictive	Sensitivity/Response	Peginterferon Alfa-2a	essential thrombocythemia	2224	ET	hematologic cancer	2531	555	559	exon_variant		80	Somatic
CALR_EXON_9_FRAMESHIFT	B	4	Prognostic	Better Outcome		myelofibrosis	4971	PMF	hematologic cancer	2531	555	559	exon_variant		80	Somatic
CTNNB1_S45F	B	4	Prognostic	Poor Outcome		desmoid tumor	80366	DES	benign neoplasm	60072	1260	1286	missense_variant		80	Somatic
CTNNB1_S45F	B	4	Diagnostic	Positive		desmoid tumor	80366	DES	benign neoplasm	60072	1260	1286	missense_variant		80	Somatic
CTNNB1_S45F	B	4	Diagnostic	Positive		desmoid tumor	80366	DES	benign neoplasm	60072	1260	1286	missense_variant		80	Somatic
ERBB2_Overexpression	B	4	Predictive	Sensitivity/Response	Trastuzumab Emtansine	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	849	875	N/A		77.5	N/A
DNAJB1::PRKACA	B	4	Diagnostic	Positive		fibrolamellar carcinoma	5015	FLC	liver cancer	3571	31	31	transcript_fusion		75	Somatic
DNAJB1::PRKACA	B	4	Diagnostic	Positive		fibrolamellar carcinoma	5015	FLC	liver cancer	3571	31	31	transcript_fusion		75	Somatic
FOXL2_C134W	B	4	Diagnostic	Positive		granulosa cell tumor	2999	GRCT	sex cord-gonadal stromal tumor	192	198	198	missense_variant		70	Somatic
FUS::DDIT3	B	4	Diagnostic	Positive		liposarcoma	3382	LIPO	connective tissue cancer	201	703	722	transcript_fusion		70	Somatic
HEY1::NCOA2	B	4	Diagnostic	Positive		mesenchymal chondrosarcoma	4545	MCHS	connective tissue cancer	201	2454	2581	transcript_fusion		70	Somatic
HEY1::NCOA2	B	4	Diagnostic	Positive		mesenchymal chondrosarcoma	4545	MCHS	connective tissue cancer	201	2454	2581	transcript_fusion		70	Somatic
HEY1::NCOA2	B	4	Diagnostic	Positive		mesenchymal chondrosarcoma	4545	MCHS	connective tissue cancer	201	2454	2581	transcript_fusion		70	Somatic
EGFRvIII	B	4	Predictive	Sensitivity/Response	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Rindopepimut, Gefitinib, Erlotinib	glioblastoma	3068	GB	central nervous system cancer	3620	308	312	disruptive_inframe_deletion		69	Somatic
KIT_D816V	B	4	Predictive	Sensitivity/Response	Midostaurin	systemic mastocytosis	349	SM	hematopoietic system disease	74	65	65	missense_variant	KIT Exon 17	67	Somatic
KIT_D816V	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	65	65	missense_variant	KIT Exon 17	67	Somatic
KIT_D816V	B	4	Prognostic	Poor Outcome		systemic mastocytosis	349	SM	hematopoietic system disease	74	65	65	missense_variant	KIT Exon 17	67	Somatic
H3-3A_K28M	B	4	Predictive	Sensitivity/Response	Dordaviprone	glioma	60108	GLIOMA	central nervous system cancer	3620	2289	2416	non_conservative_missense_variant		65	Somatic
TP53_Overexpression	B	4	Predictive	Sensitivity/Response	Cisplatin, Etoposide, Mitomycin	stomach cancer	10534	STOMACH	stomach cancer	10534	1280	1306	N/A		65	N/A
.::TFE3	B	4	Diagnostic	Positive		renal cell carcinoma with mit translocations	81413	RCC	kidney cancer	263	3598	3730	transcript_fusion	MiT Family Translocation Renal Cell Carcinoma	65	Somatic
.::TFE3	B	4	Diagnostic	Positive		renal cell carcinoma with mit translocations	81413	RCC	kidney cancer	263	3598	3730	transcript_fusion	MiT Family Translocation Renal Cell Carcinoma	65	Somatic
.::TFE3	B	4	Diagnostic	Positive		renal cell carcinoma with mit translocations	81413	RCC	kidney cancer	263	3598	3730	transcript_fusion	MiT Family Translocation Renal Cell Carcinoma	65	Somatic
MET_Overexpression	B	4	Predictive	Resistance	Vemurafenib	skin melanoma	8923	MEL	skin cancer	4159	617	621	N/A		64	N/A
EGFR_Expression	B	4	Predictive	Sensitivity/Response	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	350	354	N/A		60	N/A
TP53_ALTERATION	B	4	Predictive	Resistance	Cisplatin, Carboplatin	ovarian cancer	2394	OVARY	ovarian cancer	2394	1281	1307			60	Somatic
PGR_Expression	B	4	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	210	210	N/A		60	N/A
TP53_ALTERATION	B	4	Prognostic	Poor Outcome		ovarian cancer	2394	OVARY	ovarian cancer	2394	1281	1307			60	Somatic
TP53_ALTERATION	B	4	Prognostic	Poor Outcome		rhabdomyosarcoma	3247	RMS	muscle cancer	4045	1281	1307			60	Somatic
CBFA2T3::GLIS2	B	4	Diagnostic	Positive		acute myeloid leukemia with cbfa2t3::glis2 fusion	9119	AMLCBFA2T3GLIS2	hematologic cancer	2531	2499	2630	transcript_fusion		60	Somatic
CBFA2T3::GLIS2	B	4	Diagnostic	Positive		acute myeloid leukemia with cbfa2t3::glis2 fusion	9119	AMLCBFA2T3GLIS2	hematologic cancer	2531	2499	2630	transcript_fusion		60	Somatic
CBFA2T3::GLIS2	B	4	Diagnostic	Positive		acute myeloid leukemia with cbfa2t3::glis2 fusion	9119	AMLCBFA2T3GLIS2	hematologic cancer	2531	2499	2630	transcript_fusion		60	Somatic
CBFA2T3::GLIS2	B	4	Diagnostic	Positive		acute myeloid leukemia with cbfa2t3::glis2 fusion	9119	AMLCBFA2T3GLIS2	hematologic cancer	2531	2499	2630	transcript_fusion		60	Somatic
ASPSCR1::TFE3	B	4	Diagnostic	Positive		alveolar soft part sarcoma	4239	ASPS	muscle cancer	4045	3490	3622	transcript_fusion		59	Somatic
ASPSCR1::TFE3	B	4	Diagnostic	Positive		alveolar soft part sarcoma	4239	ASPS	muscle cancer	4045	3490	3622	transcript_fusion		59	Somatic
AREG_Expression	B	4	Predictive	Sensitivity/Response	Panitumumab, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	311	315	N/A		58	N/A
PTEN_DEL	B	4	Prognostic	Poor Outcome		prostate adenocarcinoma	2526	PRAD	prostate cancer	10283	213	213	transcript_ablation		55	Somatic
PTEN_DEL	B	4	Prognostic	Poor Outcome		prostate cancer	10283	PROSTATE	prostate cancer	10283	213	213	transcript_ablation		55	Somatic
CTNNB1_Exon_3_Mutation	B	4	Diagnostic	Positive		childhood medulloblastoma	3869	MBL	central nervous system cancer	3620	2761	2892			55	Somatic
CTNNB1_T41A	B	4	Diagnostic	Positive		desmoid tumor	80366	DES	benign neoplasm	60072	1259	1285	missense_variant		55	Somatic
CTNNB1_T41A	B	4	Diagnostic	Positive		desmoid tumor	80366	DES	benign neoplasm	60072	1259	1285	missense_variant		55	Somatic
PAX7::FOXO1	B	4	Diagnostic	Positive		alveolar rhabdomyosarcoma	4051	ARMS	muscle cancer	4045	2456	2583	transcript_fusion		55	Somatic
PAX7::FOXO1	B	4	Diagnostic	Positive		alveolar rhabdomyosarcoma	4051	ARMS	muscle cancer	4045	2456	2583	transcript_fusion		55	Somatic
PTEN_Expression	B	4	Predictive	Sensitivity/Response	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib, Gefitinib	glioblastoma	3068	GB	central nervous system cancer	3620	309	313	N/A		54.5	N/A
CDKN2A_DEL	B	4	Prognostic	Poor Outcome		acute lymphoblastic leukemia	9952	ALL	hematologic cancer	2531	550	554	loss_of_function_variant		52.5	Somatic
PAX5_P80R	B	4	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma with pax5 p80r	81411	BLLPAX5P80R	hematologic cancer	2531	2566	2697			50	Somatic
SMARCB1_DEL	B	4	Diagnostic	Positive		atypical teratoid rhabdoid tumor	2129	ATRT	central nervous system cancer	3620	3071	3202	loss_of_function_variant		50	Somatic
FLT3_D835	B	4	Predictive	Resistance	Sorafenib, Quizartinib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	433	437	protein_altering_variant		46	Somatic
BRD4::NUTM1	B	4	Diagnostic	Positive		nut midline carcinoma	60463	NUTC	cancer	162	5152	4973	transcript_fusion		45.5	Somatic
PIK3CA_Exon_10_Mutation	B	4	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	106	106	exon_variant		45	Somatic
PIK3CA_Exon_21_Mutation	B	4	Prognostic	Better Outcome		breast cancer	1612	BREAST	breast cancer	1612	105	105	exon_variant		45	Somatic
EZH2_Y646	B	4	Diagnostic	Positive		diffuse large b-cell lymphoma	50745	DLBCL	hematologic cancer	2531	165	165	protein_altering_variant		45	Somatic
EZH2_Y646	B	4	Diagnostic	Positive		follicular lymphoma	50873	FLC	hematologic cancer	2531	165	165	protein_altering_variant		45	Somatic
SMO_Mutation	B	4	Predictive	Resistance	Vismodegib	basal cell carcinoma	2513	BCC	skin cancer	4159	296	300	coding_transcript_variant		44	Somatic
ERBB2_Y772_A775DUP	B	4	Predictive	Sensitivity/Response	Trastuzumab Deruxtecan	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	410	414	inframe_insertion		42	Somatic
CCNE1_Overexpression	B	4	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	24	24	N/A		42	N/A
CCNE1_Overexpression	B	4	Prognostic	Poor Outcome		gastric adenosquamous carcinoma	5635	STAS	stomach cancer	10534	24	24	N/A		42	N/A
BTK_C481S	B	4	Predictive	Resistance	Ibrutinib	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	168	168	missense_variant		40	Somatic
KRAS_Q61	B	4	Predictive	Resistance	Chemotherapy, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	203	203	protein_altering_variant		40	Somatic
STK11_Mutation	B	4	Predictive	Resistance	Pembrolizumab, Atezolizumab, Nivolumab	lung adenocarcinoma	3910	LUAD	lung cancer	1324	696	715	gene_variant		40	Somatic
KRAS_Q61	B	4	Prognostic	Poor Outcome		multiple myeloma	9538	MM	hematologic cancer	2531	203	203	protein_altering_variant		40	Somatic
MN1_Rearrangement	B	4	Prognostic	Better Outcome		astroblastoma, mn1-altered	80904	ASTB	central nervous system cancer	3620	5187	4993			40	Somatic
TP53_Truncating_Mutation	B	4	Prognostic	Poor Outcome		head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	223	223	frameshift_truncation		40	Somatic
FOXR2_Rearrangement	B	4	Diagnostic	Positive		cns neuroblastoma with foxr2 activation	80906	CNSNBL	central nervous system cancer	3620	4620	4575			40	Somatic
FOXR2_Rearrangement	B	4	Diagnostic	Positive		cns neuroblastoma with foxr2 activation	80906	CNSNBL	central nervous system cancer	3620	4620	4575			40	Somatic
MN1_Rearrangement	B	4	Diagnostic	Positive		astroblastoma, mn1-altered	80904	ASTB	central nervous system cancer	3620	5187	4993			40	Somatic
MYB::QKI	B	4	Diagnostic	Positive		angiocentric glioma	81261	ANGL	central nervous system cancer	3620	4217	4327	transcript_fusion		40	Somatic
MYB::QKI	B	4	Diagnostic	Positive		angiocentric glioma	81261	ANGL	central nervous system cancer	3620	4217	4327	transcript_fusion		40	Somatic
MYBL1_Rearrangement	B	4	Diagnostic	Positive		isomorphic diffuse glioma	4857	DASTR	central nervous system cancer	3620	4878	4743			40	Somatic
MYBL1_Rearrangement	B	4	Diagnostic	Positive		diffuse astrocytoma, myb- or mybl1-altered	81279	DASTR	central nervous system cancer	3620	4878	4743			40	Somatic
WWTR1::CAMTA1	B	4	Diagnostic	Positive		malignant epithelioid hemangioendothelioma	80190	EHAE	sarcoma	1115	723	742	transcript_fusion		40	Somatic
WWTR1::CAMTA1	B	4	Diagnostic	Positive		malignant epithelioid hemangioendothelioma	80190	EHAE	sarcoma	1115	723	742	transcript_fusion		40	Somatic
WWTR1::CAMTA1	B	4	Diagnostic	Positive		malignant epithelioid hemangioendothelioma	80190	EHAE	sarcoma	1115	723	742	transcript_fusion		40	Somatic
YAP1::TFE3	B	4	Diagnostic	Positive		malignant epithelioid hemangioendothelioma	80190	EHAE	sarcoma	1115	4622	4577	transcript_fusion		40	Somatic
ATRX_Underexpression	B	4	Prognostic	Poor Outcome		childhood low-grade glioma	80830	LGG	central nervous system cancer	3620	644	648	N/A		39	Somatic
AURKA_Overexpression	B	4	Predictive	Resistance	Cisplatin	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	181	181	N/A		38	N/A
FGFR2::BICC1	B	4	Diagnostic	Positive		cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	763	782	transcript_fusion		38	Somatic
PAX3::FOXO1	B	4	Diagnostic	Positive		alveolar rhabdomyosarcoma	4051	ARMS	muscle cancer	4045	2455	2582	transcript_fusion		38	Somatic
PAX3::FOXO1	B	4	Diagnostic	Positive		alveolar rhabdomyosarcoma	4051	ARMS	muscle cancer	4045	2455	2582	transcript_fusion		38	Somatic
ERBB2_Mutation	B	4	Predictive	Sensitivity/Response	Neratinib	breast cancer	1612	BREAST	breast cancer	1612	662	666	missense_variant		37.5	Somatic
CIC::DUX4	B	4	Diagnostic	Positive		cic-rearranged sarcoma	81250	RCSNOS	sarcoma	1115	3121	3252	transcript_fusion		37.5	Somatic
ERBB3_Overexpression	B	4	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	285	289	N/A		37	N/A
NRG1_Expression	B	4	Predictive	Sensitivity/Response	Patritumab	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	310	314	N/A		37	N/A
EREG_EXPRESSION	B	4	Predictive	Sensitivity/Response	Panitumumab, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	314	318	N/A		35.5	N/A
ERBB2_SERUM_LEVELS	B	4	Predictive	Sensitivity/Response	Lapatinib	breast cancer	1612	BREAST	breast cancer	1612	412	416	N/A		35	N/A
CBFB::MYH11	B	4	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	427	431	transcript_fusion		35	Somatic
EZH2_Mutation	B	4	Prognostic	Better Outcome		follicular lymphoma	50873	FLC	hematologic cancer	2531	163	163	protein_altering_variant		35	Somatic
MKI67_EXPRESSION	B	4	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	620	624	N/A		35	N/A
NOTCH1_P2514FS	B	4	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	207	207	frameshift_truncation		35	Somatic
TP53_DNA_Binding_Domain_Mutation	B	4	Prognostic	Poor Outcome		oral squamous cell carcinoma	50866	OCSC	head and neck cancer	11934	238	242	DNA_binding_site		35	Somatic
FUS::CREB3L2	B	4	Diagnostic	Positive		low-grade fibromyxoid sarcoma	80534	LGFMS	connective tissue cancer	201	5155	4975	transcript_fusion		35	Somatic
AKT1_E17K	B	4	Predictive	Sensitivity/Response	Capivasertib	cancer	162	CANCER	cancer	162	4	4	missense_variant		33.5	Somatic
KRAS_G12R	B	4	Prognostic	Poor Outcome		pancreatic cancer	1793	PANCREAS	pancreatic cancer	1793	526	530	missense_variant		32.5	Somatic
ZMIZ1::ABL1	B	4	Prognostic	Better Outcome		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	3138	3269	transcript_fusion	ABL1 fusions in B-ALL	32.5	Somatic
ETV6::ABL1	B	4	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2448	2575	transcript_fusion	ABL1 fusions in B-ALL	32.5	Somatic
MYD88_L265P	B	4	Predictive	Sensitivity/Response	Ibrutinib	lymphoplasmacytic lymphoma	60901	LPL	hematologic cancer	2531	420	424	missense_variant,gain_of_function_variant		31	Somatic
EGFR_Rare_Exon_18-21_Mutation	B	4	Predictive	Sensitivity/Response	Erlotinib, Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1739	1863	exon_variant		30	Somatic
STAG2_MUTATION	B	4	Prognostic	Poor Outcome		ewing sarcoma of bone	3368	ES	bone cancer	184	665	669	protein_altering_variant		30	N/A
FGFR2_Mutation	B	4	Predictive	Sensitivity/Response	Infigratinib	cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	507	511	transcript_variant,gain_of_function_variant		28	Somatic
NT5C2_K359Q	B	4	Prognostic	Poor Outcome		acute lymphoblastic leukemia	9952	ALL	hematologic cancer	2531	235	239	missense_variant		28	Somatic
COL1A1::PDGFB	B	4	Diagnostic	Positive		dermatofibrosarcoma protuberans	3507	DFSP	connective tissue cancer	201	2841	2972	transcript_fusion		27.5	Somatic
NPM1::ALK	B	4	Predictive	Sensitivity/Response	Crizotinib	anaplastic large cell lymphoma	50744	ALCL	hematologic cancer	2531	509	513	transcript_fusion	ALK Fusion	27	Somatic
CCNE1_AMP	B	4	Prognostic	Poor Outcome		ovarian carcinoma	4001	OVT	ovarian cancer	2394	187	187	transcript_amplification		27	Somatic
PTCH1_Mutation	B	4	Predictive	Sensitivity/Response	Sonidegib	medulloblastoma	50902	MBL	central nervous system cancer	3620	297	301	gene_variant,loss_of_function_variant		25	Somatic
.::NUTM1	B	4	Diagnostic	Positive		nut midline carcinoma	60463	NUTC	cancer	162	5151	4972	transcript_fusion		25	Somatic
.::NUTM1	B	4	Diagnostic	Positive		nut midline carcinoma	60463	NUTC	cancer	162	5151	4972	transcript_fusion		25	Somatic
CDK6_Overexpression	B	4	Predictive	Resistance	Fulvestrant	estrogen-receptor positive breast cancer	60075	BRCA	breast cancer	1612	598	602	N/A		24	N/A
GAS6_EXPRESSION	B	4	Prognostic	Poor Outcome		oral squamous cell carcinoma	50866	OCSC	head and neck cancer	11934	648	652	N/A		23	N/A
FGFR2::AHCYL1	B	4	Diagnostic	Positive		cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	764	783	transcript_fusion		23	Somatic
SMARCA4_INACTIVATING_MUTATION	B	4	Prognostic	Poor Outcome		lung adenocarcinoma	3910	LUAD	lung cancer	1324	218	218	loss_of_function_variant		20.75	Somatic
ALK_Mutation	B	4	Predictive	Sensitivity/Response	Ceritinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	508	512	gene_variant,gain_of_function_variant		20	Somatic
AR_Mutation	B	4	Predictive	Resistance	Bicalutamide, Flutamide, Cyproterone Acetate, Nilutamide	prostate cancer	10283	PROSTATE	prostate cancer	10283	596	600	transcript_variant		20	Somatic
BIRC5_Overexpression	B	4	Predictive	Resistance	Trastuzumab	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	574	578	N/A		20	N/A
EGFR_Gain-of-function	B	4	Predictive	Sensitivity/Response	Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1641	1765			20	Somatic
EGFR_Wildtype	B	4	Predictive	Resistance	Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	2050	2174	wild_type		20	Somatic
ESR1_Overexpression	B	4	Predictive	Sensitivity/Response	Palbociclib, Letrozole	breast cancer	1612	BREAST	breast cancer	1612	603	607	N/A		20	N/A
EZH2_A682G	B	4	Predictive	Sensitivity/Response	Tazemetostat	follicular lymphoma	50873	FLC	hematologic cancer	2531	4344	4415	missense_variant		20	Somatic
FGF19_Overexpression	B	4	Predictive	Sensitivity/Response	Fisogatinib	hepatocellular carcinoma	684	HCC	liver cancer	3571	2653	2784			20	N/A
FOXP3_EXPRESSION	B	4	Predictive	Sensitivity/Response	Epirubicin	breast cancer	1612	BREAST	breast cancer	1612	390	394	N/A		20	N/A
HSPA5_EXPRESSION	B	4	Predictive	Sensitivity/Response	Fluorouracil	colorectal cancer	9256	COADREAD	large intestine cancer	5672	382	386	N/A		20	N/A
IGF1R_Overexpression	B	4	Predictive	Sensitivity/Response	Exemestane, Metformin	breast cancer	1612	BREAST	breast cancer	1612	3128	3259			20	N/A
PDCD4_EXPRESSION	B	4	Predictive	Sensitivity/Response	Paclitaxel	lung cancer	1324	LUNG	lung cancer	1324	333	337	N/A		20	N/A
PML_B2_DOMAIN_MUTATION	B	4	Predictive	Resistance	Tretinoin	acute promyelocytic leukemia	60318	APL	hematologic cancer	2531	457	461	missense_variant	PML-RARa B2 Domain	20	Somatic
SLC29A1_Overexpression	B	4	Predictive	Sensitivity/Response	Gemcitabine	pancreatic adenocarcinoma	4074	PAAD	pancreatic cancer	1793	3596	3728			20	N/A
ASXL1_EXON_12_MUTATION	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	553	557	exon_variant		20	Somatic
ATR_I774FS	B	4	Prognostic	Poor Outcome		endometrial cancer	1380	UCEC	uterine cancer	363	267	271	frameshift_truncation		20	Somatic
AXL_EXPRESSION	B	4	Prognostic	Poor Outcome		esophagus squamous cell carcinoma	3748	ESCC	esophageal cancer	5041	647	651	N/A		20	N/A
BCL2_Overexpression	B	4	Prognostic	Poor Outcome		diffuse large b-cell lymphoma	50745	DLBCL	hematologic cancer	2531	152	152	N/A		20	N/A
BTK_MUTATION	B	4	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	2045	2169			20	Somatic
CD44_CD44v6	B	4	Prognostic	Poor Outcome		ovarian cancer	2394	OVARY	ovarian cancer	2394	3241	3373			20	Somatic
CDKN2A_DEL	B	4	Prognostic	Poor Outcome		childhood low-grade glioma	80830	LGG	central nervous system cancer	3620	2523	2654			20	Somatic
CDKN2B_METHYLATION	B	4	Prognostic	Poor Outcome		acute promyelocytic leukemia	60318	APL	hematologic cancer	2531	765	784	N/A		20	Somatic
CDX2_EXPRESSION	B	4	Prognostic	Better Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	406	410	N/A		20	N/A
EGFR_Copy_Number_Variation	B	4	Prognostic	Poor Outcome		head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	191	191	copy_number_change		20	Somatic
EWSR1::FLI1	B	4	Prognostic	Better Outcome		ewing sarcoma	3369	ES	bone cancer	184	164	164	transcript_fusion		20	Somatic
EZH2_Overexpression	B	4	Prognostic	Poor Outcome		cancer	162	CANCER	cancer	162	287	291	N/A		20	N/A
H3-3A_MUTATION	B	4	Prognostic	Poor Outcome		childhood low-grade glioma	80830	LGG	central nervous system cancer	3620	2521	2652			20	Somatic
IGH::CRLF2	B	4	Prognostic	Poor Outcome		b-cell adult acute lymphocytic leukemia	60592	BLL	hematologic cancer	2531	2532	2663	transcript_fusion		20	Somatic
IKZF1_IKZF1_deletion_and_mutation	B	4	Prognostic	Poor Outcome		childhood b-cell acute lymphoblastic leukemia	80146	BLL	hematologic cancer	2533	2613	2744			20	Somatic
KRAS_G13	B	4	Prognostic	Poor Outcome		multiple myeloma	9538	MM	hematologic cancer	2531	80	80	missense_variant,inframe_insertion		20	Somatic
LRP1B_DEL	B	4	Prognostic	Poor Outcome		glioblastoma	3068	GB	central nervous system cancer	3620	643	647	transcript_ablation		20	N/A
MYB_AMP	B	4	Prognostic	Better Outcome		childhood low-grade glioma	80830	LGG	central nervous system cancer	3620	2524	2655			20	Somatic
NOTCH1_D1642H	B	4	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	135	135	missense_variant		20	Somatic
NOTCH1_R2327W	B	4	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	136	136	missense_variant		20	Somatic
NOTCH1_S2275FS	B	4	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	138	138	plus_1_frameshift_variant		20	Somatic
NOTCH1_V2444FS	B	4	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	137	137	frameshift_variant		20	Somatic
NRAS_G12/G13	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	592	596	protein_altering_variant		20	Somatic
NT5C2_Mutation	B	4	Prognostic	Poor Outcome		childhood acute lymphocytic leukemia	80144	ALL	hematologic cancer	2533	2767	2898			20	Somatic
NTRK1_Overexpression	B	4	Prognostic	Better Outcome		neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	834	860	N/A		20	N/A
NUP98::NSD1	B	4	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	2466	2593	transcript_fusion		20	Somatic
PRPS1_PRPS1_MUTATION	B	4	Prognostic	Poor Outcome		b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2785	2916			20	Somatic
STK11_EXON_1-2_MUTATION	B	4	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	299	303	exon_variant		20	Somatic
U2AF1_MUTATION	B	4	Prognostic	Poor Outcome		myelofibrosis	4971	PMF	hematologic cancer	2531	517	521	protein_altering_variant		20	Somatic
.::TFEB	B	4	Diagnostic	Positive		renal cell carcinoma with mit translocations	81413	RCC	kidney cancer	263	4747	4646	transcript_fusion		20	Somatic
AKAP9::BRAF	B	4	Diagnostic	Positive		thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	184	184	transcript_fusion	BRAF Fusions	20	Somatic
BCL2_reg_e@[IGH]::BCL2	B	4	Diagnostic	Positive		diffuse large b-cell lymphoma	50745	DLBCL	hematologic cancer	2531	151	151	transcript_regulatory_region_fusion		20	Somatic
DICER1_E1705K	B	4	Diagnostic	Positive		sertoli-leydig cell tumor	2997	SLCT	sex cord-gonadal stromal tumor	192	1926	2050	missense_variant		20	Somatic
FGFR1_Internal_Duplication	B	4	Diagnostic	Positive		childhood low-grade glioma	80830	LGG	central nervous system cancer	3620	2528	2659			20	Somatic
H3-3A_G34W	B	4	Diagnostic	Positive		bone giant cell tumor	4305	GCTB	bone cancer	184	2294	2421			20	Somatic
H3-3B_K36M	B	4	Diagnostic	Positive		chondroblastoma	2649	CHBL	connective tissue cancer	201	2293	2420			20	Somatic
REL_AMP	B	4	Diagnostic	Positive		diffuse large b-cell lymphoma	50745	DLBCL	hematologic cancer	2531	154	154	transcript_amplification		20	Somatic
STAT3_SH2_DOMAIN_MUTATION	B	4	Diagnostic	Positive		t-cell large granular lymphocyte leukemia	50751	TLGL	hematologic cancer	2531	407	411	protein_altering_variant		20	Somatic
TOP1_AMP	B	4	Predictive	Sensitivity/Response	Cetuximab, FOLFIRI Regimen	colorectal cancer	9256	COADREAD	large intestine cancer	5672	367	371	transcript_amplification		5	Somatic
ERBB2_G776delinsVC	B	4	Predictive	Sensitivity/Response	Trastuzumab Deruxtecan	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4467	4489			0	Somatic
MLH1_DEL	B	4	Predictive	Sensitivity/Response	Nivolumab	cancer	162	CANCER	cancer	162	4733	4641			0	Somatic
PML::RARA	B	4	Predictive	Resistance	Arsenic Trioxide	acute promyelocytic leukemia	60318	APL	hematologic cancer	2531	5239	108	transcript_fusion		0	Somatic
MN1::BEND2	B	4	Diagnostic	Positive		astroblastoma, mn1-altered	80904	ASTB	central nervous system cancer	3620	5191	4995	transcript_fusion		0	Somatic
YAP1::.	B	4	Diagnostic	Positive		supratentorial ependymoma, yap1 fusion-positive	81253	EPM	central nervous system cancer	3620	4954	4798	transcript_fusion		0	Somatic
YAP1::MAMLD1	B	4	Diagnostic	Positive		supratentorial ependymoma, yap1 fusion-positive	81253	EPM	central nervous system cancer	3620	4952	4796	transcript_fusion		0	Somatic
BRAF_V600E	B	3	Predictive	Sensitivity/Response	Vemurafenib	ovarian cancer	2394	OVARY	ovarian cancer	2394	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	3	Predictive	Sensitivity/Response	Trametinib, Dabrafenib	biliary tract cancer	4607	BILIARY_TRACT	biliary tract cancer	4607	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	3	Predictive	Sensitivity/Response	Trametinib, Dabrafenib	cancer	162	CANCER	cancer	162	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	3	Predictive	Sensitivity/Response	Vemurafenib	low grade glioma	80829	LGG	central nervous system cancer	3620	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	3	Prognostic	Poor Outcome		melanoma	1909	MEL	cancer	162	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	3	Prognostic	Poor Outcome		thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	3	Prognostic	Poor Outcome		thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	3	Prognostic	Poor Outcome		thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	3	Prognostic	Poor Outcome		multiple myeloma	9538	MM	hematologic cancer	2531	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	3	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	3	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	3	Prognostic	Poor Outcome		thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	B	3	Diagnostic	Positive		thyroid cancer	1781	THYROID	thyroid cancer	1781	12	12	missense_variant		1378.5	Somatic
ERBB2_AMP	B	3	Predictive	Sensitivity/Response	Lapatinib	gastric adenocarcinoma	3717	STAD	stomach cancer	10534	302	306	transcript_amplification		891	Somatic
ERBB2_AMP	B	3	Predictive	Sensitivity/Response	Pertuzumab, Trastuzumab	bladder carcinoma	4007	BLADDER	urinary bladder cancer	11054	302	306	transcript_amplification		891	N/A
ERBB2_AMP	B	3	Predictive	Sensitivity/Response	Trastuzumab Deruxtecan	stomach cancer	10534	STOMACH	stomach cancer	10534	302	306	transcript_amplification		891	Somatic
.::ALK	B	3	Predictive	Sensitivity/Response	Entrectinib	cancer	162	CANCER	cancer	162	495	499	transcript_fusion	ALK Fusion	798	Somatic
KRAS_Mutation	B	3	Predictive	Resistance	Erlotinib, Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	332	336	protein_altering_variant		545.5	Somatic
KRAS_Mutation	B	3	Predictive	Sensitivity/Response	Binimetinib	ovary serous adenocarcinoma	5744	SOC	ovarian cancer	2394	332	336	protein_altering_variant		545.5	Somatic
KRAS_Mutation	B	3	Prognostic	Poor Outcome		pseudomyxoma peritonei	3559	PMP	appendix cancer	11239	332	336	protein_altering_variant		545.5	Somatic
KRAS_Mutation	B	3	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	332	336	protein_altering_variant		545.5	Somatic
DNMT3A_R882	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	3	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	3	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	3	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
DNMT3A_R882	B	3	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	32	32	missense_variant		510	Somatic
BRCA2_Mutation	B	3	Predictive	Sensitivity/Response	Platinum Compound	ovarian carcinoma	4001	OVT	ovarian cancer	2394	186	186	gene_variant,loss_of_function_variant		462.5	Somatic
BRAF_V600	B	3	Predictive	Resistance	Panitumumab, Vemurafenib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	17	17	protein_altering_variant	Other BRAF V600's	460	Somatic
BRAF_V600	B	3	Predictive	Sensitivity/Response	Vemurafenib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	17	17	protein_altering_variant	Other BRAF V600's	460	Somatic
BRAF_V600	B	3	Predictive	Sensitivity/Response	Vemurafenib	langerhans-cell histiocytosis	2571	LCH	lymphatic system disease	75	17	17	protein_altering_variant	Other BRAF V600's	460	Somatic
BRCA1_Mutation	B	3	Predictive	Sensitivity/Response	Platinum Compound	ovarian carcinoma	4001	OVT	ovarian cancer	2394	185	185	gene_variant,loss_of_function_variant		455	Somatic
NPM1_EXON_12_MUTATION	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	3	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
NPM1_EXON_12_MUTATION	B	3	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
FLT3_ITD	B	3	Predictive	Resistance	Tretinoin	acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	3	Prognostic	Poor Outcome		acute promyelocytic leukemia	60318	APL	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
FLT3_ITD	B	3	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
PIK3CA_Mutation	B	3	Predictive	Resistance	Trastuzumab	breast cancer	1612	BREAST	breast cancer	1612	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	B	3	Predictive	Resistance	Trastuzumab, Lapatinib, Capecitabine	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	B	3	Predictive	Resistance	Erlotinib, Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	B	3	Predictive	Sensitivity/Response	Aspirin	colorectal cancer	9256	COADREAD	large intestine cancer	5672	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	B	3	Predictive	Sensitivity/Response	Celecoxib, Sulindac, Aspirin	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	B	3	Prognostic	Better Outcome		breast cancer	1612	BREAST	breast cancer	1612	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	B	3	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	B	3	Prognostic	Better Outcome		breast cancer	1612	BREAST	breast cancer	1612	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
TP53_Mutation	B	3	Predictive	Sensitivity/Response	Chemotherapy	gastric adenocarcinoma	3717	STAD	stomach cancer	10534	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	3	Predictive	Sensitivity/Response	Vorinostat, Pazopanib	solid tumor	NA	SOLID	cancer	162	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	3	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	222	222	protein_altering_variant		437	Somatic
TP53_Mutation	B	3	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	222	222	protein_altering_variant		437	Somatic
EGFR_T790M	B	3	Predictive	Resistance	Gefitinib, Erlotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	34	34	missense_variant	EGFR TKI Resistance	406.25	Somatic
EGFR_L858R	B	3	Prognostic	Better Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	33	33	missense_variant		379	Somatic
BCR::ABL1	B	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma with bcr-abl1	80643	BLLBCRABL1	hematologic cancer	2531	1	1	transcript_fusion	ABL1 fusions in B-ALL	353.5	Somatic
CD274_Expression	B	3	Prognostic	Better Outcome		lung squamous cell carcinoma	3907	LUSC	lung cancer	1324	272	276	N/A		330	N/A
CD274_Expression	B	3	Prognostic	Better Outcome		ovarian serous carcinoma	50933	SOC	ovarian cancer	2394	272	276	N/A		330	N/A
CD274_Expression	B	3	Prognostic	Poor Outcome		thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	272	276	N/A		330	N/A
CD274_Expression	B	3	Prognostic	Better Outcome		stomach carcinoma	5517	STOMACH	stomach cancer	10534	272	276	N/A		330	N/A
CD274_Expression	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	272	276	N/A		330	N/A
ETV6::NTRK3	B	3	Prognostic	Poor Outcome		thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	779	801	transcript_fusion		314	Somatic
ETV6::NTRK3	B	3	Diagnostic	Positive		congenital mesoblastic nephroma	4773	CMN	kidney cancer	263	779	801	transcript_fusion		314	Somatic
ETV6::NTRK3	B	3	Diagnostic	Positive		congenital fibrosarcoma	8418	FIBS	connective tissue cancer	201	779	801	transcript_fusion		314	Somatic
ETV6::NTRK3	B	3	Diagnostic	Positive		congenital fibrosarcoma	8418	FIBS	connective tissue cancer	201	779	801	transcript_fusion		314	Somatic
ETV6::NTRK3	B	3	Diagnostic	Positive		congenital mesoblastic nephroma	4773	CMN	kidney cancer	263	779	801	transcript_fusion		314	Somatic
ETV6::NTRK3	B	3	Diagnostic	Positive		breast secretory carcinoma	4922	JSCB	breast cancer	1612	779	801	transcript_fusion		314	Somatic
ETV6::NTRK3	B	3	Diagnostic	Positive		breast secretory carcinoma	4922	JSCB	breast cancer	1612	779	801	transcript_fusion		314	Somatic
ETV6::NTRK3	B	3	Diagnostic	Positive		breast secretory carcinoma	4922	JSCB	breast cancer	1612	779	801	transcript_fusion		314	Somatic
PTEN_DEL	B	3	Predictive	Resistance	Cetuximab, Panitumumab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	214	214	loss_of_function_variant		272	Somatic
PTEN_DEL	B	3	Predictive	Resistance	Trastuzumab	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	214	214	loss_of_function_variant		272	Somatic
EGFR_Mutation	B	3	Prognostic	Better Outcome		lung adenocarcinoma	3910	LUAD	lung cancer	1324	438	442	inframe_variant		260	Somatic
IKZF1_DEL	B	3	Prognostic	Poor Outcome		b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	200	200	transcript_ablation		240	Somatic
IKZF1_DEL	B	3	Prognostic	Poor Outcome		acute lymphoblastic leukemia	9952	ALL	hematologic cancer	2531	200	200	transcript_ablation		240	Somatic
IKZF1_DEL	B	3	Prognostic	Poor Outcome		acute lymphoblastic leukemia	9952	ALL	hematologic cancer	2531	200	200	transcript_ablation		240	Somatic
IKZF1_DEL	B	3	Prognostic	Poor Outcome		b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	200	200	transcript_ablation		240	Somatic
NRAS_Mutation	B	3	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	208	208	transcript_variant,gain_of_function_variant		213	Somatic
NRAS_Mutation	B	3	Prognostic	Poor Outcome		melanoma	1909	MEL	cancer	162	208	208	transcript_variant,gain_of_function_variant		213	Somatic
IDH1_R132	B	3	Prognostic	Better Outcome		astrocytoma	3069	ASTR	central nervous system cancer	3620	58	58	protein_altering_variant		199	Somatic
IDH1_R132	B	3	Prognostic	Better Outcome		glioblastoma	3068	GB	central nervous system cancer	3620	58	58	protein_altering_variant		199	Somatic
KIT_Exon_11_Mutation	B	3	Predictive	Sensitivity/Response	Imatinib	melanoma	1909	MEL	cancer	162	66	66	coding_sequence_variant	KIT Exon 11	197.5	Somatic
KIT_Exon_11_Mutation	B	3	Predictive	Resistance	Sunitinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	66	66	coding_sequence_variant	KIT Exon 11	197.5	Somatic
KIT_Exon_11_Mutation	B	3	Predictive	Sensitivity/Response	Regorafenib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	66	66	coding_sequence_variant	KIT Exon 11	197.5	Somatic
KIT_Exon_11_Mutation	B	3	Prognostic	Poor Outcome		gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	66	66	coding_sequence_variant	KIT Exon 11	197.5	Somatic
.::RET	B	3	Predictive	Sensitivity/Response	Cabozantinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	1595	1687	transcript_fusion		192.5	Somatic
KRAS_G12/G13	B	3	Predictive	Resistance	Erlotinib, Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	77	77	protein_altering_variant		191	Somatic
KRAS_G12/G13	B	3	Predictive	Resistance	Cetuximab, Chemotherapy, Panitumumab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	77	77	protein_altering_variant		191	Somatic
FGFR1_AMP	B	3	Predictive	Sensitivity/Response	Infigratinib	lung squamous cell carcinoma	3907	LUSC	lung cancer	1324	263	267	transcript_amplification		185.5	Somatic
FGFR1_AMP	B	3	Predictive	Sensitivity/Response	Lucitanib	breast cancer	1612	BREAST	breast cancer	1612	263	267	transcript_amplification		185.5	Somatic
FGFR1_AMP	B	3	Prognostic	Poor Outcome		lung squamous cell carcinoma	3907	LUSC	lung cancer	1324	263	267	transcript_amplification		185.5	Somatic
CDKN2A_p16_Expression	B	3	Predictive	Resistance	Panitumumab	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	268	272	N/A		180	N/A
CDKN2A_p16_Expression	B	3	Predictive	Sensitivity/Response	Panitumumab	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	268	272	N/A		180	Somatic
CDKN2A_p16_Expression	B	3	Prognostic	Better Outcome		head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	268	272	N/A		180	N/A
KRAS_G12C	B	3	Predictive	Resistance	Gefitinib, Erlotinib, Chemotherapy, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	78	78	missense_variant	EGFR TKI Resistance	176.5	Somatic
KRAS_G12C	B	3	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	78	78	missense_variant	EGFR TKI Resistance	176.5	Somatic
EGFR_AMP	B	3	Predictive	Sensitivity/Response	Panitumumab, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	190	190	transcript_amplification		173	Somatic
EGFR_AMP	B	3	Prognostic	Poor Outcome		barrett's adenocarcinoma	7941	ESCA	esophageal cancer	5041	190	190	transcript_amplification		173	Somatic
EGFR_AMP	B	3	Prognostic	Poor Outcome		cervical squamous cell carcinoma	3744	CESC	uterine cancer	363	190	190	transcript_amplification		173	Somatic
KRAS_Exon_2_Mutation	B	3	Predictive	Resistance	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	colorectal cancer	9256	COADREAD	large intestine cancer	5672	75	75	missense_variant		168	Somatic
KRAS_Exon_2_Mutation	B	3	Prognostic	Poor Outcome		pancreatic carcinoma	4905	PANCREAS	pancreatic cancer	1793	75	75	missense_variant		168	Somatic
BRAF_Mutation	B	3	Predictive	Resistance	Cetuximab, Chemotherapy, Oxaliplatin, Irinotecan, Bevacizumab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	395	399	gene_variant,gain_of_function_variant		166	Somatic
BRAF_Mutation	B	3	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	395	399	gene_variant,gain_of_function_variant		166	Somatic
BRAF_Mutation	B	3	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	395	399	gene_variant,gain_of_function_variant		166	Somatic
MYOD1_L122R	B	3	Prognostic	Poor Outcome		spindle cell rhabdomyosarcoma	3260	SCRMS	muscle cancer	4045	2901	3032	missense_variant		165	Somatic
BCOR_ITD_	B	3	Diagnostic	Positive		central nervous system tumor with bcor internal tandem duplication	81315	CNS	central nervous system cancer	3620	4547	4527	tandem_duplication		165	Somatic
BCOR_ITD_	B	3	Diagnostic	Positive		kidney clear cell sarcoma	4880	CCSK	kidney cancer	263	4547	4527	tandem_duplication		165	Somatic
BCOR_ITD_	B	3	Diagnostic	Positive		central nervous system tumor with bcor internal tandem duplication	81315	CNS	central nervous system cancer	3620	4547	4527	tandem_duplication		165	Somatic
BCOR_ITD_	B	3	Diagnostic	Positive		sarcoma	1115	SARCOMA	sarcoma	1115	4547	4527	tandem_duplication		165	Somatic
KRAS_G12D	B	3	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	79	79	missense_variant	EGFR TKI Resistance	162	Somatic
KRAS_G12D	B	3	Prognostic	Better Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	79	79	missense_variant	EGFR TKI Resistance	162	Somatic
KRAS_G12D	B	3	Prognostic	Poor Outcome		malignant exocrine pancreas neoplasm	1795	PANCREAS	pancreatic cancer	1793	79	79	missense_variant	EGFR TKI Resistance	162	Somatic
KRAS_G12D	B	3	Prognostic	Poor Outcome		pancreatic ductal carcinoma	3587	PACT	pancreatic cancer	1793	79	79	missense_variant	EGFR TKI Resistance	162	Somatic
KRAS_G12D	B	3	Diagnostic	Positive		lung cancer	1324	LUNG	lung cancer	1324	79	79	missense_variant	EGFR TKI Resistance	162	Somatic
EGFR_Overexpression	B	3	Prognostic	Poor Outcome		brain glioblastoma multiforme	3073	GBM	central nervous system cancer	3620	193	193	N/A		145	N/A
EGFR_Overexpression	B	3	Prognostic	Poor Outcome		head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	193	193	N/A		145	N/A
EGFR_Overexpression	B	3	Prognostic	Poor Outcome		esophagus squamous cell carcinoma	3748	ESCC	esophageal cancer	5041	193	193	N/A		145	N/A
SS18::SSX1	B	3	Prognostic	Poor Outcome		synovial sarcoma	5485	SYNS	connective tissue cancer	201	444	448	transcript_fusion	SYT-SSX fusions	145	Somatic
SS18::SSX1	B	3	Diagnostic	Positive		synovial sarcoma	5485	SYNS	connective tissue cancer	201	444	448	transcript_fusion	SYT-SSX fusions	145	Somatic
SS18::SSX1	B	3	Diagnostic	Positive		malignant peripheral nerve sheath tumor	5940	MPNST	peripheral nervous system neoplasm	1192	444	448	transcript_fusion	SYT-SSX fusions	145	Somatic
.::NTRK1	B	3	Diagnostic	Positive		lipofibromatosis-like neural tumor	80894	LPF-NT	connective tissue cancer	201	415	419	transcript_fusion	NTRK1 Fusions	135	Somatic
ATM_Mutation	B	3	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	178	178	transcription_variant,loss_of_function_variant		130.5	Somatic
WT1_Exon_7_Mutation	B	3	Predictive	Resistance	Daunorubicin, Cytarabine	acute myeloid leukemia	9119	AML	hematologic cancer	2531	129	129	exon_variant		130	Somatic
SF3B1_Mutation	B	3	Prognostic	Better Outcome		myelodysplastic syndrome	50908	MDS	hematologic cancer	2531	215	215	protein_altering_variant		130	Somatic
WT1_Exon_7_Mutation	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	129	129	exon_variant		130	Somatic
WT1_Exon_7_Mutation	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	129	129	exon_variant		130	Somatic
WT1_Exon_7_Mutation	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	129	129	exon_variant		130	Somatic
WT1_Exon_7_Mutation	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	129	129	exon_variant		130	Somatic
KIT_Exon_9_Mutation	B	3	Predictive	Sensitivity/Response	Sunitinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	505	509	exon_variant		122.5	Somatic
FLT3_TKD_MUTATION	B	3	Predictive	Sensitivity/Response	Midostaurin	acute myeloid leukemia	9119	AML	hematologic cancer	2531	56	56			120	Somatic
FLT3_TKD_MUTATION	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	56	56			120	Somatic
RUNX1::RUNX1T1	B	3	Diagnostic	Positive		acute myeloid leukemia with t(8;21); (q22; q22.1)	81093	AMLRUNX1RUNX1T1	hematologic cancer	2531	2995	3126	transcript_fusion		120	Somatic
RUNX1::RUNX1T1	B	3	Diagnostic	Positive		acute myeloid leukemia with t(8;21); (q22; q22.1)	81093	AMLRUNX1RUNX1T1	hematologic cancer	2531	2995	3126	transcript_fusion		120	Somatic
RUNX1::RUNX1T1	B	3	Diagnostic	Positive		acute myeloid leukemia with t(8;21); (q22; q22.1)	81093	AMLRUNX1RUNX1T1	hematologic cancer	2531	2995	3126	transcript_fusion		120	Somatic
CCND1_Overexpression	B	3	Predictive	Resistance	Tamoxifen	estrogen-receptor positive breast cancer	60075	BRCA	breast cancer	1612	20	20	N/A		116	N/A
DNMT3A_Mutation	B	3	Predictive	Sensitivity/Response	Decitabine	acute myeloid leukemia	9119	AML	hematologic cancer	2531	189	189	transcript_variant		115	Somatic
DNMT3A_Mutation	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	189	189	transcript_variant		115	Somatic
DNMT3A_Mutation	B	3	Prognostic	Poor Outcome		myelodysplastic syndrome	50908	MDS	hematologic cancer	2531	189	189	transcript_variant		115	Somatic
KRAS_G12	B	3	Prognostic	Poor Outcome		multiple myeloma	9538	MM	hematologic cancer	2531	76	76	protein_altering_variant		115	Somatic
KRAS_G12	B	3	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	76	76	protein_altering_variant		115	Somatic
KRAS_G12	B	3	Diagnostic	Positive		acute leukemia	12603	AL	hematologic cancer	2531	76	76	protein_altering_variant		115	Somatic
RUNX1_Mutation	B	3	Prognostic	Poor Outcome		acute lymphoblastic leukemia	9952	ALL	hematologic cancer	2531	155	155	transcript_variant,loss_of_function_variant		110	Somatic
RUNX1_Mutation	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	155	155	transcript_variant,loss_of_function_variant		110	Somatic
METx14del	B	3	Predictive	Sensitivity/Response	Tepotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	320	324	exon_loss_variant		108.5	Somatic
BRAF_V600K	B	3	Predictive	Sensitivity/Response	Trametinib, Dabrafenib	skin melanoma	8923	MEL	skin cancer	4159	559	563	missense_variant	Other BRAF V600's	107.5	Somatic
.::NTRK3	B	3	Predictive	Sensitivity/Response	Entrectinib	cancer	162	CANCER	cancer	162	1251	1277	transcript_fusion		105	Somatic
EGFR_Exon_20_Insertion	B	3	Predictive	Resistance	Afatinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	707	726	inframe_insertion		105	Somatic
CEBPA_Mutation	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	29	29	transcript_variant,loss_of_function_variant		105	Somatic
CEBPA_Mutation	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	29	29	transcript_variant,loss_of_function_variant		105	Somatic
TERT_Promoter_Mutation	B	3	Prognostic	Poor Outcome		skin melanoma	8923	MEL	skin cancer	4159	220	220	regulatory_region_variant		105	Somatic
TERT_Promoter_Mutation	B	3	Prognostic	Poor Outcome		thyroid cancer	1781	THYROID	thyroid cancer	1781	220	220	regulatory_region_variant		105	Somatic
TERT_Promoter_Mutation	B	3	Prognostic	Poor Outcome		glioblastoma	3068	GB	central nervous system cancer	3620	220	220	regulatory_region_variant		105	Somatic
TERT_Promoter_Mutation	B	3	Diagnostic	Positive		thyroid cancer	1781	THYROID	thyroid cancer	1781	220	220	regulatory_region_variant		105	Somatic
TERT_Promoter_Mutation	B	3	Diagnostic	Positive		brain glioma	60108	GLIOMA	central nervous system cancer	3620	220	220	regulatory_region_variant		105	Somatic
ZFTA::RELA	B	3	Diagnostic	Positive		supratentorial ependymoma, zfta fusion-positive	81252	EPM	central nervous system cancer	3620	4548	4528	transcript_fusion		103	Somatic
ZFTA::RELA	B	3	Diagnostic	Positive		supratentorial ependymoma, zfta fusion-positive	81252	EPM	central nervous system cancer	3620	4548	4528	transcript_fusion		103	Somatic
ZFTA::RELA	B	3	Diagnostic	Positive		supratentorial ependymoma, zfta fusion-positive	81252	EPM	central nervous system cancer	3620	4548	4528	transcript_fusion		103	Somatic
IDH2_Mutation	B	3	Prognostic	Better Outcome		brain glioma	60108	GLIOMA	central nervous system cancer	3620	566	570	protein_altering_variant		101.5	Somatic
RRM1_Underexpression	B	3	Predictive	Sensitivity/Response	Gemcitabine	pancreatic cancer	1793	PANCREAS	pancreatic cancer	1793	1231	1257	N/A		100	N/A
ASXL1_Mutation	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	177	177	protein_altering_variant		100	Somatic
ASXL1_Mutation	B	3	Prognostic	Poor Outcome		myelofibrosis	4971	PMF	hematologic cancer	2531	177	177	protein_altering_variant		100	Somatic
NOTCH1_Mutation	B	3	Prognostic	Poor Outcome		mantle cell lymphoma	50746	MCL	hematologic cancer	2531	206	206	protein_altering_variant		100	Somatic
ASXL1_Mutation	B	3	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	177	177	protein_altering_variant		100	Somatic
NRAS_Q61	B	3	Diagnostic	Positive		melanoma	1909	MEL	cancer	162	94	94	missense_variant		100	Somatic
FGFR2::.	B	3	Predictive	Sensitivity/Response	Erdafitinib	cancer	162	CANCER	cancer	162	2078	2202	transcript_fusion	FGFR fusions	95	Somatic
IDH1_Mutation	B	3	Predictive	Sensitivity/Response	Ivosidenib	cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	641	645	transcript_variant		90.5	Somatic
IDH1_Mutation	B	3	Prognostic	Better Outcome		brain glioma	60108	GLIOMA	central nervous system cancer	3620	641	645	transcript_variant		90.5	Somatic
EWSR1::FLI1	B	3	Diagnostic	Positive		ewing sarcoma of bone	3368	ES	bone cancer	184	687	706	transcript_fusion		90	Somatic
EWSR1::FLI1	B	3	Diagnostic	Positive		ewing sarcoma	3369	ES	bone cancer	184	687	706	transcript_fusion		90	Somatic
SS18::SSX2	B	3	Prognostic	Better Outcome		synovial sarcoma	5485	SYNS	connective tissue cancer	201	445	449	transcript_fusion	SYT-SSX fusions	85	Somatic
SS18::SSX2	B	3	Prognostic	Better Outcome		synovial sarcoma	5485	SYNS	connective tissue cancer	201	445	449	transcript_fusion	SYT-SSX fusions	85	Somatic
SS18::SSX2	B	3	Diagnostic	Positive		synovial sarcoma	5485	SYNS	connective tissue cancer	201	445	449	transcript_fusion	SYT-SSX fusions	85	Somatic
CTNNB1_S45F	B	3	Prognostic	Poor Outcome		desmoid tumor	80366	DES	benign neoplasm	60072	1260	1286	missense_variant		80	Somatic
TP53_Deleterious_Mutation	B	3	Predictive	Resistance	RG7112	leukemia	1240	LEUKEMIA	hematologic cancer	2531	221	221	N/A		78	Somatic
TP53_Deleterious_Mutation	B	3	Prognostic	Poor Outcome		head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	221	221	N/A		78	Somatic
FGFR2::.	B	3	Predictive	Sensitivity/Response	Derazantinib	intrahepatic cholangiocarcinoma	4928	IHCH	biliary tract cancer	4607	4685	4612	transcript_fusion		75	Somatic
FGFR3_Mutation	B	3	Predictive	Sensitivity/Response	Infigratinib	bladder carcinoma	4007	BLADDER	urinary bladder cancer	11054	805	827			70	Somatic
FGFR3_Mutation	B	3	Predictive	Sensitivity/Response	Cisplatin, Gemcitabine	urinary bladder cancer	11054	BLADDER	urinary bladder cancer	11054	805	827			70	Somatic
TP53_Wildtype	B	3	Predictive	Sensitivity/Response	Cetuximab, Capecitabine, Oxaliplatin	colorectal cancer	9256	COADREAD	large intestine cancer	5672	365	369	wild_type		68	N/A
TP53_Wildtype	B	3	Predictive	Sensitivity/Response	Chemotherapy	esophageal carcinoma	1107	ESCA	esophageal cancer	5041	365	369	wild_type		68	N/A
TP53_Wildtype	B	3	Predictive	Sensitivity/Response	Adjuvant Chemotherapy	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	365	369	wild_type		68	N/A
TP53_Wildtype	B	3	Predictive	Sensitivity/Response	RG7112	leukemia	1240	LEUKEMIA	hematologic cancer	2531	365	369	wild_type		68	N/A
KRAS_G12V	B	3	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	421	425	missense_variant		67.5	Somatic
KRAS_G12V	B	3	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	421	425	missense_variant		67.5	Somatic
MGMT_Underexpression	B	3	Predictive	Sensitivity/Response	Temozolomide	glioblastoma	3068	GB	central nervous system cancer	3620	1229	1255	N/A		65	N/A
MGMT_Underexpression	B	3	Predictive	Sensitivity/Response	Temozolomide	high grade glioma	3070	HGG	central nervous system cancer	3620	1229	1255	N/A		65	N/A
TP53_Overexpression	B	3	Predictive	Resistance	Carboplatin, Cisplatin	ovarian cancer	2394	OVARY	ovarian cancer	2394	1280	1306	N/A		65	N/A
TP53_Overexpression	B	3	Prognostic	Poor Outcome		ovarian cancer	2394	OVARY	ovarian cancer	2394	1280	1306	N/A		65	N/A
TP53_Overexpression	B	3	Prognostic	Poor Outcome		renal wilms' tumor	5176	WT	kidney cancer	263	1280	1306	N/A		65	N/A
H3-3A_K28M	B	3	Diagnostic	Positive		diffuse midline glioma, h3 k27m-mutant	80684	DIFG	central nervous system cancer	3620	2289	2416	non_conservative_missense_variant		65	Somatic
H3-3A_K28M	B	3	Diagnostic	Positive		diffuse midline glioma, h3 k27m-mutant	80684	DIFG	central nervous system cancer	3620	2289	2416	non_conservative_missense_variant		65	Somatic
H3-3A_K28M	B	3	Diagnostic	Positive		brain glioblastoma multiforme	3073	GBM	central nervous system cancer	3620	2289	2416	non_conservative_missense_variant		65	Somatic
KRAS_G12A	B	3	Predictive	Resistance	Erlotinib, Gefitinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	148	148	missense_variant	EGFR TKI Resistance	63	Somatic
KRAS_G12A	B	3	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	148	148	missense_variant	EGFR TKI Resistance	63	Somatic
EGFR_Expression	B	3	Predictive	Sensitivity/Response	Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	350	354	N/A		60	N/A
IDH2_R140	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	62	62	protein_altering_variant		60	Somatic
PGR_Expression	B	3	Prognostic	Better Outcome		breast cancer	1612	BREAST	breast cancer	1612	210	210	N/A		60	N/A
ASPSCR1::TFE3	B	3	Diagnostic	Positive		alveolar soft part sarcoma	4239	ASPS	muscle cancer	4045	3490	3622	transcript_fusion		59	Somatic
ASPSCR1::TFE3	B	3	Diagnostic	Positive		renal cell carcinoma with mit translocations	81413	RCC	kidney cancer	263	3490	3622	transcript_fusion		59	Somatic
IDH1_R132C	B	3	Diagnostic	Positive		acute myeloid leukemia	9119	AML	hematologic cancer	2531	59	59	missense_variant		56	Somatic
PTEN_DEL	B	3	Predictive	Sensitivity/Response	Everolimus	prostate cancer	10283	PROSTATE	prostate cancer	10283	213	213	transcript_ablation		55	Somatic
CTNNB1_T41A	B	3	Prognostic	Better Outcome		desmoid tumor	80366	DES	benign neoplasm	60072	1259	1285	missense_variant		55	Somatic
PAX7::FOXO1	B	3	Prognostic	Better Outcome		alveolar rhabdomyosarcoma	4051	ARMS	muscle cancer	4045	2456	2583	transcript_fusion		55	Somatic
CTNNB1_Exon_3_Mutation	B	3	Diagnostic	Positive		childhood medulloblastoma	3869	MBL	central nervous system cancer	3620	2761	2892			55	Somatic
PTEN_Expression	B	3	Predictive	Sensitivity/Response	Trastuzumab	breast cancer	1612	BREAST	breast cancer	1612	309	313	N/A		54.5	N/A
U2AF1_Q157P/R	B	3	Prognostic	Poor Outcome		myelodysplastic syndrome	50908	MDS	hematologic cancer	2531	127	127	missense_variant		50	Somatic
PAX5_P80R	B	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma with pax5 p80r	81411	BLLPAX5P80R	hematologic cancer	2531	2566	2697			50	Somatic
PAX5_P80R	B	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma with pax5 p80r	81411	BLLPAX5P80R	hematologic cancer	2531	2566	2697			50	Somatic
CCND1_AMP	B	3	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	18	18	transcript_amplification		47	Somatic
TP53_R248Q	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	117	117	missense_variant		46	Somatic
TP53_R248Q	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	117	117	missense_variant		46	Somatic
BRD4::NUTM1	B	3	Diagnostic	Positive		nut midline carcinoma	60463	NUTC	cancer	162	5152	4973	transcript_fusion		45.5	Somatic
PIK3CA_AMP	B	3	Predictive	Sensitivity/Response	Ibuprofen, Sulindac, Aspirin	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	212	212	transcript_amplification		45	N/A
PIK3CA_Exon_21_Mutation	B	3	Predictive	Resistance	Chemotherapy, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	105	105	exon_variant		45	Somatic
PIK3CA_AMP	B	3	Prognostic	Poor Outcome		gastric adenocarcinoma	3717	STAD	stomach cancer	10534	212	212	transcript_amplification		45	Somatic
TP53_R273C	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	121	121	missense_variant		44.5	Somatic
TP53_R273C	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	121	121	missense_variant		44.5	Somatic
MYB_Rearrangement	B	3	Diagnostic	Positive		diffuse astrocytoma, myb- or mybl1-altered	81279	DASTR	central nervous system cancer	3620	4218	4328			42.5	Somatic
MYB_Rearrangement	B	3	Diagnostic	Positive		diffuse astrocytoma, myb- or mybl1-altered	81279	DASTR	central nervous system cancer	3620	4218	4328			42.5	Somatic
TP53_R273H	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	122	122	missense_variant		41	Somatic
TP53_R273H	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	122	122	missense_variant		41	Somatic
BRCA1_Mutation	B	3	Predictive	Sensitivity/Response	Olaparib	prostate cancer	10283	PROSTATE	prostate cancer	10283	4409	185	gene_variant,loss_of_function_variant		40	Combined
TYMS_Overexpression	B	3	Predictive	Resistance	Pemetrexed	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	343	347	N/A		40	N/A
MN1_Rearrangement	B	3	Diagnostic	Positive		astroblastoma, mn1-altered	80904	ASTB	central nervous system cancer	3620	5187	4993			40	Somatic
MYB::QKI	B	3	Diagnostic	Positive		angiocentric glioma	81261	ANGL	central nervous system cancer	3620	4217	4327	transcript_fusion		40	Somatic
TERT_C228T	B	3	Diagnostic	Positive		thyroid cancer	1781	THYROID	thyroid cancer	1781	244	248	regulatory_region_variant		40	Somatic
YAP1::TFE3	B	3	Diagnostic	Positive		malignant epithelioid hemangioendothelioma	80190	EHAE	sarcoma	1115	4622	4577	transcript_fusion		40	Somatic
ATRX_Underexpression	B	3	Predictive	Sensitivity/Response	PCV Regimen, Temozolomide	astrocytoma	3069	ASTR	central nervous system cancer	3620	644	648	N/A		39	N/A
ATM_Underexpression	B	3	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	179	179	N/A		39	N/A
AURKA_Overexpression	B	3	Predictive	Resistance	Platinum Compound	ovarian serous carcinoma	50933	SOC	ovarian cancer	2394	181	181	N/A		38	N/A
KRAS_G12S	B	3	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	887	913	missense_variant		38	Somatic
PAX3::FOXO1	B	3	Prognostic	Poor Outcome		alveolar rhabdomyosarcoma	4051	ARMS	muscle cancer	4045	2455	2582	transcript_fusion		38	Somatic
CIC::DUX4	B	3	Diagnostic	Positive		cic-rearranged sarcoma	81250	RCSNOS	sarcoma	1115	3121	3252	transcript_fusion		37.5	Somatic
CIC::DUX4	B	3	Diagnostic	Positive		cic-rearranged sarcoma	81250	RCSNOS	sarcoma	1115	3121	3252	transcript_fusion		37.5	Somatic
KIT_EXPRESSION	B	3	Predictive	Sensitivity/Response	Sunitinib	glioblastoma	3068	GB	central nervous system cancer	3620	425	429	N/A		35	Somatic
TP53_DNA_Binding_Domain_Mutation	B	3	Predictive	Resistance	Tamoxifen	breast cancer	1612	BREAST	breast cancer	1612	238	242	DNA_binding_site		35	Somatic
ERBB2_SERUM_LEVELS	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	412	416	N/A		35	N/A
EZH2_Mutation	B	3	Prognostic	Poor Outcome		myelodysplastic syndrome	50908	MDS	hematologic cancer	2531	163	163	protein_altering_variant		35	Somatic
IDH2_R172K	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	63	63	missense_variant		35	Somatic
MKI67_EXPRESSION	B	3	Prognostic	Poor Outcome		prostate cancer	10283	PROSTATE	prostate cancer	10283	620	624	N/A		35	N/A
NOTCH1_P2514FS	B	3	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	207	207	frameshift_truncation		35	Somatic
WT1_Exon_9_Mutation	B	3	Prognostic	Poor Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	130	130	exon_variant		35	Somatic
ACVR1_G328V	B	3	Diagnostic	Positive		diffuse midline glioma, h3 k27m-mutant	80684	DIFG	central nervous system cancer	3620	1594	1686	missense_variant	ACVR1 kinase domain mutation	35	Somatic
ACVR1_G328V	B	3	Diagnostic	Positive		diffuse midline glioma, h3 k27m-mutant	80684	DIFG	central nervous system cancer	3620	1594	1686	missense_variant	ACVR1 kinase domain mutation	35	Somatic
CBFB::MYH11	B	3	Diagnostic	Positive		acute myeloid leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)	81084	AMLCBFBMYH11	hematologic cancer	2531	427	431	transcript_fusion		35	Somatic
CTNNB1_S45P	B	3	Diagnostic	Positive		desmoid tumor	80366	DES	benign neoplasm	60072	1261	1287	missense_variant		35	Somatic
CTNNB1_S45P	B	3	Diagnostic	Positive		desmoid tumor	80366	DES	benign neoplasm	60072	1261	1287	missense_variant		35	Somatic
FUS::CREB3L2	B	3	Diagnostic	Positive		low-grade fibromyxoid sarcoma	80534	LGFMS	connective tissue cancer	201	5155	4975	transcript_fusion		35	Somatic
ARID1A_Underexpression	B	3	Prognostic	Poor Outcome		clear cell renal cell carcinoma	4467	CCRCC	kidney cancer	263	1984	2108	N/A		34	N/A
ARID1A_Underexpression	B	3	Prognostic	Poor Outcome		ovarian clear cell carcinoma	50934	CCOV	ovarian cancer	2394	1984	2108	N/A		34	N/A
AURKA_EXPRESSION	B	3	Predictive	Sensitivity/Response	Fluorouracil, Radiation Therapy, Cisplatin	esophagus squamous cell carcinoma	3748	ESCC	esophageal cancer	5041	158	158	N/A		30	N/A
BRAF_D594K	B	3	Predictive	Resistance	Irinotecan, Oxaliplatin	colorectal cancer	9256	COADREAD	large intestine cancer	5672	2271	2398			30	Somatic
CDK4_AMP	B	3	Predictive	Sensitivity/Response	Palbociclib	liposarcoma	3382	LIPO	connective tissue cancer	201	549	553	transcript_amplification		30	Somatic
ERCC1_Underexpression	B	3	Predictive	Sensitivity/Response	Gemcitabine, Carboplatin	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	2282	2409	N/A		30	N/A
ERCC1_Underexpression	B	3	Predictive	Sensitivity/Response	Platinum Compound	epithelial ovarian cancer	2152	OVT	ovarian cancer	2394	2282	2409	N/A		30	N/A
SMARCA4_Underexpression	B	3	Predictive	Sensitivity/Response	Vinorelbine, Cisplatin	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	345	349	N/A		30	N/A
TP53_R249	B	3	Predictive	Sensitivity/Response	Doxorubicin	breast cancer	1612	BREAST	breast cancer	1612	119	119	protein_altering_variant		30	Somatic
ALDH1A2_Overexpression	B	3	Prognostic	Better Outcome		head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	468	472	N/A		30	N/A
ALDH1A2_Overexpression	B	3	Prognostic	Better Outcome		head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	468	472	N/A		30	N/A
AURKA_EXPRESSION	B	3	Prognostic	Better Outcome		ovarian carcinoma	4001	OVT	ovarian cancer	2394	158	158	N/A		30	Somatic
CCND1_Expression	B	3	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	19	19	N/A		30	Somatic
CDKN2A_Promoter_Hypermethylation	B	3	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	27	27	N/A		30	Somatic
CDKN2A_Promoter_Hypermethylation	B	3	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	27	27	N/A		30	Somatic
MIR218-1_EXPRESSION	B	3	Prognostic	Better Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	472	476	N/A		30	N/A
MIR218-1_EXPRESSION	B	3	Prognostic	Better Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	472	476	N/A		30	N/A
PBRM1_Mutation	B	3	Prognostic	Better Outcome		renal cell carcinoma	4450	RCC	kidney cancer	263	161	161	transcription_variant,loss_of_function_variant		30	Somatic
SMARCA4_Underexpression	B	3	Prognostic	Poor Outcome		lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	345	349	N/A		30	Somatic
TP53_R249	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	119	119	protein_altering_variant		30	Somatic
CSF3R_Mutation	B	3	Diagnostic	Positive		chronic neutrophilic leukemia	80187	CNL	hematologic cancer	2531	556	560	protein_altering_variant		30	Somatic
CSF3R_Mutation	B	3	Diagnostic	Positive		atypical chronic myeloid leukemia	60597	ACML	hematologic cancer	2531	556	560	protein_altering_variant		30	Somatic
MNX1::ETV6	B	3	Diagnostic	Positive		acute myeloid leukemia with mnx1::etv6 fusion	9119	AMLMNX1ETV6	hematologic cancer	2531	5195	4999	transcript_fusion		30	Somatic
MNX1::ETV6	B	3	Diagnostic	Positive		acute myeloid leukemia with mnx1::etv6 fusion	9119	AMLMNX1ETV6	hematologic cancer	2531	5195	4999	transcript_fusion		30	Somatic
MNX1::ETV6	B	3	Diagnostic	Positive		acute myeloid leukemia with mnx1::etv6 fusion	9119	AMLMNX1ETV6	hematologic cancer	2531	5195	4999	transcript_fusion		30	Somatic
PAX5::JAK2	B	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2730	2861	transcript_fusion	JAK2 fusions in B-ALL	30	Somatic
KRAS_AMP	B	3	Prognostic	Poor Outcome		endometrial cancer	1380	UCEC	uterine cancer	363	588	592	transcript_amplification		27	Somatic
NUP214::ABL1	B	3	Prognostic	Better Outcome		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2529	2660	transcript_fusion	ABL1 fusions in B-ALL	27	Somatic
PRPS1_A190T	B	3	Prognostic	Poor Outcome		b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2798	2929			26	Somatic
EGFR_G719	B	3	Predictive	Sensitivity/Response	Gefitinib, Erlotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	699	718	protein_altering_variant		25	Somatic
FGFR2_AMP	B	3	Predictive	Sensitivity/Response	Fexagratinib	stomach carcinoma	5517	STOMACH	stomach cancer	10534	625	629	transcript_amplification		25	N/A
MMP2_SERUM_LEVELS	B	3	Predictive	Sensitivity/Response	Bevacizumab	inflammatory breast carcinoma	6263	IBC	breast cancer	1612	483	487	N/A		25	N/A
TOP1_EXPRESSION	B	3	Predictive	Sensitivity/Response	Irinotecan	colorectal cancer	9256	COADREAD	large intestine cancer	5672	380	384	N/A		25	N/A
HIF1A_OVEREXPRESSION	B	3	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	430	434	N/A		25	N/A
SMAD4_Mutation	B	3	Prognostic	Poor Outcome		pancreatic adenocarcinoma	4074	PAAD	pancreatic cancer	1793	216	216	transcript_variant,loss_of_function_variant		25	Somatic
TP53_R175H	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	116	116	missense_variant		25	Somatic
U2AF1_S34Y/F	B	3	Prognostic	Poor Outcome		myelodysplastic syndrome	50908	MDS	hematologic cancer	2531	128	128	missense_variant		25	Somatic
RET_Overexpression	B	3	Prognostic	Poor Outcome		lung adenocarcinoma	3910	LUAD	lung cancer	1324	593	597	N/A		24.5	N/A
GNA11_Mutation	B	3	Predictive	Sensitivity/Response	Cabozantinib	uveal melanoma	6039	UM	ocular cancer	2174	502	506			24	Somatic
SGK1_Overexpression	B	3	Predictive	Resistance	Alpelisib	breast cancer	1612	BREAST	breast cancer	1612	674	693	N/A		24	N/A
EGFR_G719S	B	3	Predictive	Sensitivity/Response	Gefitinib, Erlotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	134	134	missense_variant		23	Somatic
FGFR3::TACC3	B	3	Predictive	Sensitivity/Response	Erdafitinib	cancer	162	CANCER	cancer	162	808	830	transcript_fusion		22.5	Somatic
MTOR_Mutation	B	3	Prognostic	Poor Outcome		melanoma	1909	MEL	cancer	162	273	277	protein_altering_variant		22.5	Somatic
EWSR1::CREB3L1	B	3	Diagnostic	Positive		sclerosing epithelioid fibrosarcoma	3355	SEF	connective tissue cancer	201	5154	4974	transcript_fusion		22.5	Somatic
TP53_R248W	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	118	118	missense_variant		22	Somatic
KRAS_A146T	B	3	Predictive	Resistance	FOLFOX-4 Regimen, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	880	906	missense_variant		21	Somatic
FGFR3_Y373C	B	3	Diagnostic	Positive		bladder carcinoma	4007	BLADDER	urinary bladder cancer	11054	2277	2404	missense_variant		21	Somatic
SMARCA4_INACTIVATING_MUTATION	B	3	Diagnostic	Positive		small-cell carcinoma of the ovary of hypercalcemic type	7651	SCCO	ovarian cancer	2394	218	218	loss_of_function_variant		20.75	Somatic
BRAF_intron_10_rearrangement	B	3	Predictive	Resistance	Vemurafenib, Dabrafenib	melanoma	1909	MEL	cancer	162	2102	2226			20	Somatic
BRAF_intron_9_rearrangement	B	3	Predictive	Resistance	Dabrafenib, Vemurafenib	melanoma	1909	MEL	cancer	162	2101	2225			20	Somatic
TYMS_Underexpression	B	3	Predictive	Sensitivity/Response	Pemetrexed	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	378	382	N/A		20	N/A
MDM2_EXPRESSION	B	3	Prognostic	Poor Outcome		malignant pleural mesothelioma	7474	PLMESO	connective tissue cancer	201	339	343	N/A		20	Somatic
.::TFEB	B	3	Diagnostic	Positive		renal cell carcinoma with mit translocations	81413	RCC	kidney cancer	263	4747	4646	transcript_fusion		20	Somatic
H3C2_K27M	B	3	Diagnostic	Positive		diffuse midline glioma, h3 k27m-mutant	80684	DIFG	central nervous system cancer	3620	2684	2815			20	Somatic
BRAF_L505H	B	3	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	654	658	missense_variant		19	Somatic
DNMT1_EXPRESSION	B	3	Predictive	Resistance	Cisplatin	gastric adenocarcinoma	3717	STAD	stomach cancer	10534	331	335	N/A		18	N/A
KIT_V654A	B	3	Predictive	Sensitivity/Response	Sunitinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	73	73	missense_variant		18	Somatic
TSC1_Frameshift_Truncation	B	3	Predictive	Sensitivity/Response	Everolimus	invasive bladder transitional cell carcinoma	6477	BLCA	urinary bladder cancer	11054	124	124	frameshift_truncation	TSC Loss	18	Somatic
CEBPA_N-TERMINAL_FRAME_SHIFT	B	3	Prognostic	Better Outcome		acute myeloid leukemia	9119	AML	hematologic cancer	2531	28	28	frameshift_truncation,dominant_negative_variant		18	Somatic
PTPRB_Loss-of-function	B	3	Diagnostic	Positive		angiosarcoma	1816	ANGS	sarcoma	1115	797	819	loss_of_function_variant		18	Somatic
EGFR_C797S	B	3	Predictive	Resistance	Osimertinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	411	415	missense_variant		17.5	Somatic
KIT_Mutation	B	3	Predictive	Sensitivity/Response	Imatinib	melanoma	1909	MEL	cancer	162	384	388	transcript_variant		17	Somatic
MAP2K1_K57N	B	3	Prognostic	Poor Outcome		lung adenocarcinoma	3910	LUAD	lung cancer	1324	1246	1272	missense_variant		17	Somatic
SIRT1_Overexpression	B	3	Prognostic	Poor Outcome		pancreatic ductal carcinoma	3587	PACT	pancreatic cancer	1793	525	529	N/A		16	N/A
AKT2_EXPRESSION	B	3	Predictive	Sensitivity/Response	Trastuzumab	breast cancer	1612	BREAST	breast cancer	1612	274	278	N/A		15	N/A
ALCAM_EXPRESSION	B	3	Predictive	Resistance	Fluorouracil	colorectal cancer	9256	COADREAD	large intestine cancer	5672	352	356	N/A		15	N/A
AR-V7	B	3	Predictive	Resistance	Abiraterone, Enzalutamide	prostate cancer	10283	PROSTATE	prostate cancer	10283	358	362			15	N/A
BIRC5_NUCLEAR_EXPRESSION	B	3	Predictive	Sensitivity/Response	Taxane Compound, Platinum Compound	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	364	368	N/A		15	N/A
BRAF_G469	B	3	Predictive	Sensitivity/Response	BRAF Inhibitor, Mitogen-Activated Protein Kinase Kinase Inhibitor	melanoma	1909	MEL	cancer	162	2691	2822			15	Somatic
BRAF_K601E	B	3	Predictive	Sensitivity/Response	Cobimetinib, Vemurafenib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	4707	584	missense_variant		15	Somatic
BRCA1_Underexpression	B	3	Predictive	Sensitivity/Response	Taxane Compound, Platinum Compound	ovarian cancer	2394	OVARY	ovarian cancer	2394	399	403	N/A		15	N/A
CDKN1A_EXPRESSION	B	3	Predictive	Resistance	Fluorouracil	colorectal cancer	9256	COADREAD	large intestine cancer	5672	351	355	N/A		15	N/A
CTAG1B_Overexpression	B	3	Predictive	Sensitivity/Response	Letetresgene Autoleucel	multiple myeloma	9538	MM	hematologic cancer	2531	1247	1273	N/A		15	N/A
CTAG2_Overexpression	B	3	Predictive	Sensitivity/Response	Letetresgene Autoleucel	multiple myeloma	9538	MM	hematologic cancer	2531	1248	1274	N/A		15	N/A
DKK1_NUCLEAR_EXPRESSION	B	3	Predictive	Resistance	Oxaliplatin, Irinotecan, Levoleucovorin, Fluorouracil	colorectal cancer	9256	COADREAD	large intestine cancer	5672	336	340	N/A		15	N/A
EGFR_L861	B	3	Predictive	Sensitivity/Response	Erlotinib, Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1742	1866			15	Somatic
EGFR_Y1092_PHOSPHORYLATION	B	3	Predictive	Sensitivity/Response	Gefitinib, Erlotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	386	390	N/A		15	N/A
ERBB3_G284R	B	3	Predictive	Sensitivity/Response	Afatinib	transitional cell carcinoma	2671	TCC	cancer	162	684	703	missense_variant		15	Somatic
ERBB3_R103G	B	3	Predictive	Sensitivity/Response	Afatinib	transitional cell carcinoma	2671	TCC	cancer	162	683	702	missense_variant		15	Somatic
ERBB3_V104M	B	3	Predictive	Sensitivity/Response	Afatinib	transitional cell carcinoma	2671	TCC	cancer	162	682	701	missense_variant		15	Somatic
HLA-DRA_EXPRESSION	B	3	Predictive	Sensitivity/Response	Nivolumab, Pembrolizumab, Atezolizumab	skin melanoma	8923	MEL	skin cancer	4159	419	423	N/A		15	N/A
HMOX1_EXPRESSION	B	3	Predictive	Resistance	Sorafenib, Sunitinib	renal cell carcinoma	4450	RCC	kidney cancer	263	340	344	N/A		15	N/A
KIT_AMP	B	3	Predictive	Resistance	Imatinib	mucosal melanoma	50929	MUCM	cancer	162	582	586	transcript_amplification		15	N/A
MMP9_SERUM_LEVELS	B	3	Predictive	Resistance	Bevacizumab	inflammatory breast carcinoma	6263	IBC	breast cancer	1612	484	488	N/A		15	N/A
MS4A1_Mutation	B	3	Predictive	Resistance	R-CHOP Regimen	diffuse large b-cell lymphoma	50745	DLBCL	hematologic cancer	2531	3886	4018			15	Somatic
NFE2L2_Mutation	B	3	Predictive	Sensitivity/Response	Sapanisertib	lung squamous cell carcinoma	3907	LUSC	lung cancer	1324	2618	2749			15	Somatic
NT5E_Overexpression	B	3	Predictive	Sensitivity/Response	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	286	290	N/A		15	N/A
RB1_PHOSPHORYLATION	B	3	Predictive	Resistance	Alpelisib	breast cancer	1612	BREAST	breast cancer	1612	628	632	N/A		15	N/A
SMAD4_DEL	B	3	Predictive	Resistance	Fluorouracil	colorectal cancer	9256	COADREAD	large intestine cancer	5672	642	646	transcript_ablation		15	N/A
SSTR5_expression	B	3	Predictive	Sensitivity/Response	Pasireotide	neuroendocrine tumor	169	NET	neuroendocrine tumor	169	3620	3752			15	Somatic
STMN1_EXPRESSION	B	3	Predictive	Resistance	Paclitaxel	endometrial carcinoma	2871	UCEC	uterine cancer	363	353	357	N/A		15	N/A
TFF3_EXPRESSION	B	3	Predictive	Sensitivity/Response	Tamoxifen, Aminoglutethimide	breast cancer	1612	BREAST	breast cancer	1612	335	339	N/A		15	N/A
TSC1_Loss-of-function	B	3	Predictive	Sensitivity/Response	Everolimus	bladder carcinoma	4007	BLADDER	urinary bladder cancer	11054	125	125	loss_of_function_variant	TSC Loss	15	Somatic
TYMS_AMP	B	3	Predictive	Resistance	Pemetrexed	lung adenocarcinoma	3910	LUAD	lung cancer	1324	375	379	transcript_amplification		15	Somatic
B4GALT1_Overexpression	B	3	Prognostic	Poor Outcome		renal cell carcinoma	4450	RCC	kidney cancer	263	521	525	N/A		15	N/A
BAP1_EXPRESSION	B	3	Prognostic	Better Outcome		uveal melanoma	6039	UM	ocular cancer	2174	182	182	N/A		15	N/A
BCL2_Mutation	B	3	Prognostic	Poor Outcome		follicular lymphoma	50873	FLC	hematologic cancer	2531	2109	2233			15	Somatic
BCOR_Mutation	B	3	Prognostic	Better Outcome		stomach cancer	10534	STOMACH	stomach cancer	10534	659	663	transcript_variant		15	Somatic
CDKN2A_RS3814960	B	3	Prognostic	Poor Outcome		esophagus squamous cell carcinoma	3748	ESCC	esophageal cancer	5041	637	641	5_prime_UTR_exon_variant		15	Somatic
CIP2A_EXPRESSION	B	3	Prognostic	Poor Outcome		pancreatic ductal adenocarcinoma	3498	PAAD	pancreatic cancer	1793	470	474	N/A		15	Somatic
DCC_EXPRESSION	B	3	Prognostic	Better Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	1258	1284			15	Somatic
ETV4_Overexpression	B	3	Prognostic	Poor Outcome		prostate cancer	10283	PROSTATE	prostate cancer	10283	649	653	N/A		15	N/A
FGF13_CYTOPLASMIC_EXPRESSION	B	3	Prognostic	Poor Outcome		prostate cancer	10283	PROSTATE	prostate cancer	10283	443	447	N/A		15	N/A
GNAS_R201	B	3	Prognostic	Poor Outcome		pseudomyxoma peritonei	3559	PMP	appendix cancer	11239	850	876	amino_acid_substitution		15	Somatic
KIF23_EXPRESSION	B	3	Prognostic	Better Outcome		hepatocellular carcinoma	684	HCC	liver cancer	3571	681	700	N/A		15	Somatic
KIT_Exon_14_Mutation	B	3	Prognostic	Poor Outcome		gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	69	69	exon_variant		15	Somatic
KMT2C_MUTATION	B	3	Prognostic	Poor Outcome		skin squamous cell carcinoma	3151	SSCC	skin cancer	4159	664	668	transcription_variant,loss_of_function_variant		15	Somatic
MLH1_EXPRESSION	B	3	Prognostic	Poor Outcome		stomach carcinoma	5517	STOMACH	stomach cancer	10534	658	662	N/A		15	Somatic
NCOA3_AMP	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	204	204	transcript_amplification		15	Somatic
NCOA3_OVEREXPRESSION	B	3	Prognostic	Poor Outcome		breast cancer	1612	BREAST	breast cancer	1612	205	205	N/A		15	Somatic
NEDD9_EXPRESSION	B	3	Prognostic	Poor Outcome		hepatocellular carcinoma	684	HCC	liver cancer	3571	440	444	N/A		15	N/A
PIK3CA_Exon_10_or_Exon_21_Mutation	B	3	Prognostic	Poor Outcome		rectum cancer	1993	RECA	large intestine cancer	5672	3179	3311			15	Somatic
POLE_P286R	B	3	Prognostic	Better Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	1706	1830			15	Somatic
POLE_S459F	B	3	Prognostic	Better Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	1708	1832			15	Somatic
POLE_V411L	B	3	Prognostic	Better Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	1707	1831			15	Somatic
POT1_MUTATION	B	3	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	619	623	protein_altering_variant,loss_of_function_variant		15	Somatic
RIT1_OVEREXPRESSION	B	3	Prognostic	Poor Outcome		endometrial cancer	1380	UCEC	uterine cancer	363	292	296	N/A		15	Somatic
SETBP1_Exon_4_Mutation	B	3	Prognostic	Poor Outcome		atypical chronic myeloid leukemia	60597	ACML	hematologic cancer	2531	346	350	exon_variant		15	Somatic
SLC3A2::NRG1	B	3	Prognostic	Poor Outcome		lung adenocarcinoma	3910	LUAD	lung cancer	1324	2042	2166	transcript_fusion	NRG1 FUSIONS	15	Somatic
SMAD4_DEL	B	3	Prognostic	Poor Outcome		pancreatic cancer	1793	PANCREAS	pancreatic cancer	1793	560	564	loss_of_function_variant		15	Somatic
SMAD4_Expression	B	3	Prognostic	Better Outcome		pancreatic ductal adenocarcinoma	3498	PAAD	pancreatic cancer	1793	529	533	N/A		15	N/A
TERT_AMP	B	3	Prognostic	Poor Outcome		acral lentiginous melanoma	6367	ACRM	skin cancer	4159	219	219	transcript_amplification		15	Somatic
TGFA_EXPRESSION	B	3	Prognostic	Poor Outcome		head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	312	316	N/A		15	Somatic
THBS2_UNDEREXPRESSION	B	3	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	413	417	N/A		15	N/A
TP53_CONSERVED_DOMAIN_MUT	B	3	Prognostic	Poor Outcome		ovarian cancer	2394	OVARY	ovarian cancer	2394	1274	1300			15	Somatic
VHL_Loss-of-function	B	3	Prognostic	Poor Outcome		clear cell renal cell carcinoma	4467	CCRCC	kidney cancer	263	159	159	loss_of_function_variant		15	Somatic
ACTB::GLI1	B	3	Diagnostic	Positive		pericytoma with t(7;12)	80896	PC712	connective tissue cancer	201	761	780	transcript_fusion		15	Somatic
ACVR1_Gain-of-Function	B	3	Diagnostic	Positive		astrocytoma	3069	ASTR	central nervous system cancer	3620	1937	2061			15	Somatic
ACVR1_Mutation	B	3	Diagnostic	Positive		diffuse midline glioma, h3 k27m-mutant	80684	DIFG	central nervous system cancer	3620	2852	2983			15	Somatic
ATRX_Mutation	B	3	Diagnostic	Positive		astrocytoma	3069	ASTR	central nervous system cancer	3620	3072	3203			15	Somatic
FOXP1_AMP	B	3	Diagnostic	Positive		diffuse large b-cell lymphoma	50745	DLBCL	hematologic cancer	2531	153	153	transcript_amplification		15	Somatic
H3-3A_G34R	B	3	Diagnostic	Positive		diffuse glioma, h3 g34 mutant	80880	DIFG	central nervous system cancer	3620	3247	3379			15	Somatic
KMT2D_Loss-of-function	B	3	Diagnostic	Positive		follicular lymphoma	50873	FLC	hematologic cancer	2531	167	167	loss_of_function_variant		15	Somatic
PAX8::PPARG	B	3	Diagnostic	Positive		thyroid gland follicular carcinoma	3962	THFO	thyroid cancer	1781	209	209	transcript_fusion		15	Somatic
TMPRSS2::ERG	B	3	Diagnostic	Positive		prostate carcinoma	10286	PROSTATE	prostate cancer	10283	195	195	transcript_fusion		15	Somatic
CDKN2A_DEL	B	3	Predictive	Sensitivity/Response	Palbociclib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4750	554	loss_of_function_variant		0	Somatic
ERBB2_G778_P780dup	B	3	Predictive	Sensitivity/Response	Trastuzumab Deruxtecan	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4464	4486			0	Somatic
ESR1_Mutation	B	3	Predictive	Resistance	Palbociclib, Fulvestrant	breast cancer	1612	BREAST	breast cancer	1612	5149	3910			0	Somatic
KMT2C_DEL	B	3	Predictive	Resistance	Aromatase Inhibitor	breast cancer	1612	BREAST	breast cancer	1612	4215	4326			0	Somatic
MTAP_DEL	B	3	Predictive	Sensitivity/Response	PRMT5 Inhibitor AMG 193	solid tumor	NA	SOLID	cancer	162	4644	4585			0	Somatic
CK_High	B	3	Prognostic	Poor Outcome		chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	5120	4946			0	Somatic
Kataegis_Positive	B	3	Prognostic	Better Outcome		breast cancer	1612	BREAST	breast cancer	1612	5119	4945			0	Somatic
Methylation signature_ST-EPN-ZFTA	B	3	Prognostic	Better Outcome		supratentorial ependymoma, zfta fusion-positive	81252	EPM	central nervous system cancer	3620	5284	5049			0	Somatic
Methylation signature_ST-EPN-ZFTA	B	3	Prognostic	Better Outcome		supratentorial ependymoma, zfta fusion-positive	81252	EPM	central nervous system cancer	3620	5284	5049			0	Somatic
YWHAE::NUTM2A	B	3	Diagnostic	Positive		kidney clear cell sarcoma	4880	CCSK	kidney cancer	263	5283	5046			0	Somatic
YWHAE::NUTM2B	B	3	Diagnostic	Positive		kidney clear cell sarcoma	4880	CCSK	kidney cancer	263	5283	5047			0	Somatic
YWHAE::NUTM2E	B	3	Diagnostic	Positive		kidney clear cell sarcoma	4880	CCSK	kidney cancer	263	5283	5048			0	Somatic
MTOR_F2108L	C	5	Predictive	Resistance	Everolimus	thyroid gland carcinoma	3963	THYROID	thyroid cancer	1781	466	470	missense_variant		16.5	Somatic
KIT_V560DEL	C	5	Predictive	Sensitivity/Response	Imatinib	thymic carcinoma	3284	THYC	thymus cancer	3277	202	202	amino_acid_deletion,inframe_deletion		12.5	Somatic
TSC2_Q1178*	C	5	Predictive	Sensitivity/Response	Everolimus	thyroid gland carcinoma	3963	THYROID	thyroid cancer	1781	465	469	stop_gained		12.5	Somatic
GOLGA4::RAF1	C	5	Predictive	Sensitivity/Response	Trametinib, Cobimetinib	melanoma	1909	MEL	cancer	162	5250	5029	transcript_fusion		0	Somatic
ERBB2_AMP	C	4	Predictive	Sensitivity/Response	Trastuzumab, Irinotecan	lung small cell carcinoma	5409	SCLC	lung cancer	1324	302	306	transcript_amplification		891	Somatic
ERBB2_AMP	C	4	Predictive	Sensitivity/Response	Trastuzumab	endometrial serous adenocarcinoma	5750	USC	uterine cancer	363	302	306	transcript_amplification		891	Somatic
.::ALK	C	4	Diagnostic	Positive		inflammatory myofibroblastic tumor	50905	IMT	cancer	162	495	499	transcript_fusion	ALK Fusion	798	Somatic
ETV6::NTRK3	C	4	Predictive	Sensitivity/Response	Larotrectinib, Etoposide, Methotrexate	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	779	801	transcript_fusion		314	Somatic
ETV6::NTRK3	C	4	Predictive	Sensitivity/Response	Larotrectinib	congenital mesoblastic nephroma	4773	CMN	kidney cancer	263	779	801	transcript_fusion		314	Somatic
ABL1_T315I	C	4	Predictive	Sensitivity/Response	Axitinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4373	2	missense_variant	Imatinib Resistance	149	Somatic
LMNA::NTRK1	C	4	Predictive	Sensitivity/Response	Entrectinib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	1252	1278	transcript_fusion	NTRK1 Fusions	115	Somatic
LMNA::NTRK1	C	4	Diagnostic	Positive		lipofibromatosis-like neural tumor	80894	LPF-NT	connective tissue cancer	201	1252	1278	transcript_fusion	NTRK1 Fusions	115	Somatic
TERT_Promoter_Mutation	C	4	Prognostic	Poor Outcome		childhood low-grade glioma	80830	LGG	central nervous system cancer	3620	220	220	regulatory_region_variant		105	Somatic
ABL1_E255K	C	4	Predictive	Resistance	Imatinib, Imatinib Mesylate, Nilotinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4431	3	missense_variant	Imatinib Resistance	83	Somatic
MET_AMP	C	4	Predictive	Sensitivity/Response	Crizotinib, Vemurafenib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	266	270	transcript_amplification		81.5	N/A
TPM3::NTRK1	C	4	Predictive	Sensitivity/Response	Larotrectinib	sarcoma	1115	SARCOMA	sarcoma	1115	2861	2992	transcript_fusion		77	Somatic
DNAJB1::PRKACA	C	4	Diagnostic	Positive		mixed fibrolamellar hepatocellular carcinoma	80182	MFLCHCC	liver cancer	3571	31	31	transcript_fusion		75	Somatic
EML4::NTRK3	C	4	Predictive	Sensitivity/Response	Entrectinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	4167	4299	transcript_fusion		69.5	Somatic
ABL1_M351T	C	4	Predictive	Resistance	Imatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4556	1029	missense_variant		65.5	Somatic
NF1_Mutation	C	4	Predictive	Resistance	Vemurafenib	skin melanoma	8923	MEL	skin cancer	4159	583	587	protein_altering_variant,loss_of_function_variant		62	Somatic
EML4::ALK	C	4	Predictive	Sensitivity/Response	Crizotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	5	5	transcript_fusion	ALK Fusion	48	Somatic
EML4::ALK	C	4	Predictive	Sensitivity/Response	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	5	5	transcript_fusion	ALK Fusion	48	Somatic
EML4::ALK	C	4	Predictive	Sensitivity/Response	Alectinib	malignant pleural mesothelioma	7474	PLMESO	connective tissue cancer	201	5	5	transcript_fusion	ALK Fusion	48	Somatic
ALK_I1171	C	4	Predictive	Resistance	Alectinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	523	527	missense_variant		42.5	Somatic
ALK_I1171	C	4	Predictive	Sensitivity/Response	Ceritinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	523	527	missense_variant		42.5	Somatic
ERBB2_Y772_A775DUP	C	4	Predictive	Sensitivity/Response	Afatinib, Trastuzumab Emtansine	lung adenocarcinoma	3910	LUAD	lung cancer	1324	410	414	inframe_insertion		42	Somatic
BCR::JAK2	C	4	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2729	2860	transcript_fusion	JAK2 fusions in B-ALL	35	Somatic
BCR::JAK2	C	4	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2729	2860	transcript_fusion	JAK2 fusions in B-ALL	35	Somatic
EGFR::RAD51	C	4	Predictive	Sensitivity/Response	Erlotinib, Osimertinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	2079	2203	transcript_fusion		30	Somatic
KANK1::NTRK2	C	4	Predictive	Sensitivity/Response	Larotrectinib	anaplastic ependymoma	5889	APE	central nervous system cancer	3620	3027	3158	transcript_fusion		30	Somatic
ALK_C1156Y	C	4	Predictive	Resistance	Crizotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	4225	4331	missense_variant		29	Somatic
EML4::ALK	C	4	Predictive	Sensitivity/Response	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	499	503	transcript_fusion	ALK Fusion	25	Somatic
ETV6::JAK2	C	4	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2728	2859	transcript_fusion	JAK2 fusions in B-ALL	25	Somatic
SSBP2::JAK2	C	4	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2530	2661	transcript_fusion	JAK2 fusions in B-ALL	25	Somatic
EGFR_S492R	C	4	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	449	453	missense_variant	EGFR ECD MUTATION	23	Somatic
ALK_L1196M	C	4	Predictive	Resistance	Crizotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	4230	4324	missense_variant		21	Somatic
ALK_Alternative_Transcript_	C	4	Predictive	Sensitivity/Response	Crizotinib	skin melanoma	8923	MEL	skin cancer	4159	813	839			20	N/A
ALK_C1156Y	C	4	Predictive	Resistance	Lorlatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4253	4331	missense_variant		20	Somatic
ALK_C1156Y	C	4	Predictive	Sensitivity/Response	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4253	4331	missense_variant		20	Somatic
EGFR_G465R	C	4	Predictive	Sensitivity/Response	Futuximab/Modotuximab Mixture	colorectal cancer	9256	COADREAD	large intestine cancer	5672	439	443	missense_variant	EGFR ECD MUTATION	20	Somatic
EGFR_G465R	C	4	Predictive	Resistance	Cetuximab, Panitumumab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	439	443	missense_variant	EGFR ECD MUTATION	20	Somatic
MET_D1228V	C	4	Predictive	Sensitivity/Response	Cabozantinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	776	798	missense_variant		20	Somatic
MET_D1228V	C	4	Predictive	Resistance	Savolitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	776	798	missense_variant		20	Somatic
EGFR_E746_A750del	C	4	Predictive	Sensitivity/Response	Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	976	1002	inframe_deletion		19.5	Somatic
ALK_T1151dup	C	4	Predictive	Resistance	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4308	4389	inframe_insertion		18	Somatic
.::NRG1	C	4	Predictive	Sensitivity/Response	Afatinib	pancreatic adenocarcinoma	4074	PAAD	pancreatic cancer	1793	2162	2286	transcript_fusion	NRG1 FUSIONS	17.5	Somatic
ALK_G1269A	C	4	Predictive	Resistance	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4312	308	missense_variant		17.5	Somatic
ALK_I1171N	C	4	Predictive	Resistance	Alectinib	malignant pleural mesothelioma	7474	PLMESO	connective tissue cancer	201	4328	588	missense_variant		17.5	Somatic
BRAF_AMP	C	4	Predictive	Resistance	Trametinib, Dabrafenib	melanoma	1909	MEL	cancer	162	1243	1269	transcript_amplification		17.5	Somatic
ERBB2_Kinase_Domain_Mutation	C	4	Predictive	Sensitivity/Response	Trastuzumab, Afatinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	409	413	protein_altering_variant		17.5	Somatic
PALB2_Biallelic_Inactivation	C	4	Predictive	Sensitivity/Response	Mitomycin	pancreatic cancer	1793	PANCREAS	pancreatic cancer	1793	528	532	loss_of_function_variant		17.5	Somatic
TPR::NTRK1	C	4	Predictive	Sensitivity/Response	Larotrectinib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	3333	3465	transcript_fusion		17.5	Somatic
AKT1_Q79K	C	4	Predictive	Resistance	Dabrafenib	melanoma	1909	MEL	cancer	162	169	169	missense_variant		16	Somatic
CSF3R_T618I	C	4	Predictive	Sensitivity/Response	Ruxolitinib	chronic neutrophilic leukemia	80187	CNL	hematologic cancer	2531	2260	2387	missense_variant		14	Somatic
ETV6::NTRK2	C	4	Predictive	Sensitivity/Response	Larotrectinib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	2269	2396	transcript_fusion		13	Somatic
BRAF_L597R	C	4	Predictive	Sensitivity/Response	Vemurafenib	melanoma	1909	MEL	cancer	162	284	288	missense_variant	Other BRAF V600's	12	Somatic
ABL1_Double_Ph	C	4	Predictive	Resistance	Imatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	2878	3009			10	Somatic
ALK_I1171T	C	4	Predictive	Sensitivity/Response	Ceritinib	neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	3239	3371			10	Somatic
ALK_L1152R	C	4	Predictive	Resistance	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4255	307	missense_variant		10	Somatic
BTK_T316A	C	4	Predictive	Resistance	Ibrutinib	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	844	870	missense_variant		10	Somatic
DPYD_EXON_11-19_DELETION	C	4	Predictive	Sensitivity/Response	Fluorouracil, Leucovorin	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	2762	2893	inframe_deletion		10	Somatic
EGFR_D770_N771insGL	C	4	Predictive	Resistance	Erlotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	1422	1514	inframe_insertion		10	Somatic
EGFR_D770delinsGY	C	4	Predictive	Resistance	Erlotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	2090	2214	inframe_insertion,delins		10	Somatic
ETV6::NTRK3	C	4	Predictive	Resistance	Entrectinib	mammary analogue secretory carcinoma	80808	HNMASC	head and neck cancer	11934	5161	801	transcript_fusion		10	Somatic
JAK1_Q503*	C	4	Predictive	Resistance	Pembrolizumab	skin melanoma	8923	MEL	skin cancer	4159	610	614	stop_gained		10	Somatic
JAK2_c.1641+1dup	C	4	Predictive	Resistance	Pembrolizumab	skin melanoma	8923	MEL	skin cancer	4159	611	615			10	Somatic
MAP2K1_C121S	C	4	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	623	627	missense_variant		10	Somatic
MAP2K1_Q56_V60del	C	4	Predictive	Sensitivity/Response	Selumetinib	ovarian serous carcinoma	50933	SOC	ovarian cancer	2394	651	655	inframe_deletion		10	Somatic
MAPK1_E322K	C	4	Predictive	Sensitivity/Response	Erlotinib	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	316	320	missense_variant,gain_of_function_variant		10	Somatic
PIK3CA_F930S	C	4	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	3535	3667			10	Somatic
PIK3CA_K944N	C	4	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	3534	3666			10	Somatic
PIK3CA_K966E	C	4	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	3537	3669			10	Somatic
PIK3CA_V955G	C	4	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	3536	3668			10	Somatic
PIK3CA_V955I	C	4	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	2870	3001	missense_variant		10	Somatic
PREX2_R172I	C	4	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	2237	2364	missense_variant		10	Somatic
RAD50_L1237F	C	4	Predictive	Sensitivity/Response	Irinotecan, Checkpoint Kinase Inhibitor AZD7762	ureter small cell carcinoma	6886	SCBC	ureter cancer	11819	2044	2168			10	Somatic
RANBP2::ALK	C	4	Predictive	Sensitivity/Response	Crizotinib	inflammatory myofibroblastic tumor	50905	IMT	cancer	162	510	514	transcript_fusion	ALK Fusion	10	Somatic
EIF1AX_MUTATION	C	4	Prognostic	Better Outcome		uveal melanoma	6039	UM	ocular cancer	2174	670	674	transcript_variant		10	Somatic
GOPC::ROS1	C	4	Predictive	Sensitivity/Response	Entrectinib	melanoma	1909	MEL	cancer	162	2639	2770	transcript_fusion		3	Somatic
ANO10::RAF1	C	4	Predictive	Sensitivity/Response	Trametinib	melanoma	1909	MEL	cancer	162	5251	5030	transcript_fusion		0	Somatic
CD74::ROS1	C	4	Predictive	Resistance	Crizotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	5075	4908	transcript_fusion		0	Somatic
FLT3_D835Y	C	4	Predictive	Resistance	Sorafenib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	4616	3011	missense_variant		0	Somatic
LMNA::NTRK1	C	4	Predictive	Resistance	Entrectinib	colorectal adenocarcinoma	50861	COADREAD	large intestine cancer	5672	5244	1278	transcript_fusion	NTRK1 Fusions	0	Somatic
PML::RARA	C	4	Predictive	Resistance	Tretinoin	acute promyelocytic leukemia	60318	APL	hematologic cancer	2531	5239	108	transcript_fusion		0	Somatic
ZMYM2::FGFR1	C	4	Predictive	Sensitivity/Response	Midostaurin	myeloproliferative neoplasm	2226	MPN	hematologic cancer	2531	4477	4496	transcript_fusion		0	Somatic
BRAF_V600E	C	3	Predictive	Sensitivity/Response	Vemurafenib, Trametinib, Dabrafenib	gastrointestinal neuroendocrine tumor	50626	GINET	gastrointestinal system cancer	3119	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	C	3	Predictive	Sensitivity/Response	Vemurafenib	multiple myeloma	9538	MM	hematologic cancer	2531	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	C	3	Predictive	Sensitivity/Response	Vemurafenib	childhood pilocytic astrocytoma	6812	PAST	central nervous system cancer	3620	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	C	3	Predictive	Sensitivity/Response	Vemurafenib	ovarian serous carcinoma	50933	SOC	ovarian cancer	2394	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	C	3	Predictive	Sensitivity/Response	Dabrafenib, Trametinib, Panitumumab, Irinotecan, Vemurafenib	cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	C	3	Predictive	Sensitivity/Response	Dabrafenib, Trametinib	intrahepatic cholangiocarcinoma	4928	IHCH	biliary tract cancer	4607	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	C	3	Predictive	Sensitivity/Response	Pertuzumab	thyroid gland anaplastic carcinoma	80522	THAP	thyroid cancer	1781	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	C	3	Predictive	Sensitivity/Response	Vemurafenib	laryngeal squamous cell carcinoma	2876	LXSC	head and neck cancer	11934	12	12	missense_variant		1378.5	Somatic
ERBB2_AMP	C	3	Predictive	Sensitivity/Response	Pertuzumab, Trastuzumab	cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	302	306	transcript_amplification		891	Somatic
.::ALK	C	3	Predictive	Sensitivity/Response	Crizotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	495	499	transcript_fusion	ALK Fusion	798	Somatic
.::ALK	C	3	Predictive	Sensitivity/Response	Crizotinib	thyroid gland anaplastic carcinoma	80522	THAP	thyroid cancer	1781	495	499	transcript_fusion	ALK Fusion	798	Somatic
EGFR_T790M	C	3	Predictive	Sensitivity/Response	Erlotinib, Pemetrexed	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	34	34	missense_variant	EGFR TKI Resistance	406.25	Somatic
EGFR_L858R	C	3	Predictive	Resistance	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	33	33	missense_variant		379	Somatic
BCR::ABL1	C	3	Predictive	Sensitivity/Response	Dasatinib	acute lymphoblastic leukemia	9952	ALL	hematologic cancer	2531	1	1	transcript_fusion	ABL1 fusions in B-ALL	353.5	Somatic
ETV6::NTRK3	C	3	Predictive	Sensitivity/Response	Entrectinib	mammary analogue secretory carcinoma	80808	HNMASC	head and neck cancer	11934	779	801	transcript_fusion		314	Somatic
ETV6::NTRK3	C	3	Predictive	Sensitivity/Response	Larotrectinib	breast secretory carcinoma	4922	JSCB	breast cancer	1612	779	801	transcript_fusion		314	Somatic
PTEN_DEL	C	3	Predictive	Sensitivity/Response	Paclitaxel, Buparlisib, Carboplatin	cancer	162	CANCER	cancer	162	214	214	loss_of_function_variant		272	Somatic
KIT_Exon_11_Mutation	C	3	Predictive	Sensitivity/Response	Sunitinib	melanoma	1909	MEL	cancer	162	66	66	coding_sequence_variant	KIT Exon 11	197.5	Somatic
.::RET	C	3	Predictive	Sensitivity/Response	Alectinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1595	1687	transcript_fusion		192.5	Somatic
FGFR1_AMP	C	3	Predictive	Sensitivity/Response	Pazopanib	adenosquamous lung carcinoma	4829	LUAS	lung cancer	1324	263	267	transcript_amplification		185.5	Somatic
KRAS_G12C	C	3	Predictive	Resistance	Panitumumab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	78	78	missense_variant	EGFR TKI Resistance	176.5	Somatic
KRAS_G12D	C	3	Predictive	Sensitivity/Response	Therapeutic Tumor Infiltrating Lymphocytes	colorectal cancer	9256	COADREAD	large intestine cancer	5672	79	79	missense_variant	EGFR TKI Resistance	162	Somatic
KRAS_G12D	C	3	Predictive	Resistance	Panitumumab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	79	79	missense_variant	EGFR TKI Resistance	162	Somatic
ABL1_T315I	C	3	Predictive	Resistance	Imatinib Mesylate	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4373	2	missense_variant	Imatinib Resistance	149	Somatic
KIT_Exon_9_Mutation	C	3	Predictive	Reduced Sensitivity	Regorafenib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	505	509	exon_variant		122.5	Somatic
ABL1_F317L	C	3	Predictive	Resistance	Imatinib Mesylate	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4376	1028	missense_variant		121.5	Somatic
LMNA::NTRK1	C	3	Predictive	Sensitivity/Response	Entrectinib	colorectal adenocarcinoma	50861	COADREAD	large intestine cancer	5672	1252	1278	transcript_fusion	NTRK1 Fusions	115	Somatic
LMNA::NTRK1	C	3	Predictive	Sensitivity/Response	Larotrectinib	sarcoma	1115	SARCOMA	sarcoma	1115	1252	1278	transcript_fusion	NTRK1 Fusions	115	Somatic
LMNA::NTRK1	C	3	Predictive	Sensitivity/Response	Crizotinib	congenital fibrosarcoma	8418	FIBS	connective tissue cancer	201	1252	1278	transcript_fusion	NTRK1 Fusions	115	Somatic
LMNA::NTRK1	C	3	Predictive	Sensitivity/Response	TRK Inhibitor	spindle cell sarcoma	4235	SCS	sarcoma	1115	1252	1278	transcript_fusion	NTRK1 Fusions	115	Somatic
LMNA::NTRK1	C	3	Predictive	Sensitivity/Response	Larotrectinib	solid tumor	NA	SOLID	cancer	162	1252	1278	transcript_fusion	NTRK1 Fusions	115	Somatic
LMNA::NTRK1	C	3	Predictive	Sensitivity/Response	Entrectinib	lipofibromatosis-like neural tumor	80894	LPF-NT	connective tissue cancer	201	1252	1278	transcript_fusion	NTRK1 Fusions	115	Somatic
LMNA::NTRK1	C	3	Diagnostic	Positive		spitzoid melanoma	70326	SPZM	skin cancer	4159	1252	1278	transcript_fusion	NTRK1 Fusions	115	Somatic
LMNA::NTRK1	C	3	Diagnostic	Positive		lipofibromatosis-like neural tumor	80894	LPF-NT	connective tissue cancer	201	1252	1278	transcript_fusion	NTRK1 Fusions	115	Somatic
LMNA::NTRK1	C	3	Diagnostic	Positive		lipofibromatosis-like neural tumor	80894	LPF-NT	connective tissue cancer	201	1252	1278	transcript_fusion	NTRK1 Fusions	115	Somatic
LMNA::NTRK1	C	3	Diagnostic	Positive		lipofibromatosis-like neural tumor	80894	LPF-NT	connective tissue cancer	201	1252	1278	transcript_fusion	NTRK1 Fusions	115	Somatic
KRAS_G13D	C	3	Predictive	Resistance	Panitumumab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	81	81	missense_variant		108.5	Somatic
METx14del	C	3	Predictive	Sensitivity/Response	Crizotinib, Capmatinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	320	324	exon_loss_variant		108.5	Somatic
METx14del	C	3	Predictive	Sensitivity/Response	Crizotinib	histiocytic and dendritic cell cancer	5621	HDCN	hematologic cancer	2531	320	324	exon_loss_variant		108.5	Somatic
IDH2_Mutation	C	3	Predictive	Sensitivity/Response	Venetoclax	acute myeloid leukemia	9119	AML	hematologic cancer	2531	566	570	protein_altering_variant		101.5	Somatic
PDGFRA_D842V	C	3	Predictive	Resistance	Sunitinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	99	99	missense_variant	Imatinib Resistance	100.5	Somatic
PIK3CA_H1047R	C	3	Predictive	Resistance	Cetuximab, Irinotecan	colorectal cancer	9256	COADREAD	large intestine cancer	5672	107	107	missense_variant		96.5	Somatic
IDH1_Mutation	C	3	Predictive	Sensitivity/Response	Venetoclax	acute myeloid leukemia	9119	AML	hematologic cancer	2531	641	645	transcript_variant		90.5	Somatic
ABL1_E255K	C	3	Predictive	Resistance	Dasatinib	acute lymphoblastic leukemia	9952	ALL	hematologic cancer	2531	4431	3	missense_variant	Imatinib Resistance	83	Somatic
ABL1_Y253H	C	3	Predictive	Resistance	Imatinib Mesylate, Nilotinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4550	4529	missense_variant		82	Somatic
MET_AMP	C	3	Predictive	Sensitivity/Response	Onartuzumab	gastric adenocarcinoma	3717	STAD	stomach cancer	10534	266	270	transcript_amplification		81.5	Somatic
MET_AMP	C	3	Predictive	Sensitivity/Response	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	266	270	transcript_amplification		81.5	Somatic
MET_AMP	C	3	Predictive	Sensitivity/Response	Crizotinib	glioblastoma	3068	GB	central nervous system cancer	3620	266	270	transcript_amplification		81.5	Somatic
MET_AMP	C	3	Predictive	Sensitivity/Response	Crizotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	266	270	transcript_amplification		81.5	Somatic
MET_AMP	C	3	Predictive	Sensitivity/Response	Crizotinib	cancer	162	CANCER	cancer	162	266	270	transcript_amplification		81.5	N/A
RCSD1::ABL1	C	3	Predictive	Sensitivity/Response	Imatinib	b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2550	2681	transcript_fusion	ABL1 fusions in B-ALL	80.5	Somatic
RCSD1::ABL1	C	3	Predictive	Sensitivity/Response	Imatinib, Dasatinib, Ponatinib	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2550	2681	transcript_fusion	ABL1 fusions in B-ALL	80.5	Somatic
RCSD1::ABL1	C	3	Predictive	Reduced Sensitivity	Dasatinib	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2550	2681	transcript_fusion	ABL1 fusions in B-ALL	80.5	Somatic
RCSD1::ABL1	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2550	2681	transcript_fusion	ABL1 fusions in B-ALL	80.5	Somatic
ERBB2_Overexpression	C	3	Predictive	Sensitivity/Response	Zoledronic Acid, Capecitabine, Trastuzumab	salivary gland cancer	8850	SACA	head and neck cancer	11934	849	875	N/A		77.5	N/A
PIK3CA_E545K	C	3	Predictive	Resistance	Panitumumab, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	104	104	missense_variant		77.5	Somatic
TPM3::NTRK1	C	3	Predictive	Sensitivity/Response	Larotrectinib	spindle cell sarcoma	4235	SCS	sarcoma	1115	2861	2992	transcript_fusion		77	Somatic
TPM3::NTRK1	C	3	Predictive	Sensitivity/Response	Larotrectinib	thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	2861	2992	transcript_fusion		77	Somatic
TPM3::NTRK1	C	3	Predictive	Sensitivity/Response	Larotrectinib	lung carcinoma	3905	LUNG	lung cancer	1324	2861	2992	transcript_fusion		77	Somatic
EML4::NTRK3	C	3	Predictive	Sensitivity/Response	Larotrectinib	high grade glioma	3070	HGG	central nervous system cancer	3620	4167	4299	transcript_fusion		69.5	Somatic
EML4::NTRK3	C	3	Diagnostic	Positive		congenital fibrosarcoma	8418	FIBS	connective tissue cancer	201	4167	4299	transcript_fusion		69.5	Somatic
EML4::NTRK3	C	3	Diagnostic	Positive		congenital mesoblastic nephroma	4773	CMN	kidney cancer	263	4167	4299	transcript_fusion		69.5	Somatic
EML4::NTRK3	C	3	Diagnostic	Positive		congenital fibrosarcoma	8418	FIBS	connective tissue cancer	201	4167	4299	transcript_fusion		69.5	Somatic
KRAS_G12V	C	3	Predictive	Resistance	Panitumumab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	421	425	missense_variant		67.5	Somatic
ABL1_G250E	C	3	Predictive	Resistance	Imatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4555	1023	missense_variant		67	Somatic
PCM1::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	567	571	transcript_fusion	JAK2 fusions in B-ALL	57.5	Somatic
CDKN2A_DEL	C	3	Predictive	Sensitivity/Response	Letrozole, Palbociclib	her2-receptor negative breast cancer	60080	BRCA	breast cancer	1612	550	554	loss_of_function_variant		52.5	Somatic
.::ROS1	C	3	Predictive	Sensitivity/Response	Crizotinib	bronchiolo-alveolar adenocarcinoma	4926	BAC	lung cancer	1324	2562	2693	transcript_fusion		50	Somatic
BRAF_V600D	C	3	Predictive	Sensitivity/Response	BRAF Inhibitor, Mitogen-Activated Protein Kinase Kinase Inhibitor	melanoma	1909	MEL	cancer	162	11	11	missense_variant	Other BRAF V600's	47	Somatic
BRD4::NUTM1	C	3	Predictive	Sensitivity/Response	Birabresib	nut midline carcinoma	60463	NUTC	cancer	162	5152	4973	transcript_fusion		45.5	Somatic
SQSTM1::NTRK1	C	3	Predictive	Sensitivity/Response	Entrectinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	778	800	transcript_fusion	NTRK1 Fusions	45	Somatic
SQSTM1::NTRK1	C	3	Predictive	Sensitivity/Response	Larotrectinib	congenital fibrosarcoma	8418	FIBS	connective tissue cancer	201	778	800	transcript_fusion	NTRK1 Fusions	45	Somatic
SQSTM1::NTRK1	C	3	Predictive	Sensitivity/Response	Larotrectinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	778	800	transcript_fusion	NTRK1 Fusions	45	Somatic
SQSTM1::NTRK1	C	3	Predictive	Sensitivity/Response	Larotrectinib	thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	778	800	transcript_fusion	NTRK1 Fusions	45	Somatic
BRAF_D594G	C	3	Predictive	Resistance	Cetuximab, Irinotecan	colorectal cancer	9256	COADREAD	large intestine cancer	5672	607	611	missense_variant		43.5	Somatic
MYB_Rearrangement	C	3	Diagnostic	Positive		isomorphic diffuse glioma	4857	DASTR	central nervous system cancer	3620	4218	4328			42.5	Somatic
FGFR2::BICC1	C	3	Predictive	Sensitivity/Response	Erdafitinib	transitional cell carcinoma	2671	TCC	cancer	162	763	782	transcript_fusion		38	Somatic
FGFR2::BICC1	C	3	Predictive	Sensitivity/Response	Erdafitinib	endometrial cancer	1380	UCEC	uterine cancer	363	763	782	transcript_fusion		38	Somatic
ERBB2_Mutation	C	3	Predictive	Sensitivity/Response	Platinum Compound	bladder carcinoma	4007	BLADDER	urinary bladder cancer	11054	662	666	missense_variant		37.5	Somatic
BCR::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2729	2860	transcript_fusion	JAK2 fusions in B-ALL	35	Somatic
BCR::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2729	2860	transcript_fusion	JAK2 fusions in B-ALL	35	Somatic
FUS::CREB3L2	C	3	Diagnostic	Positive		low-grade fibromyxoid sarcoma	80534	LGFMS	connective tissue cancer	201	5155	4975	transcript_fusion		35	Somatic
AKT1_E17K	C	3	Predictive	Sensitivity/Response	Capivasertib	breast cancer	1612	BREAST	breast cancer	1612	4	4	missense_variant		33.5	Somatic
EBF1::PDGFRB	C	3	Predictive	Sensitivity/Response	Imatinib, Chemotherapy	b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	531	535	transcript_fusion		32.5	Somatic
EBF1::PDGFRB	C	3	Predictive	Sensitivity/Response	Imatinib	childhood b-cell acute lymphoblastic leukemia	80146	BLL	hematologic cancer	2533	531	535	transcript_fusion		32.5	Somatic
ETV6::ABL1	C	3	Predictive	Sensitivity/Response	Imatinib	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2448	2575	transcript_fusion	ABL1 fusions in B-ALL	32.5	Somatic
KRAS_G12R	C	3	Predictive	Resistance	Chemotherapy, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	526	530	missense_variant		32.5	Somatic
SFPQ::ABL1	C	3	Predictive	Sensitivity/Response	Imatinib, Dasatinib	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	3156	3287	transcript_fusion	ABL1 fusions in B-ALL	32.5	Somatic
EWSR1::ERG	C	3	Diagnostic	Positive		ewing sarcoma	3369	ES	bone cancer	184	4668	4602	transcript_fusion		32.5	Somatic
SFPQ::ABL1	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	3156	3287	transcript_fusion	ABL1 fusions in B-ALL	32.5	Somatic
SNX2::ABL1	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2547	2678	transcript_fusion	ABL1 fusions in B-ALL	30.5	Somatic
SNX2::ABL1	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2547	2678	transcript_fusion	ABL1 fusions in B-ALL	30.5	Somatic
KANK1::NTRK2	C	3	Predictive	Sensitivity/Response	Larotrectinib	glioblastoma	3068	GB	central nervous system cancer	3620	3027	3158	transcript_fusion		30	Somatic
PAX5::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2730	2861	transcript_fusion	JAK2 fusions in B-ALL	30	Somatic
PAX5::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2730	2861	transcript_fusion	JAK2 fusions in B-ALL	30	Somatic
KIT_N822K	C	3	Predictive	Resistance	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	1237	1263	missense_variant	KIT Exon 17	29.5	Somatic
ALK_C1156Y	C	3	Predictive	Resistance	Crizotinib, Luminespib, Ceritinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4225	4331	missense_variant		29	Somatic
ALK_C1156Y	C	3	Predictive	Sensitivity/Response	Lorlatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4225	4331	missense_variant		29	Somatic
COL1A1::PDGFB	C	3	Predictive	Sensitivity/Response	Sunitinib	dermatofibrosarcoma protuberans	3507	DFSP	connective tissue cancer	201	2841	2972	transcript_fusion		27.5	Somatic
EML4::ALK	C	3	Predictive	Sensitivity/Response	Crizotinib	cancer	162	CANCER	cancer	162	499	503	transcript_fusion	ALK Fusion	25	Somatic
SSBP2::JAK2	C	3	Predictive	Sensitivity/Response	Ruxolitinib	b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2530	2661	transcript_fusion	JAK2 fusions in B-ALL	25	Somatic
ETV6::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2728	2859	transcript_fusion	JAK2 fusions in B-ALL	25	Somatic
ETV6::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2728	2859	transcript_fusion	JAK2 fusions in B-ALL	25	Somatic
SSBP2::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2530	2661	transcript_fusion	JAK2 fusions in B-ALL	25	Somatic
NRAS_Q61K	C	3	Predictive	Resistance	Cetuximab, Chemotherapy	colorectal cancer	9256	COADREAD	large intestine cancer	5672	423	427	missense_variant		24.5	Somatic
RET_Overexpression	C	3	Predictive	Sensitivity/Response	Sunitinib	papillary adenocarcinoma	3112	PA	cancer	162	593	597	N/A		24.5	Somatic
FGFR3::TACC3	C	3	Predictive	Sensitivity/Response	Infigratinib	transitional cell carcinoma	2671	TCC	cancer	162	808	830	transcript_fusion		22.5	Somatic
MTOR_Mutation	C	3	Predictive	Sensitivity/Response	Everolimus, Pazopanib	bladder carcinoma	4007	BLADDER	urinary bladder cancer	11054	273	277	protein_altering_variant		22.5	Somatic
EWSR1::CREB3L1	C	3	Diagnostic	Positive		sclerosing epithelioid fibrosarcoma	3355	SEF	connective tissue cancer	201	5154	4974	transcript_fusion		22.5	Somatic
EWSR1::CREB3L1	C	3	Diagnostic	Positive		sclerosing epithelioid fibrosarcoma	3355	SEF	connective tissue cancer	201	5154	4974	transcript_fusion		22.5	Somatic
KIT_T670I	C	3	Predictive	Resistance	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	1241	1267	missense_variant		21.5	Somatic
EGFR_S768I	C	3	Predictive	Sensitivity/Response	Erlotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	558	562	missense_variant		20.5	Somatic
EGFR_E746_A750del	C	3	Predictive	Sensitivity/Response	Erlotinib	bronchiolo-alveolar adenocarcinoma	4926	BAC	lung cancer	1324	976	1002	inframe_deletion		19.5	Somatic
CLTC::ALK	C	3	Predictive	Sensitivity/Response	Crizotinib	diffuse large b-cell lymphoma	50745	DLBCL	hematologic cancer	2531	516	520	transcript_fusion	ALK Fusion	19	Somatic
CLTC::ALK	C	3	Prognostic	Poor Outcome		diffuse large b-cell lymphoma	50745	DLBCL	hematologic cancer	2531	516	520	transcript_fusion	ALK Fusion	19	Somatic
ALK_I1171N	C	3	Predictive	Sensitivity/Response	Lorlatinib	malignant pleural mesothelioma	7474	PLMESO	connective tissue cancer	201	4328	588	missense_variant		17.5	Somatic
BRAF_AMP	C	3	Predictive	Resistance	Panitumumab, Dabrafenib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	1243	1269	transcript_amplification		17.5	Somatic
PALB2_Biallelic_Inactivation	C	3	Predictive	Sensitivity/Response	Olaparib	prostate cancer	10283	PROSTATE	prostate cancer	10283	528	532	loss_of_function_variant		17.5	Somatic
TPR::NTRK1	C	3	Predictive	Sensitivity/Response	Larotrectinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	3333	3465	transcript_fusion		17.5	Somatic
TPR::NTRK1	C	3	Predictive	Sensitivity/Response	Larotrectinib	thyroid gland papillary carcinoma	3969	THPA	thyroid cancer	1781	3333	3465	transcript_fusion		17.5	Somatic
ALK_AMP	C	3	Predictive	Resistance	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4172	4301			15.5	Somatic
TP53_Y220C	C	3	Predictive	Sensitivity/Response	Mitomycin, Cisplatin, Etoposide	stomach carcinoma	5517	STOMACH	stomach cancer	10534	896	922	missense_variant		15.5	Somatic
ATP1B1::NRG1	C	3	Predictive	Sensitivity/Response	Afatinib	cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	2054	2178	transcript_fusion	NRG1 FUSIONS	15	Somatic
ATP1B1::NRG1	C	3	Predictive	Sensitivity/Response	Afatinib	pancreatic ductal adenocarcinoma	3498	PAAD	pancreatic cancer	1793	2054	2178	transcript_fusion	NRG1 FUSIONS	15	Somatic
ERBB2_G778_P780DUP	C	3	Predictive	Sensitivity/Response	Afatinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	795	817	inframe_insertion		15	Somatic
ERBB2_G778_P780DUP	C	3	Predictive	Sensitivity/Response	Dacomitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	795	817	inframe_insertion		15	Somatic
POLE_Mutation	C	3	Predictive	Sensitivity/Response	Pembrolizumab	endometrial cancer	1380	UCEC	uterine cancer	363	775	797	gene_variant		15	Somatic
ATF7IP::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2715	2846	transcript_fusion	JAK2 fusions in B-ALL	15	Somatic
ATF7IP::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2715	2846	transcript_fusion	JAK2 fusions in B-ALL	15	Somatic
PPFIBP1::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2717	2848	transcript_fusion	JAK2 fusions in B-ALL	15	Somatic
PPFIBP1::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2717	2848	transcript_fusion	JAK2 fusions in B-ALL	15	Somatic
ALK_F1245C	C	3	Predictive	Sensitivity/Response	Ceritinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4221	549	missense_variant		14.5	Somatic
BRAF_L597Q	C	3	Predictive	Sensitivity/Response	Trametinib	skin melanoma	8923	MEL	skin cancer	4159	579	583	missense_variant		14.5	Somatic
KIT_D820Y	C	3	Predictive	Resistance	Imatinib	melanoma	1909	MEL	cancer	162	960	986	missense_variant	KIT Exon 17	14.5	Somatic
KIT_V560D	C	3	Predictive	Resistance	Sunitinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	945	971	missense_variant		14.5	Somatic
KIT_W557_K558del	C	3	Predictive	Resistance	Sunitinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	935	961	conservative_inframe_deletion		14.5	Somatic
SMO_D473H	C	3	Predictive	Resistance	Vismodegib	medulloblastoma	50902	MBL	central nervous system cancer	3620	295	299	missense_variant		13.5	Somatic
CCDC6::RET	C	3	Predictive	Sensitivity/Response	Agerafenib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	622	626	transcript_fusion		12.5	Somatic
ERBB2_P780INS	C	3	Predictive	Sensitivity/Response	Dacomitinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	41	41	inframe_insertion	HER2 Activating	12.5	Somatic
NRAS_Q61L	C	3	Predictive	Resistance	Irinotecan, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	95	95	missense_variant		12.5	Somatic
PDE4DIP::NTRK1	C	3	Predictive	Sensitivity/Response	Larotrectinib	sarcoma	1115	SARCOMA	sarcoma	1115	2165	2289	transcript_fusion		12.5	Somatic
PIK3CA_H1047L	C	3	Predictive	Resistance	Irinotecan, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	1125	1151	missense_variant		12.5	Somatic
ERBB2_D769Y	C	3	Predictive	Sensitivity/Response	Afatinib	extramammary paget disease	3450	EMPD	skin cancer	4159	36	36	missense_variant	HER2 Activating	11.5	Somatic
JAK1_OVEREXPRESSION	C	3	Predictive	Sensitivity/Response	Ruxolitinib	sarcoma	1115	SARCOMA	sarcoma	1115	392	396	N/A		11.5	N/A
KIT_V559D	C	3	Predictive	Sensitivity/Response	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	942	968	missense_variant		11.5	Somatic
DUX4::.	C	3	Prognostic	Better Outcome		acute lymphoblastic leukemia	9952	ALL	hematologic cancer	2531	520	524	transcript_fusion		11.5	Somatic
ALK_F1245C	C	3	Predictive	Resistance	Crizotinib	neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	545	549	missense_variant		10.5	Somatic
EGFR_L861Q	C	3	Predictive	Sensitivity/Response	Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	994	1020	missense_variant		10.5	Somatic
HAVCR2_Overexpression	C	3	Predictive	Resistance	PD1 Inhibitor	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	482	486	N/A		10.5	N/A
KRAS_Q61H	C	3	Predictive	Resistance	Chemotherapy, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	881	907	missense_variant		10.5	Somatic
MEF2D::CSF1R	C	3	Predictive	Sensitivity/Response	Imatinib	b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	30	30	transcript_fusion		10.5	Somatic
BRAF_L597S	C	3	Predictive	Sensitivity/Response	MEK Inhibitor REC-4881	skin melanoma	8923	MEL	skin cancer	4159	578	582	missense_variant		9.5	Somatic
FLT3_D835H	C	3	Predictive	Resistance	Sorafenib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	608	612	missense_variant		9.5	Somatic
FGFR1_N546K	C	3	Predictive	Sensitivity/Response	Pemigatinib	pilocytic astrocytoma	4851	PAST	central nervous system cancer	3620	511	515	missense_variant		8	Somatic
.::ALK	C	3	Predictive	Resistance	Crizotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	4236	499	transcript_fusion	ALK Fusion	7.5	Somatic
ALK_F1245V	C	3	Predictive	Sensitivity/Response	Entrectinib	neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	1269	1295	missense_variant		7.5	Somatic
ALK_G1202R	C	3	Predictive	Resistance	Lorlatinib	malignant pleural mesothelioma	7474	PLMESO	connective tissue cancer	201	4329	171	missense_variant		7.5	Somatic
APP::NRG1	C	3	Predictive	Sensitivity/Response	Afatinib	pancreatic ductal adenocarcinoma	3498	PAAD	pancreatic cancer	1793	2641	2772	transcript_fusion	NRG1 FUSIONS	7.5	Somatic
ATM_N2875H	C	3	Predictive	Sensitivity/Response	Olaparib	prostate cancer	10283	PROSTATE	prostate cancer	10283	240	244	missense_variant		7.5	Somatic
ATM_S2289*	C	3	Predictive	Sensitivity/Response	Olaparib	prostate cancer	10283	PROSTATE	prostate cancer	10283	239	243	frameshift_truncation		7.5	Somatic
B2M_S14FS	C	3	Predictive	Resistance	Pembrolizumab	skin melanoma	8923	MEL	skin cancer	4159	612	616	frameshift_truncation		7.5	Somatic
BCR::PDGFRA	C	3	Predictive	Sensitivity/Response	Imatinib	b-cell acute lymphoblastic leukemia	80638	BLL	hematologic cancer	2530	2840	2971	transcript_fusion		7.5	Somatic
BRAF_L597V	C	3	Predictive	Sensitivity/Response	Trametinib	skin melanoma	8923	MEL	skin cancer	4159	581	585	missense_variant		7.5	Somatic
BRAF_N486_P490del	C	3	Predictive	Sensitivity/Response	Trametinib	pancreatic cancer	1793	PANCREAS	pancreatic cancer	1793	2663	2794			7.5	Somatic
BRAF_V600_K601>E	C	3	Predictive	Sensitivity/Response	Mitogen-Activated Protein Kinase Kinase Inhibitor, BRAF Inhibitor	melanoma	1909	MEL	cancer	162	2689	2820			7.5	Somatic
BRCA2_K3326*	C	3	Predictive	Sensitivity/Response	Temozolomide, Olaparib	glioblastoma	3068	GB	central nervous system cancer	3620	2740	2871			7.5	Unknown
CAD::ALK	C	3	Predictive	Sensitivity/Response	Entrectinib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	2638	2769	transcript_fusion		7.5	Somatic
CRBN_Mutation	C	3	Predictive	Resistance	Pomalidomide, Lenalidomide	multiple myeloma	9538	MM	hematologic cancer	2531	694	713			7.5	Somatic
DDR2_S768R	C	3	Predictive	Sensitivity/Response	Dasatinib, Erlotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	145	145	missense_variant		7.5	Somatic
EGFR_A767_V769dupASV	C	3	Predictive	Sensitivity/Response	Osimertinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1487	1579	inframe_insertion		7.5	Somatic
EGFR_D761Y	C	3	Predictive	Resistance	Gefitinib, Erlotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	693	712	missense_variant		7.5	Somatic
EGFR_D770_N771insG	C	3	Predictive	Sensitivity/Response	Osimertinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1420	1512	inframe_insertion		7.5	Somatic
EGFR_G719D	C	3	Predictive	Sensitivity/Response	Gefitinib, Erlotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1328	1420	missense_variant		7.5	Somatic
EGFR_H773_V774insNPH	C	3	Predictive	Resistance	Erlotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	1421	1513	inframe_insertion		7.5	Somatic
EGFR_K757R	C	3	Predictive	Sensitivity/Response	Erlotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	704	723	missense_variant		7.5	Somatic
EGFR_L747_P753delinsS	C	3	Predictive	Sensitivity/Response	Erlotinib	pancreatic adenocarcinoma	4074	PAAD	pancreatic cancer	1793	986	1012	inframe_deletion		7.5	Somatic
EGFR_L747_S752delinsQ	C	3	Predictive	Sensitivity/Response	Erlotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	1488	1580	inframe_insertion,inframe_deletion,delins		7.5	Somatic
EGFR_L838P	C	3	Predictive	Sensitivity/Response	Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1365	1457	missense_variant		7.5	Somatic
EGFR_L861R	C	3	Predictive	Sensitivity/Response	Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1385	1477	missense_variant		7.5	Somatic
EGFR_P753S	C	3	Predictive	Sensitivity/Response	Cetuximab, Sirolimus	skin squamous cell carcinoma	3151	SSCC	skin cancer	4159	456	460	missense_variant		7.5	Somatic
EGFR_P772_H773insYNP	C	3	Predictive	Resistance	Erlotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1575	1667	inframe_insertion		7.5	Somatic
EGFR_S720	C	3	Predictive	Resistance	Erlotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	701	720	protein_altering_variant		7.5	Somatic
EGFR_S768_D770dup	C	3	Predictive	Sensitivity/Response	Osimertinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1419	1511	inframe_insertion		7.5	Somatic
EGFR_V769_D770insASV	C	3	Predictive	Sensitivity/Response	Erlotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	717	736	direct_tandem_duplication		7.5	Somatic
EGFR_V774A	C	3	Predictive	Sensitivity/Response	Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1768	1892	missense_variant		7.5	Somatic
EGFR_V834I	C	3	Predictive	Sensitivity/Response	Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1773	1897			7.5	Somatic
ERBB2_G776L	C	3	Predictive	Sensitivity/Response	Afatinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	794	816	missense_variant		7.5	Somatic
ERBB2_M774DELINSWLV	C	3	Predictive	Sensitivity/Response	Dacomitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	796	818	inframe_indel		7.5	Somatic
FGFR2::TACC3	C	3	Predictive	Sensitivity/Response	Pazopanib, Ponatinib	cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	54	54	transcript_fusion	FGFR fusions	7.5	Somatic
FGFR2_P253R	C	3	Predictive	Sensitivity/Response	Pazopanib	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	2774	2905			7.5	Somatic
FLT3_Overexpression	C	3	Predictive	Sensitivity/Response	Sunitinib	b-cell adult acute lymphocytic leukemia	60592	BLL	hematologic cancer	2531	599	603	N/A		7.5	Somatic
GOLGA5::JAK2	C	3	Predictive	Sensitivity/Response	Ruxolitinib	b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	3083	3214	transcript_fusion		7.5	Somatic
HLA-C_COPY-NEUTRAL_LOSS_OF_HETEROZYGOSITY	C	3	Predictive	Resistance	Therapeutic Tumor Infiltrating Lymphocytes	colorectal cancer	9256	COADREAD	large intestine cancer	5672	799	821			7.5	Somatic
HRAS_G13D	C	3	Predictive	Resistance	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	colorectal cancer	9256	COADREAD	large intestine cancer	5672	270	274	missense_variant		7.5	Somatic
JAK2_Splice_Site_	C	3	Predictive	Resistance	Pembrolizumab	melanoma	1909	MEL	cancer	162	1589	1681	splice_donor_variant		7.5	Somatic
KANK4::ALK	C	3	Predictive	Sensitivity/Response	Alectinib	pancreatic acinar cell adenocarcinoma	5742	PAAC	pancreatic cancer	1793	3869	4001	transcript_fusion		7.5	Somatic
KIF5B::EGFR	C	3	Predictive	Sensitivity/Response	Afatinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	4169	4300	transcript_fusion		7.5	Somatic
KIT_C809G	C	3	Predictive	Resistance	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	1238	1264	missense_variant	KIT Exon 17	7.5	Somatic
KIT_D816H	C	3	Predictive	Resistance	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	957	983	missense_variant	KIT Exon 17	7.5	Somatic
KIT_D820A	C	3	Predictive	Resistance	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	1239	1265	missense_variant	KIT Exon 17	7.5	Somatic
KIT_D820G	C	3	Predictive	Resistance	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	1240	1266	missense_variant	KIT Exon 17	7.5	Somatic
KIT_Internal_Duplication	C	3	Predictive	Sensitivity/Response	Imatinib	malignant anus melanoma	14145	ARMM	large intestine cancer	5672	67	67	inframe_insertion	KIT Exon 11	7.5	Somatic
KIT_Y823D	C	3	Predictive	Resistance	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	963	989	missense_variant	KIT Exon 17	7.5	Somatic
KRAS_A146P	C	3	Predictive	Resistance	Cetuximab, Irinotecan	colorectal cancer	9256	COADREAD	large intestine cancer	5672	879	905	missense_variant		7.5	Somatic
KRAS_Q61K	C	3	Predictive	Resistance	Cetuximab, Chemotherapy	colorectal cancer	9256	COADREAD	large intestine cancer	5672	884	910	missense_variant		7.5	Somatic
KRAS_Q61L	C	3	Predictive	Resistance	Cetuximab, Chemotherapy	colorectal cancer	9256	COADREAD	large intestine cancer	5672	882	908	missense_variant		7.5	Somatic
KRAS_Q61R	C	3	Predictive	Resistance	Cetuximab, Irinotecan	colorectal cancer	9256	COADREAD	large intestine cancer	5672	883	909	missense_variant		7.5	Somatic
MET::ATXN7L1	C	3	Predictive	Sensitivity/Response	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	2763	2894	transcript_fusion		7.5	N/A
MET_AMP	C	3	Predictive	Sensitivity/Response	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4366	270	transcript_amplification		7.5	Somatic
MET_R1004G	C	3	Predictive	Sensitivity/Response	Crizotinib	head and neck cancer	11934	HEAD_NECK	head and neck cancer	11934	2643	2774	missense_variant		7.5	Somatic
MSH2_DEL	C	3	Predictive	Sensitivity/Response	Durvalumab, Anti-PD-1 Monoclonal Antibody MEDI0680	transitional cell carcinoma	2671	TCC	cancer	162	786	808	loss_of_function_variant		7.5	Somatic
MSH6_DEL	C	3	Predictive	Sensitivity/Response	Durvalumab, Anti-PD-1 Monoclonal Antibody MEDI0680	transitional cell carcinoma	2671	TCC	cancer	162	787	809	loss_of_function_variant		7.5	Somatic
NF2_K159fs	C	3	Predictive	Sensitivity/Response	Temsirolimus	breast cancer	1612	BREAST	breast cancer	1612	275	279	frameshift_truncation		7.5	Somatic
NF2_Y177fs	C	3	Predictive	Resistance	Carboplatin, Cisplatin	peritoneal mesothelioma	1788	PEMESO	peritoneum cancer	1725	241	245	frameshift_elongation		7.5	Somatic
NRAS_G12C	C	3	Predictive	Resistance	Chemotherapy, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	871	897	missense_variant		7.5	Somatic
NRAS_G12D	C	3	Predictive	Resistance	Irinotecan, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	852	878	missense_variant		7.5	Somatic
NRF1::BRAF	C	3	Predictive	Sensitivity/Response	Trametinib	transitional cell carcinoma	2671	TCC	cancer	162	2752	2883	transcript_fusion		7.5	Somatic
PDGFRA_Mutation	C	3	Predictive	Sensitivity/Response	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	3143	3274			7.5	Somatic
PDGFRB_Overexpression	C	3	Predictive	Sensitivity/Response	Sunitinib	dermatofibrosarcoma protuberans	3507	DFSP	connective tissue cancer	201	2842	2973			7.5	N/A
PIK3CA_G1049R	C	3	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	914	940	missense_variant		7.5	Somatic
PIK3CA_P471L	C	3	Predictive	Sensitivity/Response	Idelalisib	merkel cell carcinoma	3965	MCC	skin cancer	4159	290	294	missense_variant		7.5	Somatic
PIK3CA_S158L	C	3	Predictive	Resistance	Irinotecan, Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	1407	1499	missense_variant		7.5	Somatic
QKI::RAF1	C	3	Predictive	Sensitivity/Response	Trametinib	spindle cell sarcoma	4235	SCS	sarcoma	1115	3868	4000	transcript_fusion		7.5	Somatic
SDC4::NRG1	C	3	Predictive	Sensitivity/Response	Afatinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	2055	2179	transcript_fusion	NRG1 FUSIONS	7.5	Somatic
STRN::ALK	C	3	Predictive	Sensitivity/Response	Ceritinib	colon adenocarcinoma	234	COAD	large intestine cancer	5672	2094	2218	transcript_fusion		7.5	Somatic
STRN::NTRK2	C	3	Predictive	Sensitivity/Response	Larotrectinib	sarcoma	1115	SARCOMA	sarcoma	1115	2163	2287	transcript_fusion		7.5	Somatic
TFG::ROS1	C	3	Predictive	Sensitivity/Response	Crizotinib	inflammatory myofibroblastic tumor	50905	IMT	cancer	162	572	576	transcript_fusion		7.5	Somatic
TNKS2::PDGFRA	C	3	Predictive	Sensitivity/Response	Imatinib	myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1	80164	MLNER	hematologic cancer	2531	755	774	transcript_fusion		7.5	Somatic
ZKSCAN1::BRAF	C	3	Predictive	Sensitivity/Response	Trametinib	melanoma	1909	MEL	cancer	162	653	657	transcript_fusion	BRAF Fusions	7.5	Somatic
ACVR1_G328E	C	3	Diagnostic	Positive		diffuse midline glioma, h3 k27m-mutant	80684	DIFG	central nervous system cancer	3620	2159	2283	missense_variant,gain_of_function_variant	ACVR1 kinase domain mutation	7.5	Somatic
EBF1::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2716	2847	transcript_fusion	JAK2 fusions in B-ALL	7.5	Somatic
EWSR1::DDIT3	C	3	Diagnostic	Positive		myxoid liposarcoma	5363	MRLS	connective tissue cancer	201	698	717	transcript_fusion		7.5	Somatic
FOS::.	C	3	Diagnostic	Positive		bone epithelioid hemangioma	6610	HEMA	benign neoplasm	60072	720	739	stop_gained,transcript_fusion,frameshift_truncation		7.5	Somatic
RFX3::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2734	2865	transcript_fusion	JAK2 fusions in B-ALL	7.5	Somatic
SMU1::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2844	2975	transcript_fusion	JAK2 fusions in B-ALL	7.5	Somatic
SNX29::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2845	2976	transcript_fusion	JAK2 fusions in B-ALL	7.5	Somatic
STRN3::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2718	2849	transcript_fusion	JAK2 fusions in B-ALL	7.5	Somatic
TBL1XR1::CSF1R	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	3227	3359	transcript_fusion		7.5	Somatic
TERF2::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2731	2862	transcript_fusion	JAK2 fusions in B-ALL	7.5	Somatic
TPR::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2719	2850	transcript_fusion	JAK2 fusions in B-ALL	7.5	Somatic
USP25::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2732	2863	transcript_fusion	JAK2 fusions in B-ALL	7.5	Somatic
ZNF274::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2733	2864	transcript_fusion	JAK2 fusions in B-ALL	7.5	Somatic
ZNF430::JAK2	C	3	Diagnostic	Positive		b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2846	2977	transcript_fusion	JAK2 fusions in B-ALL	7.5	Somatic
ABL1_D363G	C	3	Predictive	Sensitivity/Response	Dasatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4725	4637	missense_variant		0	Somatic
ABL1_E255V	C	3	Predictive	Resistance	Imatinib, Imatinib Mesylate, Nilotinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4673	4606	missense_variant		0	Somatic
ABL1_E355G	C	3	Predictive	Resistance	Imatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4678	4609	missense_variant		0	Somatic
ABL1_F359C	C	3	Predictive	Resistance	Nilotinib, Imatinib Mesylate	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4680	4610	missense_variant		0	Somatic
ABL1_F359V	C	3	Predictive	Resistance	Nilotinib, Imatinib Mesylate	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4664	4598	missense_variant		0	Somatic
ABL1_Q252H	C	3	Predictive	Resistance	Imatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4719	4634	missense_variant		0	Somatic
ABL1_S438C	C	3	Predictive	Resistance	Dasatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4903	1495	missense_variant		0	Somatic
ABL1_V379I	C	3	Predictive	Resistance	Imatinib Mesylate	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	5238	1609	missense_variant		0	Somatic
ABL1_Y253F	C	3	Predictive	Resistance	Imatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	5115	4942			0	Somatic
CD74::ROS1	C	3	Predictive	Resistance	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	5075	4908	transcript_fusion		0	Somatic
FGFR2::CCDC6	C	3	Predictive	Sensitivity/Response	Erdafitinib	adrenal carcinoma	3950	ADRENAL_GLAND	adrenal gland cancer	3953	5232	4626	transcript_fusion		0	Somatic
FIP1L1::PDGFRA	C	3	Predictive	Resistance	Imatinib	myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1	80164	MLNER	hematologic cancer	2531	5074	574	transcript_fusion		0	Somatic
PML::RARA	C	3	Predictive	Resistance	Tretinoin	acute promyelocytic leukemia	60318	APL	hematologic cancer	2531	5240	108	transcript_fusion		0	Somatic
SDC4::ROS1	C	3	Predictive	Sensitivity/Response	Crizotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	5221	5013	transcript_fusion		0	Somatic
FLT3_ITD	D	5	Predictive	Sensitivity/Response	Ponatinib, Tyrphostin AG 1296, Gilteritinib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
EGFR_T790M	D	5	Predictive	Resistance	Multikinase Inhibitor AEE788, Gefitinib	lung cancer	1324	LUNG	lung cancer	1324	34	34	missense_variant	EGFR TKI Resistance	406.25	Somatic
FGFR1_AMP	D	5	Predictive	Sensitivity/Response	PD173074	lung squamous cell carcinoma	3907	LUSC	lung cancer	1324	263	267	transcript_amplification		185.5	Somatic
ATM_Mutation	D	5	Predictive	Sensitivity/Response	Olaparib	hematologic cancer	2531	HEMATO	hematologic cancer	2531	178	178	transcription_variant,loss_of_function_variant		130.5	Somatic
EML4::ALK	D	5	Predictive	Sensitivity/Response	WHI-P154, Retaspimycin Hydrochloride	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	5	5	transcript_fusion	ALK Fusion	48	Somatic
ATM_Underexpression	D	5	Predictive	Sensitivity/Response	NU7441, KU-0060648	cancer	162	CANCER	cancer	162	179	179	N/A		39	Somatic
PRPS1_A190T	D	5	Predictive	Resistance	Thioguanine, Mercaptopurine	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2798	2929			26	Somatic
ERBB2_L755S	D	5	Predictive	Resistance	Lapatinib	breast cancer	1612	BREAST	breast cancer	1612	39	39	missense_variant		23.5	Somatic
ERBB2_L755S	D	5	Predictive	Sensitivity/Response	Neratinib	breast cancer	1612	BREAST	breast cancer	1612	39	39	missense_variant		23.5	Somatic
ESR1_D538G	D	5	Predictive	Sensitivity/Response	Tamoxifen, Fulvestrant	breast cancer	1612	BREAST	breast cancer	1612	47	47	missense_variant	ESR1 Ligand-Binding Domain	18	Somatic
ERBB2_P780INS	D	5	Predictive	Sensitivity/Response	Neratinib	breast cancer	1612	BREAST	breast cancer	1612	41	41	inframe_insertion	HER2 Activating	12.5	Somatic
ERBB2_V777L	D	5	Predictive	Sensitivity/Response	Neratinib	breast cancer	1612	BREAST	breast cancer	1612	44	44	missense_variant	HER2 Activating	11	Somatic
ABL1_R351W	D	5	Predictive	Sensitivity/Response	Imatinib, Dasatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1564	1656	missense_variant		9	Somatic
ERBB2_V842I	D	5	Predictive	Sensitivity/Response	Neratinib	breast cancer	1612	BREAST	breast cancer	1612	45	45	missense_variant	HER2 Activating	9	Somatic
MYC_Overexpression	D	5	Predictive	Sensitivity/Response	JQ-1	multiple myeloma	9538	MM	hematologic cancer	2531	1277	1303			9	Somatic
ESR1_L536Q	D	5	Predictive	Sensitivity/Response	Tamoxifen, Fulvestrant	breast cancer	1612	BREAST	breast cancer	1612	46	46	missense_variant	ESR1 Ligand-Binding Domain	8	Somatic
ESR1_Y537C	D	5	Predictive	Sensitivity/Response	Tamoxifen, Fulvestrant	breast cancer	1612	BREAST	breast cancer	1612	48	48	missense_variant	ESR1 Ligand-Binding Domain	8	Somatic
ESR1_Y537N	D	5	Predictive	Sensitivity/Response	Fulvestrant, Tamoxifen	breast cancer	1612	BREAST	breast cancer	1612	49	49	missense_variant	ESR1 Ligand-Binding Domain	8	Somatic
ESR1_Y537S	D	5	Predictive	Sensitivity/Response	Fulvestrant, Tamoxifen	breast cancer	1612	BREAST	breast cancer	1612	50	50	missense_variant	ESR1 Ligand-Binding Domain	8	Somatic
PRPS1_S103T	D	5	Predictive	Resistance	Mercaptopurine, Thioguanine	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2796	2927			8	Somatic
ERBB2_G309A	D	5	Predictive	Sensitivity/Response	Neratinib	breast cancer	1612	BREAST	breast cancer	1612	38	38	missense_variant	HER2 Activating	5	Somatic
ERBB2_L755W	D	5	Predictive	Sensitivity/Response	Neratinib	breast cancer	1612	BREAST	breast cancer	1612	40	40	missense_variant		5	Somatic
ERBB2_L755_T759del	D	5	Predictive	Sensitivity/Response	Neratinib	breast cancer	1612	BREAST	breast cancer	1612	37	37	inframe_deletion		5	Somatic
ERBB2_R678Q	D	5	Predictive	Sensitivity/Response	Neratinib, Lapatinib	breast cancer	1612	BREAST	breast cancer	1612	42	42	missense_variant		5	Somatic
ERBB2_R896C	D	5	Predictive	Sensitivity/Response	Neratinib	breast cancer	1612	BREAST	breast cancer	1612	43	43	missense_variant	HER2 Activating	5	Somatic
ERBB2_AMP	D	4	Predictive	Sensitivity/Response	Trastuzumab Emtansine	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	302	306	transcript_amplification		891	Somatic
ERBB2_AMP	D	4	Predictive	Sensitivity/Response	Pilaralisib, Pictilisib	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	302	306	transcript_amplification		891	Somatic
KRAS_Mutation	D	4	Predictive	Sensitivity/Response	Trametinib, G-573, MEK Inhibitor GDC-0623, AZD5438	cancer	162	CANCER	cancer	162	332	336	protein_altering_variant		545.5	Somatic
KRAS_Mutation	D	4	Predictive	Sensitivity/Response	Selumetinib, B-Raf/VEGFR-2 Inhibitor RAF265, Afatinib, Trametinib, Binimetinib, Palbociclib, Cetuximab, Dasatinib, Teprotumumab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	332	336	protein_altering_variant		545.5	Somatic
KRAS_Mutation	D	4	Predictive	Sensitivity/Response	PI3Kbeta Inhibitor AZD8186, SCH772984	pancreatic adenocarcinoma	4074	PAAD	pancreatic cancer	1793	332	336	protein_altering_variant		545.5	Somatic
FLT3_ITD	D	4	Predictive	Sensitivity/Response	Sorafenib, Sunitinib	leukemia	1240	LEUKEMIA	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
PIK3CA_Mutation	D	4	Predictive	Sensitivity/Response	Alpelisib	cancer	162	CANCER	cancer	162	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	D	4	Predictive	Sensitivity/Response	Phosphatidylinositide 3-Kinase Inhibitor, Ribociclib, Palbociclib, Everolimus, MTOR Kinase Inhibitor PP242	breast cancer	1612	BREAST	breast cancer	1612	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
TP53_Mutation	D	4	Predictive	Sensitivity/Response	Doxorubicin	breast cancer	1612	BREAST	breast cancer	1612	222	222	protein_altering_variant		437	Somatic
EGFR_T790M	D	4	Predictive	Resistance	Lapatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	34	34	missense_variant	EGFR TKI Resistance	406.25	Somatic
PTEN_DEL	D	4	Predictive	Sensitivity/Response	Temsirolimus	prostate cancer	10283	PROSTATE	prostate cancer	10283	214	214	loss_of_function_variant		272	Somatic
PTEN_DEL	D	4	Predictive	Resistance	Alpelisib	breast cancer	1612	BREAST	breast cancer	1612	214	214	loss_of_function_variant		272	Somatic
PTEN_DEL	D	4	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	214	214	loss_of_function_variant		272	Somatic
PTEN_DEL	D	4	Predictive	Resistance	Lapatinib	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	214	214	loss_of_function_variant		272	Somatic
BRCA2_Loss-of-function	D	4	Predictive	Sensitivity/Response	Pidnarulex, Quarfloxin	breast cancer	1612	BREAST	breast cancer	1612	132	132	loss_of_function_variant	BRCA Germline Variants	261	Unknown
BRCA1_Loss-of-function	D	4	Predictive	Sensitivity/Response	Pidnarulex, Quarfloxin	breast cancer	1612	BREAST	breast cancer	1612	131	131	loss_of_heterozygosity,loss_of_function_variant	BRCA Germline Variants	254	Unknown
NRAS_Mutation	D	4	Predictive	Sensitivity/Response	Trametinib, Omipalisib, Binimetinib	melanoma	1909	MEL	cancer	162	208	208	transcript_variant,gain_of_function_variant		213	Somatic
IDH1_R132	D	4	Predictive	Sensitivity/Response	Dasatinib	intrahepatic cholangiocarcinoma	4928	IHCH	biliary tract cancer	4607	58	58	protein_altering_variant		199	Somatic
FGFR1_AMP	D	4	Predictive	Sensitivity/Response	PD173074	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	263	267	transcript_amplification		185.5	Somatic
BRAF_Mutation	D	4	Predictive	Sensitivity/Response	Trametinib	cancer	162	CANCER	cancer	162	395	399	gene_variant,gain_of_function_variant		166	Somatic
KRAS_G12D	D	4	Predictive	Sensitivity/Response	Dactolisib, Selumetinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	79	79	missense_variant	EGFR TKI Resistance	162	Somatic
ABL1_T315I	D	4	Predictive	Resistance	Nilotinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4373	2	missense_variant	Imatinib Resistance	149	Somatic
ATM_Mutation	D	4	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	178	178	transcription_variant,loss_of_function_variant		130.5	Somatic
KRAS_G13D	D	4	Predictive	Resistance	Pictilisib	breast cancer	1612	BREAST	breast cancer	1612	81	81	missense_variant		108.5	Somatic
PDGFRA_D842V	D	4	Predictive	Sensitivity/Response	Crenolanib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	99	99	missense_variant	Imatinib Resistance	100.5	Somatic
PIK3CA_H1047R	D	4	Predictive	Sensitivity/Response	Izorlisib	breast cancer	1612	BREAST	breast cancer	1612	107	107	missense_variant		96.5	Somatic
PIK3CA_H1047R	D	4	Predictive	Sensitivity/Response	Pictilisib, Capivasertib, Trastuzumab, Lapatinib	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	107	107	missense_variant		96.5	Somatic
PIK3CA_H1047R	D	4	Predictive	Resistance	Lapatinib, Trastuzumab	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	107	107	missense_variant		96.5	Somatic
MET_AMP	D	4	Predictive	Resistance	Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	266	270	transcript_amplification		81.5	Somatic
TP53_Deleterious_Mutation	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3, Rebemadlin	cancer	162	CANCER	cancer	162	221	221	N/A		78	Somatic
PIK3CA_E545K	D	4	Predictive	Sensitivity/Response	Pictilisib	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	104	104	missense_variant		77.5	Somatic
PIK3CA_E542K	D	4	Predictive	Sensitivity/Response	Izorlisib, Sirolimus	breast cancer	1612	BREAST	breast cancer	1612	103	103	missense_variant		75.5	Somatic
TP53_Wildtype	D	4	Predictive	Sensitivity/Response	Rebemadlin, MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	365	369	wild_type		68	N/A
BRAF_V600D	D	4	Predictive	Sensitivity/Response	Vemurafenib	melanoma	1909	MEL	cancer	162	11	11	missense_variant	Other BRAF V600's	47	Somatic
FGFR1_Expression	D	4	Predictive	Sensitivity/Response	Ponatinib	lung cancer	1324	LUNG	lung cancer	1324	264	268	N/A		46	N/A
TP53_R248Q	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	117	117	missense_variant		46	Somatic
TP53_R273C	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	121	121	missense_variant		44.5	Somatic
SMO_Mutation	D	4	Predictive	Sensitivity/Response	Arsenic Trioxide, PSI	basal cell carcinoma	2513	BCC	skin cancer	4159	296	300	coding_transcript_variant		44	Somatic
ERBB2_Y772_A775DUP	D	4	Predictive	Sensitivity/Response	Afatinib	lung carcinoma	3905	LUNG	lung cancer	1324	410	414	inframe_insertion		42	Somatic
TP53_R273H	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	122	122	missense_variant		41	Somatic
ATM_Underexpression	D	4	Predictive	Sensitivity/Response	Olaparib	gastric adenocarcinoma	3717	STAD	stomach cancer	10534	179	179	N/A		39	N/A
ATRX_Underexpression	D	4	Prognostic	Poor Outcome		glioblastoma	3068	GB	central nervous system cancer	3620	644	648	N/A		39	N/A
ERBB3_Overexpression	D	4	Predictive	Resistance	HER2 Inhibitor CP-724, 714, Gefitinib, Selumetinib	cancer	162	CANCER	cancer	162	285	289	N/A		37	N/A
NRG1_Expression	D	4	Predictive	Sensitivity/Response	Lapatinib	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	310	314	N/A		37	N/A
NRG1_Expression	D	4	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	310	314	N/A		37	N/A
ARID1A_Underexpression	D	4	Prognostic	Poor Outcome		stomach cancer	10534	STOMACH	stomach cancer	10534	1984	2108	N/A		34	N/A
ALK_F1174L	D	4	Predictive	Sensitivity/Response	TAE684, Lorlatinib, Alectinib, Crizotinib, AZD3463	neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	8	8	missense_variant	ALK Crizotinib Resistance	33.5	Somatic
KIT_N822K	D	4	Predictive	Resistance	Sunitinib, Regorafenib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	1237	1263	missense_variant	KIT Exon 17	29.5	Somatic
NT5C2_K359Q	D	4	Predictive	Resistance	Thioguanine, Mercaptopurine	acute t cell leukemia	5603	ATL	hematologic cancer	2531	235	239	missense_variant		28	Somatic
CCNE1_AMP	D	4	Predictive	Sensitivity/Response	Akt Inhibitor MK2206, Dinaciclib	ovarian serous cystadenocarcinoma	5746	SOC	ovarian cancer	2394	187	187	transcript_amplification		27	Somatic
GNAQ_Mutation	D	4	Predictive	Sensitivity/Response	Sotrastaurin Acetate, Mirdametinib	uveal melanoma	6039	UM	ocular cancer	2174	501	505			26	Somatic
EML4::ALK	D	4	Predictive	Sensitivity/Response	2, 4-pyrimidinediamine, Ceritinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	499	503	transcript_fusion	ALK Fusion	25	Somatic
TP53_R175H	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	116	116	missense_variant		25	Somatic
SGK1_Overexpression	D	4	Predictive	Sensitivity/Response	Alpelisib, SGK1-Inh	breast cancer	1612	BREAST	breast cancer	1612	674	693	N/A		24	Somatic
ERBB2_L755S	D	4	Predictive	Sensitivity/Response	Lapatinib, Neratinib, Trastuzumab	colon cancer	219	COAD	large intestine cancer	5672	39	39	missense_variant		23.5	Somatic
ALK_R1275Q	D	4	Predictive	Sensitivity/Response	Lorlatinib, TAE684, Crizotinib	neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	9	9	missense_variant		23	Somatic
EGFR_G719S	D	4	Predictive	Sensitivity/Response	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	134	134	missense_variant		23	Somatic
EGFR_S492R	D	4	Predictive	Sensitivity/Response	Panitumumab, Futuximab/Modotuximab Mixture	colorectal cancer	9256	COADREAD	large intestine cancer	5672	449	453	missense_variant	EGFR ECD MUTATION	23	Somatic
TP53_R248W	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	118	118	missense_variant		22	Somatic
KIT_T670I	D	4	Predictive	Resistance	Regorafenib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	1241	1267	missense_variant		21.5	Somatic
ALK_L1196M	D	4	Predictive	Resistance	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4230	4324	missense_variant		21	Somatic
ALK_L1196M	D	4	Predictive	Sensitivity/Response	Ceritinib, Alectinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4230	4324	missense_variant		21	Somatic
NT5C2_R367Q	D	4	Predictive	Resistance	Mercaptopurine, Thioguanine	acute t cell leukemia	5603	ATL	hematologic cancer	2531	234	238	missense_variant		21	Somatic
NT5C2_R367Q	D	4	Predictive	Resistance	Mercaptopurine, Thioguanine	childhood acute lymphocytic leukemia	80144	ALL	hematologic cancer	2533	234	238	missense_variant		21	Somatic
FLT3_Y842C	D	4	Predictive	Resistance	Sorafenib, FLT3/ABL/Aurora Kinase Inhibitor KW-2449, Sunitinib, Quizartinib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	2939	3070			20	Somatic
FLT3_Y842C	D	4	Predictive	Sensitivity/Response	Lestaurtinib, Midostaurin	acute myeloid leukemia	9119	AML	hematologic cancer	2531	2939	3070			20	Somatic
CLTC::ALK	D	4	Predictive	Sensitivity/Response	TAE684	diffuse large b-cell lymphoma	50745	DLBCL	hematologic cancer	2531	516	520	transcript_fusion	ALK Fusion	19	Somatic
PTEN_R233*	D	4	Predictive	Sensitivity/Response	MTOR Inhibitor	breast cancer	1612	BREAST	breast cancer	1612	110	110	stop_gained,loss_of_function_variant	PTEN Loss-of-Function	19	Somatic
MTOR_F2108L	D	4	Predictive	Resistance	Sirolimus	breast cancer	1612	BREAST	breast cancer	1612	466	470	missense_variant		16.5	Somatic
AKT1_Q79K	D	4	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	169	169	missense_variant		16	Somatic
ALK_G1202R	D	4	Predictive	Resistance	Crizotinib, Ceritinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4237	171	missense_variant		16	Somatic
CCND2_OVEREXPRESSION	D	4	Prognostic	Poor Outcome		stomach cancer	10534	STOMACH	stomach cancer	10534	21	21	N/A		16	Somatic
CCND2_OVEREXPRESSION	D	4	Prognostic	Poor Outcome		stomach cancer	10534	STOMACH	stomach cancer	10534	21	21	N/A		16	Somatic
CCND2_OVEREXPRESSION	D	4	Prognostic	Poor Outcome		stomach cancer	10534	STOMACH	stomach cancer	10534	21	21	N/A		16	Somatic
CCND2_OVEREXPRESSION	D	4	Prognostic	Poor Outcome		stomach cancer	10534	STOMACH	stomach cancer	10534	21	21	N/A		16	Somatic
TP53_Y220C	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	896	922	missense_variant		15.5	Somatic
STAG2_Underexpression	D	4	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	418	422	N/A		14	N/A
NT5C2_R238W	D	4	Predictive	Resistance	Mercaptopurine, Thioguanine	childhood acute lymphocytic leukemia	80144	ALL	hematologic cancer	2533	2765	2896			13	Somatic
NT5C2_S445F	D	4	Predictive	Resistance	Thioguanine, Mercaptopurine	childhood acute lymphocytic leukemia	80144	ALL	hematologic cancer	2533	2766	2897	missense_variant,gain_of_function_variant		13	Somatic
PIK3CA_K111N	D	4	Predictive	Sensitivity/Response	Pictilisib	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	1208	1234	missense_variant		13	Somatic
ERBB2_D769Y	D	4	Predictive	Sensitivity/Response	Neratinib	breast cancer	1612	BREAST	breast cancer	1612	36	36	missense_variant	HER2 Activating	11.5	Somatic
JAK1_OVEREXPRESSION	D	4	Predictive	Sensitivity/Response	Enzastaurin	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	392	396	N/A		11.5	N/A
DUX4::.	D	4	Diagnostic	Positive		acute lymphoblastic leukemia	9952	ALL	hematologic cancer	2531	520	524	transcript_fusion		11.5	Somatic
ERBB2_V777L	D	4	Predictive	Sensitivity/Response	Neratinib, Trastuzumab, Lapatinib	colon cancer	219	COAD	large intestine cancer	5672	44	44	missense_variant	HER2 Activating	11	Somatic
CDK4_EXPRESSION	D	4	Predictive	Sensitivity/Response	Alpelisib	estrogen-receptor positive breast cancer	60075	BRCA	breast cancer	1612	25	25	N/A		10	Somatic
CDK4_EXPRESSION	D	4	Predictive	Sensitivity/Response	Palbociclib	sarcoma	1115	SARCOMA	sarcoma	1115	25	25	N/A		10	N/A
TP53_G245S	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	853	879	missense_variant		10	Somatic
ERBB2_V842I	D	4	Predictive	Sensitivity/Response	Neratinib, Trastuzumab, Lapatinib	colon cancer	219	COAD	large intestine cancer	5672	45	45	missense_variant	HER2 Activating	9	Somatic
IDH1_R132H	D	4	Predictive	Sensitivity/Response	AGI-5198	oligodendroglioma	3181	ODG	central nervous system cancer	3620	416	420	missense_variant		9	Somatic
MYC_Overexpression	D	4	Predictive	Sensitivity/Response	Cisplatin, Olaparib, Prexasertib	lung small cell carcinoma	5409	SCLC	lung cancer	1324	1277	1303			9	Somatic
PRPS1_L191F	D	4	Predictive	Resistance	Thioguanine, Mercaptopurine	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2788	2919			9	Somatic
PRPS1_N144S	D	4	Predictive	Resistance	Mercaptopurine, Thioguanine	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2792	2923			9	Somatic
KIT_A829P	D	4	Predictive	Resistance	Imatinib, Sunitinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	964	990	missense_variant		8	Somatic
KIT_D816E	D	4	Predictive	Resistance	Imatinib, Sunitinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	1467	1559	missense_variant		8	Somatic
MTOR_A2034V	D	4	Predictive	Resistance	Sirolimus	breast cancer	1612	BREAST	breast cancer	1612	606	610	missense_variant	1-2k via nebula	8	Somatic
NT5C2_D407A	D	4	Predictive	Resistance	Mercaptopurine, Thioguanine	acute t cell leukemia	5603	ATL	hematologic cancer	2531	236	240	missense_variant		8	Somatic
AKT3_Overexpression	D	4	Predictive	Resistance	Akt Inhibitor MK2206	breast cancer	1612	BREAST	breast cancer	1612	1275	1301			7	N/A
APC_Mutation	D	4	Predictive	Sensitivity/Response	G007-LK	colorectal cancer	9256	COADREAD	large intestine cancer	5672	174	174			7	Somatic
ARID1A_DEL	D	4	Predictive	Sensitivity/Response	GSK126, Dasatinib	ovarian clear cell carcinoma	50934	CCOV	ovarian cancer	2394	1267	1293			7	Somatic
MTOR_M2327I	D	4	Predictive	Resistance	MTOR Kinase Inhibitor AZD8055	breast cancer	1612	BREAST	breast cancer	1612	605	609	missense_variant		7	Somatic
PRPS1_D183E	D	4	Predictive	Resistance	Thioguanine, Mercaptopurine	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2789	2920			7	Somatic
PRPS1_K176N	D	4	Predictive	Resistance	Thioguanine, Mercaptopurine	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2790	2921			7	Somatic
PRPS1_S103N	D	4	Predictive	Resistance	Thioguanine, Mercaptopurine	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2795	2926			7	Somatic
PRPS1_T303S	D	4	Predictive	Resistance	Thioguanine, Mercaptopurine	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2787	2918			7	Somatic
TP53_R249S	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	1604	1696			7	Somatic
ALK_S1206Y	D	4	Predictive	Resistance	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4309	172	missense_variant	ALK Crizotinib Resistance	6	Somatic
FLT3_D835Y	D	4	Predictive	Sensitivity/Response	Gilteritinib	cancer	162	CANCER	cancer	162	2880	3011	missense_variant		6	Somatic
KIT_V560_L576DEL	D	4	Predictive	Sensitivity/Response	Imatinib, Ponatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	1458	1550	inframe_deletion		6	Somatic
FBXW7_Loss-of-function	D	4	Predictive	Sensitivity/Response	Sirolimus	cancer	162	CANCER	cancer	162	633	637	loss_of_function_variant		4.5	Somatic
AR_F877L	D	4	Predictive	Resistance	Apalutamide, Enzalutamide	prostate cancer	10283	PROSTATE	prostate cancer	10283	175	175	missense_variant		4	Somatic
AR_W742	D	4	Predictive	Resistance	Bicalutamide	prostate carcinoma	10286	PROSTATE	prostate cancer	10283	176	176	missense_variant		4	Somatic
BIRC7_AMP	D	4	Predictive	Resistance	Cisplatin	colon cancer	219	COAD	large intestine cancer	5672	247	251	transcript_amplification		4	Somatic
CDK12_Loss-of-function	D	4	Predictive	Sensitivity/Response	Olaparib	ovarian serous carcinoma	50933	SOC	ovarian cancer	2394	232	236	loss_of_function_variant		4	Somatic
CHEK1_Overexpression	D	4	Predictive	Sensitivity/Response	Prexasertib, Olaparib, Cisplatin	lung small cell carcinoma	5409	SCLC	lung cancer	1324	1601	1693			4	N/A
CTNNB1_Activating_Mutation	D	4	Predictive	Resistance	Anti-PD-L1 Monoclonal Antibody, Anti-CTLA-4 Monoclonal Antibody	melanoma	1909	MEL	cancer	162	1270	1296	transcript_variant,gain_of_function_variant		4	Somatic
DDR2_G253C	D	4	Predictive	Sensitivity/Response	Dasatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	141	141	missense_variant		4	Somatic
DDR2_G505S	D	4	Predictive	Sensitivity/Response	Dasatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	142	142	missense_variant		4	Somatic
DDR2_G774V	D	4	Predictive	Sensitivity/Response	Dasatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	144	144	missense_variant		4	Somatic
DDR2_I638F	D	4	Predictive	Sensitivity/Response	Dasatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	143	143	missense_variant		4	Somatic
DDR2_L239R	D	4	Predictive	Sensitivity/Response	Dasatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	140	140	missense_variant		4	Somatic
DDR2_L63V	D	4	Predictive	Sensitivity/Response	Dasatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	139	139	missense_variant		4	Somatic
DDX43_Overexpression	D	4	Predictive	Resistance	Mirdametinib, Trametinib, Selumetinib	uveal melanoma	6039	UM	ocular cancer	2174	477	481	N/A		4	Somatic
EGFR_Exon_4_Deletion	D	4	Predictive	Resistance	Cisplatin	epithelial ovarian cancer	2152	OVT	ovarian cancer	2394	248	252	exon_loss_variant		4	Somatic
EGFR_G724S	D	4	Predictive	Sensitivity/Response	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	313	317	missense_variant		4	Somatic
ERBB2_D769H	D	4	Predictive	Sensitivity/Response	Neratinib, Lapatinib	breast cancer	1612	BREAST	breast cancer	1612	35	35	missense_variant	HER2 Activating	4	Somatic
ERBB2_L866M	D	4	Predictive	Sensitivity/Response	Lapatinib, Neratinib, Trastuzumab	colon cancer	219	COAD	large intestine cancer	5672	492	496	missense_variant		4	Somatic
ERBB2_S310F/Y	D	4	Predictive	Sensitivity/Response	Neratinib, Lapatinib, Trastuzumab	colon cancer	219	COAD	large intestine cancer	5672	493	497	missense_variant		4	Somatic
ERBB4_Mutation	D	4	Predictive	Sensitivity/Response	Lapatinib	melanoma	1909	MEL	cancer	162	306	310	transcript_variant,gain_of_function_variant		4	Somatic
FGF2_EXPRESSION	D	4	Predictive	Resistance	Quizartinib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	669	673	N/A		4	N/A
GATA2_EXPRESSION	D	4	Predictive	Sensitivity/Response	Fasudil, Bortezomib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	57	57	N/A		4	Somatic
GSTP1_DEL	D	4	Predictive	Sensitivity/Response	Cisplatin, Carboplatin, Paclitaxel	ovarian carcinoma	4001	OVT	ovarian cancer	2394	246	250	transcript_ablation		4	Somatic
JAK1_S703I	D	4	Predictive	Sensitivity/Response	Ruxolitinib	hepatocellular carcinoma	684	HCC	liver cancer	3571	800	822	missense_variant		4	Somatic
MAPK1_AMP	D	4	Predictive	Resistance	WZ4002	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	317	321	transcript_amplification		4	Somatic
NF2_DEL	D	4	Predictive	Sensitivity/Response	Selumetinib	thyroid gland carcinoma	3963	THYROID	thyroid cancer	1781	678	697	loss_of_function_variant		4	Somatic
PDGFRA_D842I	D	4	Predictive	Sensitivity/Response	Crenolanib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	98	98	missense_variant	Imatinib Resistance	4	Somatic
PDGFRA_D842Y	D	4	Predictive	Sensitivity/Response	Crenolanib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	100	100	missense_variant	Imatinib Resistance	4	Somatic
PDGFRA_D842_I843delinsVM	D	4	Predictive	Sensitivity/Response	Crenolanib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	102	102	missense_variant	Imatinib Resistance	4	Somatic
PRPS1_S103I	D	4	Predictive	Resistance	Mercaptopurine, Thioguanine	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2794	2925			4	Somatic
RAC1_P29S	D	4	Predictive	Resistance	Vemurafenib, Dabrafenib	melanoma	1909	MEL	cancer	162	363	367	missense_variant		4	Somatic
SMARCA4_DEL	D	4	Predictive	Sensitivity/Response	Abemaciclib, Palbociclib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	2513	2644			4	N/A
SOX10_DEL	D	4	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	668	672	loss_of_function_variant		4	N/A
STAG3_Underexpression	D	4	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	650	654	N/A		4	N/A
TP53_R158L	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	1607	1699	missense_variant		4	Somatic
TP53_R280K	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	1605	1697			4	Somatic
TP53_R280T	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	1606	1698			4	Somatic
TP53_V157F	D	4	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	cancer	162	CANCER	cancer	162	1066	1092	missense_variant		4	Somatic
BRAF_V600E	D	4	Predictive	Sensitivity/Response	JQEZ5	skin melanoma	8923	MEL	skin cancer	4159	4241	12	missense_variant		0	Somatic
BRAF_V600E	D	3	Predictive	Sensitivity/Response	Sorafenib, PLX4720, Pictilisib Bismesylate, Capecitabine, Bevacizumab, Gefitinib, GDC-0879, Dactolisib, Erlotinib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	D	3	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	12	12	missense_variant		1378.5	Somatic
BRAF_V600E	D	3	Predictive	Sensitivity/Response	Cobimetinib	cancer	162	CANCER	cancer	162	12	12	missense_variant		1378.5	Somatic
ERBB2_AMP	D	3	Predictive	Sensitivity/Response	AKTi-1/2, Lapatinib, Trastuzumab, Pictilisib	breast cancer	1612	BREAST	breast cancer	1612	302	306	transcript_amplification		891	Somatic
ERBB2_AMP	D	3	Predictive	Sensitivity/Response	Afatinib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	302	306	transcript_amplification		891	Somatic
KRAS_Mutation	D	3	Predictive	Sensitivity/Response	Decitabine	ovarian cancer	2394	OVARY	ovarian cancer	2394	332	336	protein_altering_variant		545.5	Somatic
NPM1_EXON_12_MUTATION	D	3	Predictive	Sensitivity/Response	Tretinoin, NSC348884	acute myeloid leukemia	9119	AML	hematologic cancer	2531	86	86	exon_variant	NPM1 Exon 12	454	Somatic
FLT3_ITD	D	3	Predictive	Resistance	Daunorubicin, SU5614	acute myeloid leukemia	9119	AML	hematologic cancer	2531	55	55	inframe_insertion		448.5	Somatic
PIK3CA_Mutation	D	3	Predictive	Sensitivity/Response	Cabozantinib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	D	3	Predictive	Sensitivity/Response	Dactolisib	head and neck cancer	11934	HEAD_NECK	head and neck cancer	11934	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	D	3	Predictive	Sensitivity/Response	Taselisib, Radiation Therapy	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	D	3	Predictive	Sensitivity/Response	Capivasertib	stomach cancer	10534	STOMACH	stomach cancer	10534	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
PIK3CA_Mutation	D	3	Predictive	Sensitivity/Response	Pictilisib	endometrial cancer	1380	UCEC	uterine cancer	363	307	311	transcript_variant,gain_of_function_variant		446.5	Somatic
TP53_Mutation	D	3	Predictive	Sensitivity/Response	Docetaxel, Selumetinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	222	222	protein_altering_variant		437	Somatic
EGFR_T790M	D	3	Predictive	Sensitivity/Response	Dacomitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	34	34	missense_variant	EGFR TKI Resistance	406.25	Somatic
EGFR_T790M	D	3	Predictive	Resistance	Gefitinib, Erlotinib, Multikinase Inhibitor AEE788	cancer	162	CANCER	cancer	162	34	34	missense_variant	EGFR TKI Resistance	406.25	Somatic
EGFR_L858R	D	3	Predictive	Sensitivity/Response	Lapatinib, Neratinib, Canertinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	33	33	missense_variant		379	Somatic
EGFR_L858R	D	3	Predictive	Sensitivity/Response	Gefitinib, Erlotinib, Multikinase Inhibitor AEE788	cancer	162	CANCER	cancer	162	33	33	missense_variant		379	Somatic
EGFR_L858R	D	3	Predictive	Sensitivity/Response	Erlotinib	high grade glioma	3070	HGG	central nervous system cancer	3620	33	33	missense_variant		379	Somatic
BCR::ABL1	D	3	Predictive	Resistance	Imatinib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	1	1	transcript_fusion	ABL1 fusions in B-ALL	353.5	Somatic
BCR::ABL1	D	3	Predictive	Sensitivity/Response	Bafetinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	1	1	transcript_fusion	ABL1 fusions in B-ALL	353.5	Somatic
ETV6::NTRK3	D	3	Predictive	Sensitivity/Response	Entrectinib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	779	801	transcript_fusion		314	Somatic
PTEN_DEL	D	3	Predictive	Sensitivity/Response	PI3K/BET Inhibitor LY294002, Trastuzumab, Pictilisib	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	214	214	loss_of_function_variant		272	Somatic
PTEN_DEL	D	3	Predictive	Sensitivity/Response	Capivasertib	cancer	162	CANCER	cancer	162	214	214	loss_of_function_variant		272	Somatic
PTEN_DEL	D	3	Predictive	Sensitivity/Response	Temsirolimus	endometrial cancer	1380	UCEC	uterine cancer	363	214	214	loss_of_function_variant		272	Somatic
NRAS_Mutation	D	3	Predictive	Sensitivity/Response	Metformin, Trametinib	cancer	162	CANCER	cancer	162	208	208	transcript_variant,gain_of_function_variant		213	Somatic
KRAS_G12/G13	D	3	Prognostic	Poor Outcome		colorectal cancer	9256	COADREAD	large intestine cancer	5672	77	77	protein_altering_variant		191	Somatic
FGFR1_AMP	D	3	Predictive	Resistance	Afimoxifene	breast cancer	1612	BREAST	breast cancer	1612	263	267	transcript_amplification		185.5	Somatic
FGFR1_AMP	D	3	Predictive	Sensitivity/Response	Ponatinib	ewing sarcoma of bone	3368	ES	bone cancer	184	263	267	transcript_amplification		185.5	N/A
FGFR1_AMP	D	3	Predictive	Sensitivity/Response	Ponatinib	estrogen-receptor positive breast cancer	60075	BRCA	breast cancer	1612	263	267	transcript_amplification		185.5	Somatic
KRAS_G12C	D	3	Predictive	Sensitivity/Response	ARS-853, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	cancer	162	CANCER	cancer	162	78	78	missense_variant	EGFR TKI Resistance	176.5	Somatic
KRAS_G12C	D	3	Predictive	Sensitivity/Response	Adagrasib	solid tumor	NA	SOLID	cancer	162	78	78	missense_variant	EGFR TKI Resistance	176.5	Somatic
EGFR_AMP	D	3	Predictive	Resistance	Rociletinib, Osimertinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	190	190	transcript_amplification		173	Somatic
KRAS_G12D	D	3	Predictive	Sensitivity/Response	Dactolisib, Selumetinib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	79	79	missense_variant	EGFR TKI Resistance	162	Somatic
KRAS_G12D	D	3	Predictive	Resistance	Cetuximab	ovarian cancer	2394	OVARY	ovarian cancer	2394	79	79	missense_variant	EGFR TKI Resistance	162	Somatic
ABL1_T315I	D	3	Predictive	Resistance	Bafetinib, Nilotinib, Imatinib, Dasatinib	cancer	162	CANCER	cancer	162	4373	2	missense_variant	Imatinib Resistance	149	Somatic
ABL1_T315I	D	3	Predictive	Resistance	Imatinib, Dasatinib, Nilotinib	acute lymphoblastic leukemia	9952	ALL	hematologic cancer	2531	4373	2	missense_variant	Imatinib Resistance	149	Somatic
.::NTRK1	D	3	Predictive	Sensitivity/Response	Larotrectinib, Lestaurtinib, Crizotinib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	415	419	transcript_fusion	NTRK1 Fusions	135	Somatic
ATM_Mutation	D	3	Predictive	Sensitivity/Response	Temozolomide	glioblastoma	3068	GB	central nervous system cancer	3620	178	178	transcription_variant,loss_of_function_variant		130.5	Somatic
ATM_Mutation	D	3	Predictive	Sensitivity/Response	Temozolomide	melanoma	1909	MEL	cancer	162	178	178	transcription_variant,loss_of_function_variant		130.5	Somatic
ATM_Mutation	D	3	Predictive	Sensitivity/Response	Olaparib	mantle cell lymphoma	50746	MCL	hematologic cancer	2531	178	178	transcription_variant,loss_of_function_variant		130.5	Somatic
ABL1_F317L	D	3	Predictive	Sensitivity/Response	Ponatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4376	1028	missense_variant		121.5	Somatic
ABL1_F317L	D	3	Predictive	Resistance	Dasatinib, Imatinib	cancer	162	CANCER	cancer	162	4376	1028	missense_variant		121.5	Somatic
LMNA::NTRK1	D	3	Predictive	Sensitivity/Response	Entrectinib, Repotrectinib	cancer	162	CANCER	cancer	162	1252	1278	transcript_fusion	NTRK1 Fusions	115	N/A
KIAA1549::BRAF	D	3	Predictive	Sensitivity/Response	Trametinib	childhood pilocytic astrocytoma	6812	PAST	central nervous system cancer	3620	614	618	transcript_fusion	BRAF Fusions	109.5	Somatic
METx14del	D	3	Predictive	Sensitivity/Response	Crizotinib, Capmatinib	cancer	162	CANCER	cancer	162	320	324	exon_loss_variant		108.5	Somatic
JAK2_V617F	D	3	Predictive	Sensitivity/Response	Fedratinib	polycythemia vera	8997	PV	hematologic cancer	2531	64	64	missense_variant,gain_of_function_variant		103	Somatic
BAP1_Mutation	D	3	Predictive	Sensitivity/Response	Vorinostat, Panobinostat, Valproic Acid, Trichostatin A	uveal melanoma	6039	UM	ocular cancer	2174	183	183	protein_altering_variant,loss_of_function_variant		98.5	Somatic
PIK3CA_H1047R	D	3	Predictive	Sensitivity/Response	Dactolisib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	107	107	missense_variant		96.5	Somatic
PIK3CA_H1047R	D	3	Predictive	Sensitivity/Response	Perifosine, Temsirolimus	thyroid cancer	1781	THYROID	thyroid cancer	1781	107	107	missense_variant		96.5	Somatic
PIK3CA_H1047R	D	3	Predictive	Resistance	Vemurafenib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	107	107	missense_variant		96.5	Somatic
PIK3CA_H1047R	D	3	Predictive	Sensitivity/Response	Akt Inhibitor MK2206, Vemurafenib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	107	107	missense_variant		96.5	Somatic
IDH1_Mutation	D	3	Predictive	Sensitivity/Response	Olaparib	brain glioma	60108	GLIOMA	central nervous system cancer	3620	641	645	transcript_variant		90.5	Somatic
RET_M918T	D	3	Predictive	Resistance	Motesanib	thyroid gland medullary carcinoma	3973	THME	thyroid cancer	1781	113	113	missense_variant	RET Motesanib Resistance	86	Somatic
RET_M918T	D	3	Predictive	Sensitivity/Response	JAK2 Inhibitor AZD1480	thyroid gland medullary carcinoma	3973	THME	thyroid cancer	1781	113	113	missense_variant	RET Motesanib Resistance	86	Somatic
ABL1_E255K	D	3	Predictive	Resistance	Dasatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4431	3	missense_variant	Imatinib Resistance	83	Somatic
MET_AMP	D	3	Predictive	Resistance	Anti-EGFR Monoclonal Antibody	colorectal cancer	9256	COADREAD	large intestine cancer	5672	266	270	transcript_amplification		81.5	Somatic
MET_AMP	D	3	Predictive	Sensitivity/Response	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	266	270	transcript_amplification		81.5	Somatic
RCSD1::ABL1	D	3	Predictive	Sensitivity/Response	Dasatinib	b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	2550	2681	transcript_fusion	ABL1 fusions in B-ALL	80.5	Somatic
PIK3CA_E545K	D	3	Predictive	Sensitivity/Response	Pictilisib, Akt Inhibitor MK2206	breast cancer	1612	BREAST	breast cancer	1612	104	104	missense_variant		77.5	Somatic
PIK3CA_E545K	D	3	Predictive	Sensitivity/Response	Cisplatin, Pictilisib	cervix carcinoma	2893	CERVIX	uterine cancer	363	104	104	missense_variant		77.5	Somatic
PIK3CA_E545K	D	3	Predictive	Resistance	Cisplatin, Radiation Ionizing Radiotherapy	cervical cancer	4362	CERVIX	uterine cancer	363	104	104	missense_variant		77.5	Somatic
PIK3CA_E545K	D	3	Predictive	Resistance	Lapatinib, Trastuzumab	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	104	104	missense_variant		77.5	Somatic
PIK3CA_E542K	D	3	Predictive	Sensitivity/Response	Temsirolimus, Perifosine	thyroid cancer	1781	THYROID	thyroid cancer	1781	103	103	missense_variant		75.5	Somatic
EGFRvIII	D	3	Predictive	Sensitivity/Response	Erlotinib	high grade glioma	3070	HGG	central nervous system cancer	3620	308	312	disruptive_inframe_deletion		69	Somatic
KRAS_G12V	D	3	Predictive	Sensitivity/Response	Dactolisib, Selumetinib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	421	425	missense_variant		67.5	Somatic
ABL1_G250E	D	3	Predictive	Resistance	Bafetinib, Imatinib	cancer	162	CANCER	cancer	162	4555	1023	missense_variant		67	Somatic
ABL1_G250E	D	3	Predictive	Sensitivity/Response	Dasatinib	cancer	162	CANCER	cancer	162	4555	1023	missense_variant		67	Somatic
ABL1_M351T	D	3	Predictive	Sensitivity/Response	Imatinib, Nilotinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4556	1029	missense_variant		65.5	Somatic
ABL1_M351T	D	3	Predictive	Resistance	Imatinib	cancer	162	CANCER	cancer	162	4556	1029	missense_variant		65.5	Somatic
MET_Overexpression	D	3	Predictive	Resistance	Selumetinib, Trametinib	uveal melanoma	6039	UM	ocular cancer	2174	617	621	N/A		64	N/A
FIP1L1::PDGFRA	D	3	Predictive	Sensitivity/Response	Ponatinib	myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1	80164	MLNER	hematologic cancer	2531	570	574	transcript_fusion		63.5	Somatic
FIP1L1::PDGFRA	D	3	Predictive	Sensitivity/Response	Sunitinib, Sorafenib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	570	574	transcript_fusion		63.5	Somatic
NF1_Mutation	D	3	Predictive	Sensitivity/Response	Sirolimus, Mirdametinib	skin melanoma	8923	MEL	skin cancer	4159	583	587	protein_altering_variant,loss_of_function_variant		62	Somatic
AREG_Expression	D	3	Predictive	Resistance	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	311	315	N/A		58	N/A
IDH1_R132C	D	3	Predictive	Sensitivity/Response	GSK321, BPTES	acute myeloid leukemia	9119	AML	hematologic cancer	2531	59	59	missense_variant		56	Somatic
IDH1_R132C	D	3	Predictive	Sensitivity/Response	Olaparib	cancer	162	CANCER	cancer	162	59	59	missense_variant		56	Somatic
CDKN2A_DEL	D	3	Predictive	Sensitivity/Response	Palbociclib	renal cell carcinoma	4450	RCC	kidney cancer	263	550	554	loss_of_function_variant		52.5	Somatic
CDKN2A_DEL	D	3	Predictive	Sensitivity/Response	Palbociclib	skin melanoma	8923	MEL	skin cancer	4159	550	554	loss_of_function_variant		52.5	Somatic
CDKN2A_DEL	D	3	Predictive	Sensitivity/Response	Palbociclib	ovarian cancer	2394	OVARY	ovarian cancer	2394	550	554	loss_of_function_variant		52.5	Somatic
FGFR1_Expression	D	3	Predictive	Sensitivity/Response	Infigratinib	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	264	268	N/A		46	N/A
FGFR1_Expression	D	3	Predictive	Sensitivity/Response	Infigratinib, Fexagratinib, FGF/VEGF Receptor Tyrosine Kinase Inhibitor,  PD173074	sarcoma	1115	SARCOMA	sarcoma	1115	264	268	N/A		46	Somatic
FLT3_D835	D	3	Predictive	Resistance	Ponatinib, SU5614	acute myeloid leukemia	9119	AML	hematologic cancer	2531	433	437	protein_altering_variant		46	Somatic
MYCN_AMP	D	3	Predictive	Sensitivity/Response	FACT Complex-targeting Curaxin CBL0137, Panobinostat, JQ1	neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	294	298	transcript_amplification		46	Somatic
BRD4::NUTM1	D	3	Predictive	Sensitivity/Response	JQ1, Panobinostat	nut midline carcinoma	60463	NUTC	cancer	162	5152	4973	transcript_fusion		45.5	Somatic
PIK3CA_AMP	D	3	Predictive	Sensitivity/Response	Alpelisib	stomach carcinoma	5517	STOMACH	stomach cancer	10534	212	212	transcript_amplification		45	Somatic
BRAF_D594G	D	3	Predictive	Sensitivity/Response	Sorafenib	skin melanoma	8923	MEL	skin cancer	4159	607	611	missense_variant		43.5	Somatic
BRAF_D594G	D	3	Predictive	Resistance	U0126	skin melanoma	8923	MEL	skin cancer	4159	607	611	missense_variant		43.5	Somatic
ALK_I1171	D	3	Predictive	Sensitivity/Response	TAE684	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	523	527	missense_variant		42.5	Somatic
ALK_I1171	D	3	Predictive	Resistance	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	523	527	missense_variant		42.5	Somatic
ERBB2_Y772_A775DUP	D	3	Predictive	Sensitivity/Response	Afatinib, Sirolimus	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	410	414	inframe_insertion		42	Somatic
TP53_R273H	D	3	Predictive	Resistance	Methotrexate, Doxorubicin	osteosarcoma	3347	OS	bone cancer	184	122	122	missense_variant		41	Somatic
AURKA_Overexpression	D	3	Predictive	Resistance	Paclitaxel	cervical adenocarcinoma	3702	CEAD	uterine cancer	363	181	181	N/A		38	Somatic
FGFR2::BICC1	D	3	Predictive	Sensitivity/Response	Infigratinib, PD173074	cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	763	782	transcript_fusion		38	Somatic
PAX3::FOXO1	D	3	Predictive	Sensitivity/Response	BET Inhibitor	alveolar rhabdomyosarcoma	4051	ARMS	muscle cancer	4045	2455	2582	transcript_fusion		38	Somatic
ERBB3_Overexpression	D	3	Predictive	Sensitivity/Response	Afatinib, Selumetinib	cancer	162	CANCER	cancer	162	285	289	N/A		37	N/A
NRG1_Expression	D	3	Predictive	Sensitivity/Response	Seribantumab	ovarian cancer	2394	OVARY	ovarian cancer	2394	310	314	N/A		37	N/A
NRG1_Expression	D	3	Predictive	Sensitivity/Response	Carboplatin, Gemcitabine, Cisplatin, Paclitaxel	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	310	314	N/A		37	N/A
NRG1_Expression	D	3	Predictive	Sensitivity/Response	Anti-ErbB3 Monoclonal Antibody AV-203	cancer	162	CANCER	cancer	162	310	314	N/A		37	N/A
ALK_F1174L	D	3	Predictive	Resistance	Crizotinib	inflammatory myofibroblastic tumor	50905	IMT	cancer	162	8	8	missense_variant	ALK Crizotinib Resistance	33.5	Somatic
ALK_F1174L	D	3	Predictive	Resistance	Crizotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	8	8	missense_variant	ALK Crizotinib Resistance	33.5	Somatic
ALK_F1174L	D	3	Predictive	Resistance	Crizotinib	neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	8	8	missense_variant	ALK Crizotinib Resistance	33.5	Somatic
PTEN_Mutation	D	3	Predictive	Resistance	Taselisib	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	506	510	protein_altering_variant		31	Somatic
PTEN_Mutation	D	3	Predictive	Sensitivity/Response	Ipatasertib	cancer	162	CANCER	cancer	162	506	510	protein_altering_variant		31	Somatic
PTEN_Mutation	D	3	Predictive	Sensitivity/Response	Enzalutamide, PI3Kbeta Inhibitor AZD8186, Alpelisib	prostate cancer	10283	PROSTATE	prostate cancer	10283	506	510	protein_altering_variant		31	Somatic
SNX2::ABL1	D	3	Predictive	Resistance	Imatinib, Dasatinib	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2547	2678	transcript_fusion	ABL1 fusions in B-ALL	30.5	Somatic
FGFR2_Mutation	D	3	Predictive	Sensitivity/Response	Ponatinib	endometrial cancer	1380	UCEC	uterine cancer	363	507	511	transcript_variant,gain_of_function_variant		28	Somatic
CCNE1_AMP	D	3	Predictive	Resistance	Palbociclib	estrogen-receptor positive breast cancer	60075	BRCA	breast cancer	1612	187	187	transcript_amplification		27	N/A
PRPS1_A190T	D	3	Predictive	Sensitivity/Response	Lometrexol, Mercaptopurine	b-lymphoblastic leukemia/lymphoma	80630	BLL	hematologic cancer	2531	2798	2929			26	Somatic
TP53_R175H	D	3	Predictive	Sensitivity/Response	Doxorubicin	breast cancer	1612	BREAST	breast cancer	1612	116	116	missense_variant		25	Somatic
NRAS_Q61K	D	3	Predictive	Sensitivity/Response	Everolimus, Binimetinib	neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	423	427	missense_variant		24.5	Somatic
NRAS_Q61K	D	3	Predictive	Sensitivity/Response	Dactolisib, Selumetinib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	423	427	missense_variant		24.5	Somatic
GNA11_Mutation	D	3	Predictive	Sensitivity/Response	Mirdametinib, Sotrastaurin Acetate	uveal melanoma	6039	UM	ocular cancer	2174	502	506			24	Somatic
ALK_R1275Q	D	3	Predictive	Resistance	TAE684	neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	9	9	missense_variant		23	Somatic
FGFR2::AHCYL1	D	3	Predictive	Sensitivity/Response	PD173074, Infigratinib	cholangiocarcinoma	4947	CHOL	biliary tract cancer	4607	764	783	transcript_fusion		23	Somatic
GAS6_EXPRESSION	D	3	Predictive	Resistance	Docetaxel	prostate cancer	10283	PROSTATE	prostate cancer	10283	648	652	N/A		23	N/A
HRAS_Mutation	D	3	Predictive	Sensitivity/Response	Mirdametinib, Binimetinib, Everolimus, MTOR Kinase Inhibitor AZD8055, Selumetinib	cancer	162	CANCER	cancer	162	271	275	coding_transcript_variant		23	Somatic
STK11_DEL	D	3	Predictive	Resistance	Selumetinib, Docetaxel	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	481	485	loss_of_function_variant		23	Somatic
FGFR3_S249C	D	3	Predictive	Resistance	Cisplatin	transitional cell carcinoma	2671	TCC	cancer	162	624	628	missense_variant		21	Somatic
KRAS_A146T	D	3	Predictive	Sensitivity/Response	Selumetinib, Dactolisib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	880	906	missense_variant		21	Somatic
FLT3_D835V	D	3	Predictive	Resistance	Tandutinib	acute myeloid leukemia	9119	AML	hematologic cancer	2531	1276	1302	missense_variant		19	Somatic
FLT3_D835V	D	3	Predictive	Sensitivity/Response	Tyrphostin AG 1296, AS602868	acute myeloid leukemia	9119	AML	hematologic cancer	2531	1276	1302	missense_variant		19	Somatic
ALK_T1151dup	D	3	Predictive	Resistance	Alectinib, TAE684	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4308	4389	inframe_insertion		18	Somatic
CEBPA_N-TERMINAL_FRAME_SHIFT	D	3	Predictive	Sensitivity/Response	OICR-9429	acute myeloid leukemia	9119	AML	hematologic cancer	2531	28	28	frameshift_truncation,dominant_negative_variant		18	Somatic
DNMT1_EXPRESSION	D	3	Predictive	Sensitivity/Response	Decitabine	ovarian cancer	2394	OVARY	ovarian cancer	2394	331	335	N/A		18	N/A
ESR1_D538G	D	3	Predictive	Resistance	Hormone Therapy	breast cancer	1612	BREAST	breast cancer	1612	47	47	missense_variant	ESR1 Ligand-Binding Domain	18	Somatic
KIT_V654A	D	3	Predictive	Resistance	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	73	73	missense_variant		18	Somatic
PTPRB_Loss-of-function	D	3	Predictive	Sensitivity/Response	Sunitinib, Vatalanib	angiosarcoma	1816	ANGS	sarcoma	1115	797	819	loss_of_function_variant		18	Somatic
TSC1_Frameshift_Truncation	D	3	Predictive	Sensitivity/Response	Sirolimus	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	124	124	frameshift_truncation	TSC Loss	18	Somatic
ALK_G1202R	D	3	Predictive	Resistance	Alectinib, Brigatinib	cancer	162	CANCER	cancer	162	4237	171	missense_variant		16	Somatic
KIT_L576P	D	3	Predictive	Resistance	Sorafenib, Imatinib, Nilotinib	melanoma	1909	MEL	cancer	162	72	72	missense_variant	KIT Exon 11	16	Somatic
KIT_L576P	D	3	Predictive	Sensitivity/Response	Dasatinib	melanoma	1909	MEL	cancer	162	72	72	missense_variant	KIT Exon 11	16	Somatic
KIT_L576P	D	3	Predictive	Sensitivity/Response	Imatinib, Dasatinib, Nilotinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	72	72	missense_variant	KIT Exon 11	16	Somatic
PIK3CA_C420R	D	3	Predictive	Sensitivity/Response	Pictilisib	her2-receptor positive breast cancer	60079	BRCA	breast cancer	1612	905	931	missense_variant		15.5	Somatic
KIT_V560D	D	3	Predictive	Sensitivity/Response	Sunitinib, Regorafenib, Imatinib, Ponatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	945	971	missense_variant		14.5	Somatic
KIT_W557_K558del	D	3	Predictive	Sensitivity/Response	Ponatinib, Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	935	961	conservative_inframe_deletion		14.5	Somatic
ARAF_S214C	D	3	Predictive	Sensitivity/Response	Sorafenib, Trametinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	10	10	missense_variant		14	Somatic
BRAF_G466V	D	3	Predictive	Sensitivity/Response	Panitumumab, Irinotecan	colorectal cancer	9256	COADREAD	large intestine cancer	5672	2098	2222	missense_variant		14	Somatic
NPM1_W288FS	D	3	Predictive	Sensitivity/Response	NSC348884	acute myeloid leukemia	9119	AML	hematologic cancer	2531	87	87	frameshift_elongation	NPM1 Exon 12	13.75	Somatic
SMO_D473H	D	3	Predictive	Resistance	Vismodegib	basal cell carcinoma	2513	BCC	skin cancer	4159	295	299	missense_variant		13.5	Somatic
SMO_D473H	D	3	Predictive	Sensitivity/Response	Patidegib	medulloblastoma	50902	MBL	central nervous system cancer	3620	295	299	missense_variant		13.5	Somatic
ABL1_F317V	D	3	Predictive	Resistance	Dasatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4381	1525	missense_variant		13	Somatic
ABL1_F317V	D	3	Predictive	Resistance	Dasatinib	cancer	162	CANCER	cancer	162	4381	1525	missense_variant		13	Somatic
ALK_V1180L	D	3	Predictive	Resistance	Alectinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4351	528	missense_variant		13	Somatic
ALK_V1180L	D	3	Predictive	Sensitivity/Response	Ceritinib, TAE684	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4351	528	missense_variant		13	Somatic
ETV6::NTRK2	D	3	Predictive	Sensitivity/Response	Entrectinib	cancer	162	CANCER	cancer	162	2269	2396	transcript_fusion		13	Somatic
PIK3CA_H1047L	D	3	Predictive	Sensitivity/Response	Pictilisib	breast cancer	1612	BREAST	breast cancer	1612	1125	1151	missense_variant		12.5	Somatic
ALK_F1245C	D	3	Predictive	Sensitivity/Response	Lorlatinib	neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	545	549	missense_variant		10.5	Somatic
EGFR_L861Q	D	3	Predictive	Sensitivity/Response	Erlotinib	high grade glioma	3070	HGG	central nervous system cancer	3620	994	1020	missense_variant		10.5	Somatic
HAVCR2_Overexpression	D	3	Predictive	Sensitivity/Response	PD1 Inhibitor, Anti-TIM-3 Monoclonal Antibody	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	482	486	N/A		10.5	N/A
MEF2D::CSF1R	D	3	Predictive	Sensitivity/Response	Imatinib, GW-2580	acute lymphoblastic leukemia	9952	ALL	hematologic cancer	2531	30	30	transcript_fusion		10.5	Somatic
.::ALK	D	3	Predictive	Sensitivity/Response	Ceritinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4311	499	transcript_fusion	ALK Fusion	10	Somatic
.::ALK	D	3	Predictive	Resistance	Alectinib	cancer	162	CANCER	cancer	162	4311	499	transcript_fusion	ALK Fusion	10	Somatic
ETV6::NTRK3	D	3	Predictive	Resistance	Entrectinib, Crizotinib, ALK/TRK Inhibitor TSR-011, Larotrectinib	cancer	162	CANCER	cancer	162	5161	801	transcript_fusion		10	Somatic
KIT_K642E	D	3	Predictive	Sensitivity/Response	Ponatinib, Sunitinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	952	978	missense_variant		10	Somatic
TP53_R158H	D	3	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	vulva squamous cell carcinoma	2101	VSC	vulva cancer	1245	1603	1695	missense_variant		9	Somatic
ABCB1_Overexpression	D	3	Predictive	Resistance	Dasatinib, Bafetinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	2784	2915	N/A		8	Somatic
BCL2_F104I	D	3	Predictive	Resistance	Venetoclax	follicular lymphoma	50873	FLC	hematologic cancer	2531	2951	3082	missense_variant		8	Somatic
BCL2_G101V	D	3	Predictive	Resistance	Venetoclax	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	2829	2960	missense_variant		8	Somatic
ESR1_L536Q	D	3	Predictive	Resistance	Hormone Therapy	breast cancer	1612	BREAST	breast cancer	1612	46	46	missense_variant	ESR1 Ligand-Binding Domain	8	Somatic
ESR1_Y537C	D	3	Predictive	Resistance	Hormone Therapy	breast cancer	1612	BREAST	breast cancer	1612	48	48	missense_variant	ESR1 Ligand-Binding Domain	8	Somatic
ESR1_Y537N	D	3	Predictive	Resistance	Hormone Therapy	breast cancer	1612	BREAST	breast cancer	1612	49	49	missense_variant	ESR1 Ligand-Binding Domain	8	Somatic
ESR1_Y537S	D	3	Predictive	Resistance	Hormone Therapy	breast cancer	1612	BREAST	breast cancer	1612	50	50	missense_variant	ESR1 Ligand-Binding Domain	8	Somatic
GNAQ_Q209P	D	3	Predictive	Resistance	PLX4720	skin melanoma	8923	MEL	skin cancer	4159	600	604	missense_variant		8	Somatic
KRAS_A146V	D	3	Predictive	Sensitivity/Response	Selumetinib, Dactolisib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	318	322	missense_variant		8	Somatic
APC_Mutation	D	3	Predictive	Sensitivity/Response	JW55	colon carcinoma	1520	COAD	large intestine cancer	5672	174	174			7	Somatic
TP53_M237I	D	3	Predictive	Resistance	MDM2 Inhibitor AMGMDS3	glioblastoma	3068	GB	central nervous system cancer	3620	1040	1066	missense_variant		7	Somatic
ASS1_DEL	D	3	Predictive	Sensitivity/Response	Pegargiminase, Chloroquine	sarcoma	1115	SARCOMA	sarcoma	1115	2106	2230			6	Somatic
ASS1_DEL	D	3	Predictive	Resistance	Taxol, Cisplatin, Carboplatin	ovarian cancer	2394	OVARY	ovarian cancer	2394	2106	2230			6	Somatic
BRAF_G469E	D	3	Predictive	Sensitivity/Response	Sorafenib	skin melanoma	8923	MEL	skin cancer	4159	967	993	missense_variant		6	Somatic
BRAF_G469E	D	3	Predictive	Resistance	U0126	skin melanoma	8923	MEL	skin cancer	4159	967	993	missense_variant		6	Somatic
EGFR_K467T	D	3	Predictive	Sensitivity/Response	Panitumumab, Futuximab/Modotuximab Mixture	colorectal cancer	9256	COADREAD	large intestine cancer	5672	451	455	missense_variant	EGFR ECD MUTATION	6	Somatic
EGFR_K467T	D	3	Predictive	Resistance	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	451	455	missense_variant	EGFR ECD MUTATION	6	Somatic
ERBB3_EXPRESSION	D	3	Predictive	Sensitivity/Response	Pertuzumab, 9F7-F11	pancreatic ductal adenocarcinoma	3498	PAAD	pancreatic cancer	1793	357	361	N/A		6	N/A
FGFR3_Overexpression	D	3	Predictive	Sensitivity/Response	PD173074, Tyrosine Kinase Inhibitor SU5402, Dovitinib	bladder carcinoma	4007	BLADDER	urinary bladder cancer	11054	321	325	N/A		6	N/A
FGFR3_Overexpression	D	3	Predictive	Sensitivity/Response	R3Mab	cancer	162	CANCER	cancer	162	321	325	N/A		6	Somatic
FLT3_F691L	D	3	Predictive	Resistance	Lestaurtinib, Midostaurin	acute myeloid leukemia	9119	AML	hematologic cancer	2531	2940	3071			6	Somatic
IGF2_Overexpression	D	3	Predictive	Sensitivity/Response	Linsitinib, Cabazitaxel, Docetaxel	prostate cancer	10283	PROSTATE	prostate cancer	10283	156	156	N/A		6	Somatic
KIT_P551_E554delPMYE	D	3	Predictive	Sensitivity/Response	Ponatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	1405	1497	inframe_deletion		6	Somatic
LMNA::NTRK1	D	3	Predictive	Sensitivity/Response	Repotrectinib	cancer	162	CANCER	cancer	162	4503	1278	transcript_fusion	NTRK1 Fusions	6	N/A
LMNA::NTRK1	D	3	Predictive	Sensitivity/Response	Repotrectinib, Entrectinib	cancer	162	CANCER	cancer	162	4505	1278	transcript_fusion	NTRK1 Fusions	6	N/A
LMNA::NTRK1	D	3	Predictive	Resistance	Larotrectinib, Entrectinib	cancer	162	CANCER	cancer	162	4503	1278	transcript_fusion	NTRK1 Fusions	6	N/A
LMNA::NTRK1	D	3	Predictive	Resistance	Larotrectinib	cancer	162	CANCER	cancer	162	4505	1278	transcript_fusion	NTRK1 Fusions	6	N/A
PAPSS1::BRAF	D	3	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	282	286	gene_fusion,transcript_fusion	BRAF Fusions	6	Somatic
PAPSS1::BRAF	D	3	Predictive	Sensitivity/Response	Trametinib	melanoma	1909	MEL	cancer	162	282	286	gene_fusion,transcript_fusion	BRAF Fusions	6	Somatic
RB1_Loss-of-function	D	3	Predictive	Resistance	Palbociclib	breast cancer	1612	BREAST	breast cancer	1612	602	606	loss_of_function_variant		6	Somatic
RB1_Loss-of-function	D	3	Predictive	Resistance	Palbociclib	glioblastoma	3068	GB	central nervous system cancer	3620	602	606	loss_of_function_variant		6	Somatic
TRIM24::BRAF	D	3	Predictive	Sensitivity/Response	Trametinib	melanoma	1909	MEL	cancer	162	283	287	transcript_fusion	BRAF Fusions	6	Somatic
TRIM24::BRAF	D	3	Predictive	Resistance	Vemurafenib	skin melanoma	8923	MEL	skin cancer	4159	283	287	transcript_fusion	BRAF Fusions	6	Somatic
CDKN2B_DEL	D	3	Predictive	Sensitivity/Response	Palbociclib	renal cell carcinoma	4450	RCC	kidney cancer	263	551	555	transcript_ablation		5	Somatic
ERBB4_EXPRESSION	D	3	Predictive	Resistance	Lapatinib	breast cancer	1612	BREAST	breast cancer	1612	361	365	N/A		5	N/A
KIT_V560G	D	3	Predictive	Sensitivity/Response	Regorafenib, Ponatinib, Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	946	972	missense_variant		5	Somatic
PDGFRA_I843DEL	D	3	Predictive	Sensitivity/Response	Crenolanib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	101	101	inframe_deletion	Imatinib Resistance	5	Somatic
SF3B1_K700E	D	3	Predictive	Sensitivity/Response	Olaparib, Etoposide	leukemia	1240	LEUKEMIA	hematologic cancer	2531	561	565	missense_variant	SF3B1 HEAT domain mutation	5	Somatic
ZEB1_Expression	D	3	Predictive	Sensitivity/Response	Doxorubicin, Salinomycin	mantle cell lymphoma	50746	MCL	hematologic cancer	2531	372	376	N/A		5	Somatic
ABCC10_Overexpression	D	3	Predictive	Resistance	Paclitaxel	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	404	408	N/A		3	N/A
ABCC3_AMP	D	3	Predictive	Resistance	Monomethyl Auristatin E, Paclitaxel	breast cancer	1612	BREAST	breast cancer	1612	403	407	transcript_amplification		3	Somatic
ABL1_G340L	D	3	Predictive	Sensitivity/Response	Imatinib Mesylate, Dasatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	1565	1657	coding_sequence_variant		3	Somatic
AFAP1::NTRK2	D	3	Predictive	Sensitivity/Response	Entrectinib	cancer	162	CANCER	cancer	162	3570	3702	transcript_fusion		3	N/A
AKT3_E17K	D	3	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	1201	1227	missense_variant		3	Somatic
ALK_Exon_4-11_Deletion	D	3	Predictive	Sensitivity/Response	Brigatinib	neuroblastoma	769	NBL	peripheral nervous system neoplasm	1192	546	550	inframe_deletion		3	Somatic
AR_OVEREXPRESSION	D	3	Predictive	Sensitivity/Response	Dactolisib	breast cancer	1612	BREAST	breast cancer	1612	355	359	N/A		3	Somatic
ATM_A2062V	D	3	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	1143	1169	missense_variant	1-2k via nebula	3	Somatic
ATM_D1682H	D	3	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	1142	1168	missense_variant		3	Somatic
ATM_E2187*	D	3	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	1136	1162	stop_gained		3	Somatic
ATM_F1025L	D	3	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	1132	1158	missense_variant		3	Somatic
ATM_F2732V	D	3	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	1138	1164	missense_variant		3	Somatic
ATM_K293*	D	3	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	1129	1155	stop_gained		3	Somatic
ATM_L2427P	D	3	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	1137	1163	missense_variant		3	Unknown
ATM_R3008C	D	3	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	877	903	missense_variant		3	Somatic
ATM_T2666A	D	3	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	875	901	missense_variant		3	Somatic
ATM_c.7089+1del	D	3	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	2919	3050			3	Somatic
ATM_c.7515+1_2del	D	3	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	2920	3051			3	Somatic
ATM_c.902-1G>T	D	3	Predictive	Resistance	Doxorubicin	chronic lymphocytic leukemia	1040	CLL	hematologic cancer	2531	2918	3049			3	Unknown
ATRX_DEL	D	3	Predictive	Sensitivity/Response	Fluorouracil, Cisplatin	cancer	162	CANCER	cancer	162	3177	3309	deletion		3	N/A
BAP1_ALTERNATIVE_TRANSCRIPT_	D	3	Predictive	Sensitivity/Response	Apitolisib, Olaparib	malignant mesothelioma	1790	MESO	cancer	162	2087	2211			3	Somatic
BARD1_Loss-of-function	D	3	Predictive	Sensitivity/Response	Olaparib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	2095	2219			3	Somatic
BRAF_DEL_485-490	D	3	Predictive	Sensitivity/Response	Pan-RAF Inhibitor LY3009120	cancer	162	CANCER	cancer	162	518	522	inframe_deletion		3	Somatic
BRAF_K601E	D	3	Predictive	Sensitivity/Response	Vemurafenib, Trametinib	skin melanoma	8923	MEL	skin cancer	4159	580	584	missense_variant		3	Somatic
CASP8_Overexpression	D	3	Predictive	Sensitivity/Response	Conatumumab	ewing sarcoma of bone	3368	ES	bone cancer	184	342	346	N/A		3	N/A
CCND3_DEL	D	3	Predictive	Sensitivity/Response	Palbociclib	t-cell leukemia	715	TLL	hematologic cancer	2531	23	23	loss_of_function_variant		3	Somatic
CD44_CD44s_Expression	D	3	Predictive	Sensitivity/Response	RG7356	cancer	162	CANCER	cancer	162	337	341	N/A		3	N/A
CDKN1B_CYTOPLASMIC_MISLOCALIZATION	D	3	Predictive	Resistance	Lapatinib	breast cancer	1612	BREAST	breast cancer	1612	356	360	N/A		3	Somatic
CFLAR_EXPRESSION	D	3	Predictive	Resistance	Bicalutamide	prostate cancer	10283	PROSTATE	prostate cancer	10283	388	392	N/A		3	N/A
CIP2A_Underexpression	D	3	Predictive	Sensitivity/Response	Gemcitabine	pancreatic ductal adenocarcinoma	3498	PAAD	pancreatic cancer	1793	471	475	N/A		3	Somatic
DUSP6_EXPRESSION	D	3	Predictive	Sensitivity/Response	Trametinib	cancer	162	CANCER	cancer	162	394	398	N/A		3	N/A
EGFR_A289V	D	3	Predictive	Sensitivity/Response	Erlotinib	high grade glioma	3070	HGG	central nervous system cancer	3620	970	996	missense_variant		3	Somatic
EGFR_C797Y	D	3	Predictive	Sensitivity/Response	Erlotinib	cancer	162	CANCER	cancer	162	1482	1574	missense_variant		3	Somatic
EGFR_E734Q	D	3	Predictive	Sensitivity/Response	Erlotinib	cancer	162	CANCER	cancer	162	1480	1572	missense_variant		3	Somatic
EGFR_E868G	D	3	Predictive	Sensitivity/Response	Erlotinib	cancer	162	CANCER	cancer	162	1390	1482	missense_variant		3	Somatic
EGFR_G598V	D	3	Predictive	Sensitivity/Response	Erlotinib	cancer	162	CANCER	cancer	162	971	997	missense_variant		3	Somatic
EGFR_R108K	D	3	Predictive	Sensitivity/Response	Erlotinib	high grade glioma	3070	HGG	central nervous system cancer	3620	968	994	missense_variant		3	Somatic
EGFR_R831H	D	3	Predictive	Sensitivity/Response	Erlotinib	cancer	162	CANCER	cancer	162	991	1017	missense_variant		3	Somatic
EGFR_T263P	D	3	Predictive	Sensitivity/Response	Erlotinib	high grade glioma	3070	HGG	central nervous system cancer	3620	969	995	missense_variant		3	Somatic
EGFR_T785A	D	3	Predictive	Sensitivity/Response	Erlotinib	cancer	162	CANCER	cancer	162	1481	1573	missense_variant		3	Somatic
EGFR_W731L	D	3	Predictive	Sensitivity/Response	Erlotinib	cancer	162	CANCER	cancer	162	1479	1571	missense_variant		3	Somatic
EGFR_Y801H	D	3	Predictive	Sensitivity/Response	Erlotinib	cancer	162	CANCER	cancer	162	1483	1575	missense_variant		3	Somatic
EGF_EXPRESSION	D	3	Predictive	Resistance	Cetuximab	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	338	342	N/A		3	N/A
ETV6::NTRK1	D	3	Predictive	Sensitivity/Response	Entrectinib	cancer	162	CANCER	cancer	162	3568	3700	transcript_fusion		3	N/A
FANCC_Loss-of-function	D	3	Predictive	Sensitivity/Response	Cisplatin, Melphalan, Chlorambucil, Mitomycin, Gemcitabine	pancreatic cancer	1793	PANCREAS	pancreatic cancer	1793	530	534	loss_of_function_variant		3	Unknown
FGFR2_N550K	D	3	Predictive	Sensitivity/Response	PD173074	endometrial cancer	1380	UCEC	uterine cancer	363	541	545	missense_variant,gain_of_function_variant		3	Somatic
FGFR3::BAIAP2L1	D	3	Predictive	Sensitivity/Response	PD173074	bladder carcinoma	4007	BLADDER	urinary bladder cancer	11054	53	53	transcript_fusion	FGFR fusions	3	Somatic
GOPC::ROS1	D	3	Predictive	Sensitivity/Response	Lorlatinib	glioblastoma	3068	GB	central nervous system cancer	3620	2639	2770	transcript_fusion		3	Somatic
KDR_A1065T	D	3	Predictive	Sensitivity/Response	Sunitinib, Sorafenib	angiosarcoma	1816	ANGS	sarcoma	1115	463	467	missense_variant		3	Somatic
KDR_D717V	D	3	Predictive	Sensitivity/Response	Sunitinib, Sorafenib	angiosarcoma	1816	ANGS	sarcoma	1115	464	468	missense_variant		3	Somatic
KIT_K558delinsNP	D	3	Predictive	Sensitivity/Response	Imatinib, Ponatinib, Sunitinib, Regorafenib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	1457	1549	delins		3	Somatic
LMNA::NTRK1	D	3	Predictive	Resistance	Larotrectinib, Entrectinib	cancer	162	CANCER	cancer	162	4507	1278	transcript_fusion	NTRK1 Fusions	3	N/A
LRP1B_EXON_12-22_DELETION	D	3	Predictive	Resistance	Doxorubicin	ovarian cancer	2394	OVARY	ovarian cancer	2394	262	266	exon_loss_variant		3	Somatic
MAP2K1_P124S	D	3	Predictive	Resistance	Selumetinib	melanoma	1909	MEL	cancer	162	82	82	missense_variant		3	Somatic
MAP2K1_Q56P	D	3	Predictive	Resistance	Selumetinib	melanoma	1909	MEL	cancer	162	83	83	missense_variant		3	Somatic
MERTK_OVEREXPRESSION	D	3	Predictive	Sensitivity/Response	UNC1062	melanoma	1909	MEL	cancer	162	1273	1299	N/A		3	Somatic
MTOR_H1968Y	D	3	Predictive	Sensitivity/Response	Capivasertib, PI3K/BET Inhibitor LY294002	melanoma	1909	MEL	cancer	162	279	283	missense_variant,gain_of_function_variant		3	Somatic
MTOR_P2213S	D	3	Predictive	Sensitivity/Response	Capivasertib, PI3K/BET Inhibitor LY294002	melanoma	1909	MEL	cancer	162	280	284	missense_variant,gain_of_function_variant		3	Somatic
NAPRT_Promoter_Hypermethylation	D	3	Predictive	Sensitivity/Response	GNE-617	cancer	162	CANCER	cancer	162	370	374	N/A		3	Somatic
NF1_DEL	D	3	Predictive	Sensitivity/Response	JQ1 Compound	malignant peripheral nerve sheath tumor	5940	MPNST	peripheral nervous system neoplasm	1192	679	698	loss_of_function_variant		3	Somatic
PARP1_OVEREXPRESSION	D	3	Predictive	Sensitivity/Response	Olaparib	malignant peripheral nerve sheath tumor	5940	MPNST	peripheral nervous system neoplasm	1192	2459	2586			3	N/A
PBK_OVEREXPRESSION	D	3	Predictive	Resistance	Gefitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	344	348	N/A		3	Somatic
PDGFRA_AMP	D	3	Predictive	Sensitivity/Response	Sunitinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	697	716	transcript_amplification		3	Somatic
PDGFRA_G853D	D	3	Predictive	Sensitivity/Response	Imatinib, Crenolanib	melanoma	1909	MEL	cancer	162	839	865	missense_variant		3	Somatic
PDGFRA_H845Y	D	3	Predictive	Sensitivity/Response	Crenolanib, Imatinib	melanoma	1909	MEL	cancer	162	838	864	missense_variant		3	Somatic
PDGFRA_Overexpression	D	3	Predictive	Sensitivity/Response	Sunitinib	rhabdomyosarcoma	3247	RMS	muscle cancer	4045	2813	2944			3	N/A
PDGFRA_P577S	D	3	Predictive	Sensitivity/Response	Crenolanib, Imatinib	melanoma	1909	MEL	cancer	162	836	862	missense_variant		3	Somatic
PDGFRA_R841K	D	3	Predictive	Sensitivity/Response	Crenolanib, Imatinib	melanoma	1909	MEL	cancer	162	837	863	missense_variant		3	Somatic
PDGFRA_V561A	D	3	Predictive	Sensitivity/Response	Imatinib	gastrointestinal stromal tumor	9253	GIST	gastrointestinal system cancer	3119	243	247	missense_variant		3	Somatic
PIK3R2_N561D	D	3	Predictive	Resistance	Vemurafenib	melanoma	1909	MEL	cancer	162	1560	1652			3	Somatic
PIM1_L2V	D	3	Predictive	Resistance	Ibrutinib	diffuse large b-cell lymphoma activated b-cell type	80996	ABC	hematologic cancer	2531	3511	3643			3	Somatic
PIM1_P81S	D	3	Predictive	Resistance	Ibrutinib	diffuse large b-cell lymphoma activated b-cell type	80996	ABC	hematologic cancer	2531	3512	3644			3	Somatic
PIM1_S97N	D	3	Predictive	Resistance	Ibrutinib	diffuse large b-cell lymphoma activated b-cell type	80996	ABC	hematologic cancer	2531	3513	3645			3	Somatic
PTEN_V317FS	D	3	Predictive	Sensitivity/Response	Akt Inhibitor MK2206, MEK Inhibitor CI-1040	skin melanoma	8923	MEL	skin cancer	4159	601	605	frameshift_variant		3	Somatic
PTP4A3_OVEREXPRESSION	D	3	Predictive	Sensitivity/Response	Cetuximab	colorectal cancer	9256	COADREAD	large intestine cancer	5672	374	378	N/A		3	Somatic
PTPRD_Mutation	D	3	Predictive	Sensitivity/Response	JSI-124	head and neck carcinoma	1542	HEAD_NECK	head and neck cancer	11934	323	327	transcript_variant,loss_of_function_variant		3	Somatic
RASA1_Loss-of-function	D	3	Predictive	Sensitivity/Response	Trametinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	2111	2235			3	Somatic
RET_C634W	D	3	Predictive	Resistance	Motesanib	thyroid gland medullary carcinoma	3973	THME	thyroid cancer	1781	112	112	missense_variant	RET Motesanib Resistance	3	Somatic
RIT1_Mutation	D	3	Predictive	Sensitivity/Response	Selumetinib, Pictilisib	lung adenocarcinoma	3910	LUAD	lung cancer	1324	293	297	transcript_variant		3	Somatic
SMAD4_Underexpression	D	3	Predictive	Resistance	Cetuximab	head and neck squamous cell carcinoma	5520	HNSC	head and neck cancer	11934	278	282	N/A		3	Somatic
SMARCB1_DEL	D	3	Predictive	Sensitivity/Response	Tazemetostat	rhabdoid cancer	3672	MRT	kidney cancer	263	677	696	transcript_ablation		3	Somatic
SRSF2_P95H	D	3	Predictive	Sensitivity/Response	CTX-712	myeloid neoplasm	70004	MYELOID	hematologic cancer	2531	4180	4304	missense_variant		3	Somatic
SRSF2_P95L	D	3	Predictive	Sensitivity/Response	CTX-712	myeloid neoplasm	70004	MYELOID	hematologic cancer	2531	4179	4303	missense_variant		3	Somatic
SYK_OVEREXPRESSION	D	3	Predictive	Resistance	Paclitaxel	ovarian cancer	2394	OVARY	ovarian cancer	2394	301	305	N/A		3	Somatic
TLK2_AMP	D	3	Predictive	Sensitivity/Response	GF109203X, Go6983	breast cancer	1612	BREAST	breast cancer	1612	2116	2240			3	Somatic
TP53_DEL	D	3	Predictive	Resistance	Docetaxel	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	4407	4452			3	Somatic
UGT1A_EXPRESSION	D	3	Predictive	Resistance	Ganetespib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	359	363	N/A		3	N/A
VCL::NTRK2	D	3	Predictive	Sensitivity/Response	Entrectinib	cancer	162	CANCER	cancer	162	3569	3701	transcript_fusion		3	N/A
VHL_DEL	D	3	Predictive	Sensitivity/Response	Temsirolimus	renal carcinoma	4451	RCC	kidney cancer	263	432	436	loss_of_function_variant		3	Somatic
VPS37A_Underexpression	D	3	Predictive	Resistance	Cetuximab	ovarian cancer	2394	OVARY	ovarian cancer	2394	842	868	N/A		3	Somatic
MIR218-1_UNDEREXPRESSION	D	3	Prognostic	Poor Outcome		pancreatic cancer	1793	PANCREAS	pancreatic cancer	1793	494	498	N/A		3	Somatic
SETBP1_G870S	D	3	Prognostic	Poor Outcome		chronic myeloid leukemia	8552	CML	hematologic cancer	2531	347	351	missense_variant		3	Somatic
PRKCB_D427N	D	3	Diagnostic	Positive		adult t-cell leukemia	50523	ATLL	hematologic cancer	2531	2341	2468			3	Somatic
.::ROS1	D	3	Predictive	Sensitivity/Response	Lorlatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	5066	2693	transcript_fusion		0	Somatic
ABL1_F486S	D	3	Predictive	Sensitivity/Response	Nilotinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4721	4635	missense_variant		0	Somatic
ABL1_G398R	D	3	Predictive	Sensitivity/Response	Nilotinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4872	1233	missense_variant		0	Somatic
ABL1_H396P	D	3	Predictive	Resistance	Imatinib	cancer	162	CANCER	cancer	162	4873	1531	missense_variant		0	Somatic
ABL1_H396P	D	3	Predictive	Sensitivity/Response	Dasatinib	cancer	162	CANCER	cancer	162	4873	1531	missense_variant		0	Somatic
ABL1_L248R	D	3	Predictive	Resistance	Dasatinib, Imatinib Mesylate	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4875	2340	missense_variant		0	Somatic
ABL1_M244V	D	3	Predictive	Sensitivity/Response	Imatinib	cancer	162	CANCER	cancer	162	4662	4597	missense_variant		0	Somatic
ABL1_M244V	D	3	Predictive	Resistance	Imatinib, Bafetinib	cancer	162	CANCER	cancer	162	4662	4597	missense_variant		0	Somatic
ABL1_Q252H	D	3	Predictive	Sensitivity/Response	Imatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4719	4634	missense_variant		0	Somatic
ABL1_Q252H	D	3	Predictive	Resistance	Bafetinib, Imatinib	cancer	162	CANCER	cancer	162	4719	4634	missense_variant		0	Somatic
ABL1_T315A	D	3	Predictive	Resistance	Dasatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4742	4645	missense_variant		0	Somatic
ABL1_T315A	D	3	Predictive	Resistance	Imatinib, Dasatinib	cancer	162	CANCER	cancer	162	4742	4645	missense_variant		0	Somatic
ABL1_V299L	D	3	Predictive	Sensitivity/Response	Nilotinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4730	4639	missense_variant		0	Somatic
ABL1_V299L	D	3	Predictive	Resistance	Dasatinib	chronic myeloid leukemia	8552	CML	hematologic cancer	2531	4730	4639	missense_variant		0	Somatic
ABL1_Y253F	D	3	Predictive	Resistance	Imatinib	cancer	162	CANCER	cancer	162	5115	4942			0	Somatic
AGGF1::PDGFRB	D	3	Predictive	Sensitivity/Response	CHZ868	childhood b-cell acute lymphoblastic leukemia	80146	BLL	hematologic cancer	2533	5243	2577	transcript_fusion		0	Somatic
ARID1A_Q456*	D	3	Predictive	Sensitivity/Response	Dasatinib	colorectal cancer	9256	COADREAD	large intestine cancer	5672	1418	1510	stop_gained		0	Somatic
CD74::ROS1	D	3	Predictive	Sensitivity/Response	Cabozantinib, Foretinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	5075	4908	transcript_fusion		0	Somatic
CD74::ROS1	D	3	Predictive	Resistance	AZD3463, Brigatinib, Ceritinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	5075	4908	transcript_fusion		0	Somatic
CD74::ROS1	D	3	Predictive	Sensitivity/Response	Lorlatinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	5073	4908	transcript_fusion		0	Somatic
CD74::ROS1	D	3	Predictive	Resistance	ALK Inhibitor TAE684, Crizotinib, Foretinib	lung non-small cell carcinoma	3908	NSCLC	lung cancer	1324	5125	4908	transcript_fusion		0	Somatic
FIP1L1::PDGFRA	D	3	Predictive	Sensitivity/Response	Ponatinib	myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1	80164	MLNER	hematologic cancer	2531	5074	574	transcript_fusion		0	Somatic
LMNA::NTRK1	D	3	Predictive	Resistance	Larotrectinib	cancer	162	CANCER	cancer	162	4509	1278	transcript_fusion	NTRK1 Fusions	0	N/A
RCSD1::ABL2	D	3	Predictive	Sensitivity/Response	Dasatinib	b-lymphoblastic leukemia/lymphoma, bcr-abl1-like	80650	BLLBCRABL1L	hematologic cancer	2531	3394	3526	transcript_fusion		0	Somatic
ROS1_G2032R	D	3	Predictive	Sensitivity/Response	DS-6501b	lung adenocarcinoma	3910	LUAD	lung cancer	1324	5076	1271	missense_variant		0	Somatic
